<?xml version="1.0" encoding="UTF-8" standalone="yes"?><Rowset rowCount='384'><Row><Action id="12378">Prophylactic vaccine</Action><AuthorityGroup>LOCAL_AND_MAJOR</AuthorityGroup><Company id="18630">State Research Center of Virology and Biotechnology VECTOR</Company><Country id="RU">Russian Federation</Country><Drug id="12671">measles vaccine, NPO Vector</Drug><EntityType>Biological</EntityType><HighestDevStatus id="L">Launched</HighestDevStatus><HighestDevStatusForInd id="L">Launched</HighestDevStatusForInd><Indication id="1">Measles virus infection</Indication><IsActiveCompany>true</IsActiveCompany><LatestChange>2000-03-17 00:00:00</LatestChange><ParentCompany id="18630">State Research Center of Virology and Biotechnology VECTOR</ParentCompany><Status id="L">Launched</Status><StatusDate>2000-03-17 00:00:00</StatusDate><StatusSortCode>13</StatusSortCode><TherapyArea id="746">Infectious disease</TherapyArea></Row><Row><Action id="12378">Prophylactic vaccine</Action><AuthorityGroup>OTHER</AuthorityGroup><Company id="24166">GlaxoSmithKline Biologicals</Company><Country id="BE">Belgium</Country><Drug id="17141">Priorix-Tetra</Drug><EntityType>Biological</EntityType><HighestDevStatus id="L">Launched</HighestDevStatus><HighestDevStatusForInd id="L">Launched</HighestDevStatusForInd><Indication id="1">Measles virus infection</Indication><IsActiveCompany>false</IsActiveCompany><LatestChange>2008-01-10 00:00:00</LatestChange><ParentCompany id="28355">GlaxoSmithKline plc</ParentCompany><Status id="C2">Phase 2 Clinical</Status><StatusDate>1998-02-01 00:00:00</StatusDate><StatusSortCode>9</StatusSortCode><TherapyArea id="746">Infectious disease</TherapyArea></Row><Row><Action id="12378">Prophylactic vaccine</Action><AuthorityGroup>OTHER</AuthorityGroup><Company id="28355">GlaxoSmithKline plc</Company><Country id="EU">EU</Country><Drug id="17141">Priorix-Tetra</Drug><EntityType>Biological</EntityType><HighestDevStatus id="L">Launched</HighestDevStatus><HighestDevStatusForInd id="L">Launched</HighestDevStatusForInd><Indication id="1">Measles virus infection</Indication><IsActiveCompany>true</IsActiveCompany><LatestChange>2008-01-10 00:00:00</LatestChange><ParentCompany id="28355">GlaxoSmithKline plc</ParentCompany><Status id="R">Registered</Status><StatusDate>2006-07-31 00:00:00</StatusDate><StatusSortCode>12</StatusSortCode><TherapyArea id="746">Infectious disease</TherapyArea></Row><Row><Action id="12364">Live attenuated viral vaccine</Action><AuthorityGroup>OTHER</AuthorityGroup><Company id="28355">GlaxoSmithKline plc</Company><Country id="DK">Denmark</Country><Drug id="17141">Priorix-Tetra</Drug><EntityType>Biological</EntityType><HighestDevStatus id="L">Launched</HighestDevStatus><HighestDevStatusForInd id="L">Launched</HighestDevStatusForInd><Indication id="1">Measles virus infection</Indication><IsActiveCompany>true</IsActiveCompany><LatestChange>2008-01-10 00:00:00</LatestChange><ParentCompany id="28355">GlaxoSmithKline plc</ParentCompany><Status id="R">Registered</Status><StatusDate>2007-08-07 00:00:00</StatusDate><StatusSortCode>12</StatusSortCode><TherapyArea id="746">Infectious disease</TherapyArea></Row><Row><Action id="59620">Unspecified drug target</Action><AuthorityGroup>LOCAL_AND_MAJOR</AuthorityGroup><Company id="20691">Utah State University</Company><Country id="US">US</Country><Drug id="29239">KS-753</Drug><EntityType>Chemical</EntityType><HighestDevStatus id="NDR">No Development Reported</HighestDevStatus><HighestDevStatusForInd id="NDR">No Development Reported</HighestDevStatusForInd><Indication id="1">Measles virus infection</Indication><IsActiveCompany>false</IsActiveCompany><LatestChange>2008-02-12 00:00:00</LatestChange><ParentCompany id="20691">Utah State University</ParentCompany><Status id="NDR">No Development Reported</Status><StatusDate>2008-02-12 00:00:00</StatusDate><StatusSortCode>2</StatusSortCode><TherapyArea id="746">Infectious disease</TherapyArea></Row><Row><Action id="12364">Live attenuated viral vaccine</Action><AuthorityGroup>OTHER</AuthorityGroup><Company id="24766">Crucell Switzerland AG</Company><Country id="CH">Switzerland</Country><Drug id="41069">second-generation MMR vaccine, Berna</Drug><EntityType>Biological</EntityType><HighestDevStatus id="NDR">No Development Reported</HighestDevStatus><HighestDevStatusForInd id="NDR">No Development Reported</HighestDevStatusForInd><Indication id="1">Measles virus infection</Indication><IsActiveCompany>false</IsActiveCompany><LatestChange>2006-03-28 00:00:00</LatestChange><ParentCompany id="17332">Johnson &amp; Johnson</ParentCompany><Status id="NDR">No Development Reported</Status><StatusDate>2006-03-28 00:00:00</StatusDate><StatusSortCode>2</StatusSortCode><TherapyArea id="746">Infectious disease</TherapyArea></Row><Row><Action id="12378">Prophylactic vaccine</Action><AuthorityGroup>OTHER</AuthorityGroup><Company id="24766">Crucell Switzerland AG</Company><Country id="CH">Switzerland</Country><Drug id="41069">second-generation MMR vaccine, Berna</Drug><EntityType>Biological</EntityType><HighestDevStatus id="NDR">No Development Reported</HighestDevStatus><HighestDevStatusForInd id="NDR">No Development Reported</HighestDevStatusForInd><Indication id="1">Measles virus infection</Indication><IsActiveCompany>false</IsActiveCompany><LatestChange>2006-03-28 00:00:00</LatestChange><ParentCompany id="17332">Johnson &amp; Johnson</ParentCompany><Status id="C2">Phase 2 Clinical</Status><StatusDate>2002-08-12 00:00:00</StatusDate><StatusSortCode>9</StatusSortCode><TherapyArea id="746">Infectious disease</TherapyArea></Row><Row><Action id="12378">Prophylactic vaccine</Action><AuthorityGroup>OTHER</AuthorityGroup><Company id="24244">Bavarian Nordic A/S</Company><Country id="ZA">South Africa</Country><Drug id="54328">MVA-mBN85B</Drug><EntityType>Biological</EntityType><HighestDevStatus id="NDR">No Development Reported</HighestDevStatus><HighestDevStatusForInd id="NDR">No Development Reported</HighestDevStatusForInd><Indication id="1">Measles virus infection</Indication><IsActiveCompany>false</IsActiveCompany><LatestChange>2011-11-29 00:00:00</LatestChange><ParentCompany id="24244">Bavarian Nordic A/S</ParentCompany><Status id="C2">Phase 2 Clinical</Status><StatusDate>2009-06-30 00:00:00</StatusDate><StatusSortCode>9</StatusSortCode><TherapyArea id="746">Infectious disease</TherapyArea></Row><Row><Action id="1879">DNA vaccine</Action><AuthorityGroup>LOCAL_AND_MAJOR</AuthorityGroup><Company id="20596">Johns Hopkins University</Company><Country id="US">US</Country><Drug id="57445">DNA vaccine (measles, Vaxfectin), Vical/Johns Hopkins University</Drug><EntityType>Biological</EntityType><HighestDevStatus id="NDR">No Development Reported</HighestDevStatus><HighestDevStatusForInd id="NDR">No Development Reported</HighestDevStatusForInd><Indication id="1">Measles virus infection</Indication><IsActiveCompany>false</IsActiveCompany><LatestChange>2012-11-30 00:00:00</LatestChange><ParentCompany id="20596">Johns Hopkins University</ParentCompany><Status id="NDR">No Development Reported</Status><StatusDate>2012-11-30 00:00:00</StatusDate><StatusSortCode>2</StatusSortCode><TherapyArea id="746">Infectious disease</TherapyArea></Row><Row><Action id="12378">Prophylactic vaccine</Action><AuthorityGroup>LOCAL_AND_MAJOR</AuthorityGroup><Company id="20743">Vical Inc</Company><Country id="US">US</Country><Drug id="57445">DNA vaccine (measles, Vaxfectin), Vical/Johns Hopkins University</Drug><EntityType>Biological</EntityType><HighestDevStatus id="NDR">No Development Reported</HighestDevStatus><HighestDevStatusForInd id="NDR">No Development Reported</HighestDevStatusForInd><Indication id="1">Measles virus infection</Indication><IsActiveCompany>false</IsActiveCompany><LatestChange>2012-11-30 00:00:00</LatestChange><ParentCompany id="20743">Vical Inc</ParentCompany><Status id="DR">Discovery</Status><StatusDate>2007-05-31 00:00:00</StatusDate><StatusSortCode>6</StatusSortCode><TherapyArea id="746">Infectious disease</TherapyArea></Row><Row><Action id="991">Antiviral</Action><AuthorityGroup>LOCAL_AND_MAJOR</AuthorityGroup><Company id="1064321">Universal Stabilization Technologies Inc</Company><Country id="US">US</Country><Drug id="73077">thermostable vaccines (pulmonary, measles), Universal Stabilization Technologies</Drug><EntityType>Biological</EntityType><HighestDevStatus id="NDR">No Development Reported</HighestDevStatus><HighestDevStatusForInd id="NDR">No Development Reported</HighestDevStatusForInd><Indication id="1">Measles virus infection</Indication><IsActiveCompany>false</IsActiveCompany><LatestChange>2012-10-17 00:00:00</LatestChange><ParentCompany id="1064321">Universal Stabilization Technologies Inc</ParentCompany><Status id="DR">Discovery</Status><StatusDate>2009-12-31 00:00:00</StatusDate><StatusSortCode>6</StatusSortCode><TherapyArea id="746">Infectious disease</TherapyArea></Row><Row><Action id="12379">Therapeutic vaccine</Action><AuthorityGroup>LOCAL_AND_MAJOR</AuthorityGroup><Company id="1064321">Universal Stabilization Technologies Inc</Company><Country id="US">US</Country><Drug id="73077">thermostable vaccines (pulmonary, measles), Universal Stabilization Technologies</Drug><EntityType>Biological</EntityType><HighestDevStatus id="NDR">No Development Reported</HighestDevStatus><HighestDevStatusForInd id="NDR">No Development Reported</HighestDevStatusForInd><Indication id="1">Measles virus infection</Indication><IsActiveCompany>false</IsActiveCompany><LatestChange>2012-10-17 00:00:00</LatestChange><ParentCompany id="1064321">Universal Stabilization Technologies Inc</ParentCompany><Status id="DR">Discovery</Status><StatusDate>2009-12-31 00:00:00</StatusDate><StatusSortCode>6</StatusSortCode><TherapyArea id="746">Infectious disease</TherapyArea></Row><Row><Action id="12364">Live attenuated viral vaccine</Action><AuthorityGroup>LOCAL_AND_MAJOR</AuthorityGroup><Company id="1061252">Wuhan Institute of Biological Products Co Ltd</Company><Country id="CN">China</Country><Drug id="80093">Wu Sheng Si Lin</Drug><EntityType>Biological</EntityType><HighestDevStatus id="L">Launched</HighestDevStatus><HighestDevStatusForInd id="L">Launched</HighestDevStatusForInd><Indication id="1">Measles virus infection</Indication><IsActiveCompany>true</IsActiveCompany><LatestChange>2003-12-31 00:00:00</LatestChange><ParentCompany id="1055632">Sinopharm</ParentCompany><Status id="R">Registered</Status><StatusDate>2003-12-31 00:00:00</StatusDate><StatusSortCode>12</StatusSortCode><TherapyArea id="746">Infectious disease</TherapyArea></Row><Row><Action id="12364">Live attenuated viral vaccine</Action><AuthorityGroup>LOCAL_AND_MAJOR</AuthorityGroup><Company id="1052048">Sinovac (Dalian) Vaccine Technology Co Ltd</Company><Country id="CN">China</Country><Drug id="80163">measles vaccine, Sinovac Dalian</Drug><EntityType>Biological</EntityType><HighestDevStatus id="NDR">No Development Reported</HighestDevStatus><HighestDevStatusForInd id="NDR">No Development Reported</HighestDevStatusForInd><Indication id="1">Measles virus infection</Indication><IsActiveCompany>false</IsActiveCompany><LatestChange>2014-07-07 00:00:00</LatestChange><ParentCompany id="1005255">Sinovac Biotech Ltd</ParentCompany><Status id="NDR">No Development Reported</Status><StatusDate>2014-07-07 00:00:00</StatusDate><StatusSortCode>2</StatusSortCode><TherapyArea id="746">Infectious disease</TherapyArea></Row><Row><Action id="393">Immunostimulant</Action><AuthorityGroup>LOCAL_AND_MAJOR</AuthorityGroup><Company id="1071897">Shanghai Institute of Biological Products Co Ltd</Company><Country id="CN">China</Country><Drug id="80171">human immunoglobulin (intramuscular), Shanghai Institute of Biological Products</Drug><EntityType>Biological</EntityType><HighestDevStatus id="L">Launched</HighestDevStatus><HighestDevStatusForInd id="L">Launched</HighestDevStatusForInd><Indication id="1">Measles virus infection</Indication><IsActiveCompany>true</IsActiveCompany><LatestChange>1997-12-31 00:00:00</LatestChange><ParentCompany id="1055632">Sinopharm</ParentCompany><Status id="L">Launched</Status><StatusDate>1997-12-31 00:00:00</StatusDate><StatusSortCode>13</StatusSortCode><TherapyArea id="746">Infectious disease</TherapyArea></Row><Row><Action id="59620">Unspecified drug target</Action><AuthorityGroup>LOCAL_AND_MAJOR</AuthorityGroup><Company id="1071897">Shanghai Institute of Biological Products Co Ltd</Company><Country id="CN">China</Country><Drug id="80171">human immunoglobulin (intramuscular), Shanghai Institute of Biological Products</Drug><EntityType>Biological</EntityType><HighestDevStatus id="L">Launched</HighestDevStatus><HighestDevStatusForInd id="L">Launched</HighestDevStatusForInd><Indication id="1">Measles virus infection</Indication><IsActiveCompany>true</IsActiveCompany><LatestChange>1997-12-31 00:00:00</LatestChange><ParentCompany id="1055632">Sinopharm</ParentCompany><Status id="R">Registered</Status><StatusDate>1997-12-31 00:00:00</StatusDate><StatusSortCode>12</StatusSortCode><TherapyArea id="746">Infectious disease</TherapyArea></Row><Row><Action id="991">Antiviral</Action><AuthorityGroup>LOCAL_AND_MAJOR</AuthorityGroup><Company id="1061250">Lanzhou Institute of Biological Products</Company><Country id="CN">China</Country><Drug id="80208">human immunoglobulin (pH4, intravenous), Lanzhou Institute of Biological Products</Drug><EntityType>Biological</EntityType><HighestDevStatus id="L">Launched</HighestDevStatus><HighestDevStatusForInd id="L">Launched</HighestDevStatusForInd><Indication id="1">Measles virus infection</Indication><IsActiveCompany>true</IsActiveCompany><LatestChange>2004-12-31 00:00:00</LatestChange><ParentCompany id="1055632">Sinopharm</ParentCompany><Status id="L">Launched</Status><StatusDate>2004-12-31 00:00:00</StatusDate><StatusSortCode>13</StatusSortCode><TherapyArea id="746">Infectious disease</TherapyArea></Row><Row><Action id="393">Immunostimulant</Action><AuthorityGroup>LOCAL_AND_MAJOR</AuthorityGroup><Company id="1061250">Lanzhou Institute of Biological Products</Company><Country id="CN">China</Country><Drug id="80208">human immunoglobulin (pH4, intravenous), Lanzhou Institute of Biological Products</Drug><EntityType>Biological</EntityType><HighestDevStatus id="L">Launched</HighestDevStatus><HighestDevStatusForInd id="L">Launched</HighestDevStatusForInd><Indication id="1">Measles virus infection</Indication><IsActiveCompany>true</IsActiveCompany><LatestChange>2004-12-31 00:00:00</LatestChange><ParentCompany id="1055632">Sinopharm</ParentCompany><Status id="L">Launched</Status><StatusDate>2004-12-31 00:00:00</StatusDate><StatusSortCode>13</StatusSortCode><TherapyArea id="746">Infectious disease</TherapyArea></Row><Row><Action id="12364">Live attenuated viral vaccine</Action><AuthorityGroup>LOCAL_AND_MAJOR</AuthorityGroup><Company id="1056577">Beijing Minhai Biotechnology Co Ltd</Company><Country id="CN">China</Country><Drug id="82024">measles/rubella vaccine (subcutaneous, live), Beijing Minhai Biotechnology</Drug><EntityType>Biological</EntityType><HighestDevStatus id="L">Launched</HighestDevStatus><HighestDevStatusForInd id="L">Launched</HighestDevStatusForInd><Indication id="1">Measles virus infection</Indication><IsActiveCompany>true</IsActiveCompany><LatestChange>2014-10-24 00:00:00</LatestChange><ParentCompany id="1071345">Kangtai Biological Products Co Ltd</ParentCompany><Status id="L">Launched</Status><StatusDate>2014-10-24 00:00:00</StatusDate><StatusSortCode>13</StatusSortCode><TherapyArea id="746">Infectious disease</TherapyArea></Row><Row><Action id="12378">Prophylactic vaccine</Action><AuthorityGroup>LOCAL_AND_MAJOR</AuthorityGroup><Company id="1075350">Dalian Aleph Biomedical Co Ltd</Company><Country id="CN">China</Country><Drug id="85750">measles/mumps/rubella vaccine, Dalian Aleph Biomedical</Drug><EntityType>Biological</EntityType><HighestDevStatus id="DR">Discovery</HighestDevStatus><HighestDevStatusForInd id="DR">Discovery</HighestDevStatusForInd><Indication id="1">Measles virus infection</Indication><IsActiveCompany>true</IsActiveCompany><LatestChange>2013-06-14 00:00:00</LatestChange><ParentCompany id="1015871">Shanghai Fosun Pharmaceutical (Group) Co Ltd</ParentCompany><Status id="DR">Discovery</Status><StatusDate>2013-06-14 00:00:00</StatusDate><StatusSortCode>6</StatusSortCode><TherapyArea id="746">Infectious disease</TherapyArea></Row><Row><Action id="1596">Immunomodulator</Action><AuthorityGroup>LOCAL_AND_MAJOR</AuthorityGroup><Company id="1081842">Sichuan Yuanda Shuyang Pharmaceutical Co Ltd</Company><Country id="CN">China</Country><Drug id="84689">human immunoglobulin (intramuscular, measles/hepatitis virus infection), Sichuan Yuanda Shuyang Pharmaceutical</Drug><EntityType>Biological</EntityType><HighestDevStatus id="L">Launched</HighestDevStatus><HighestDevStatusForInd id="L">Launched</HighestDevStatusForInd><Indication id="1">Measles virus infection</Indication><IsActiveCompany>true</IsActiveCompany><LatestChange>1998-12-31 00:00:00</LatestChange><ParentCompany id="1081842">Sichuan Yuanda Shuyang Pharmaceutical Co Ltd</ParentCompany><Status id="R">Registered</Status><StatusDate>1998-12-31 00:00:00</StatusDate><StatusSortCode>12</StatusSortCode><TherapyArea id="746">Infectious disease</TherapyArea></Row><Row><Action id="59620">Unspecified drug target</Action><AuthorityGroup>LOCAL_AND_MAJOR</AuthorityGroup><Company id="1079335">Guangdong Weilun Biological Products Co Ltd</Company><Country id="CN">China</Country><Drug id="84826">human immunoglobulin (intramuscular, measles/hepatitis virus infection), Guangdong Weilun Biological Products</Drug><EntityType>Biological</EntityType><HighestDevStatus id="L">Launched</HighestDevStatus><HighestDevStatusForInd id="L">Launched</HighestDevStatusForInd><Indication id="1">Measles virus infection</Indication><IsActiveCompany>true</IsActiveCompany><LatestChange>2000-12-31 00:00:00</LatestChange><ParentCompany id="1079335">Guangdong Weilun Biological Products Co Ltd</ParentCompany><Status id="L">Launched</Status><StatusDate>2000-12-31 00:00:00</StatusDate><StatusSortCode>13</StatusSortCode><TherapyArea id="746">Infectious disease</TherapyArea></Row><Row><Action id="12364">Live attenuated viral vaccine</Action><AuthorityGroup>LOCAL_AND_MAJOR</AuthorityGroup><Company id="1059311">Bio-Manguinhos/Fiocruz</Company><Country id="BR">Brazil</Country><Drug id="94952">MMR vaccine, Bio-Manguinhos/Fiocruz</Drug><EntityType>Biological</EntityType><HighestDevStatus id="C3">Phase 3 Clinical</HighestDevStatus><HighestDevStatusForInd id="C3">Phase 3 Clinical</HighestDevStatusForInd><Indication id="1">Measles virus infection</Indication><IsActiveCompany>true</IsActiveCompany><LatestChange>2015-04-13 00:00:00</LatestChange><ParentCompany id="16154">Fundacao Oswaldo Cruz (Fiocruz)</ParentCompany><Status id="DR">Discovery</Status><StatusDate>2014-08-08 00:00:00</StatusDate><StatusSortCode>6</StatusSortCode><TherapyArea id="746">Infectious disease</TherapyArea></Row><Row><Action id="12364">Live attenuated viral vaccine</Action><AuthorityGroup>LOCAL_AND_MAJOR</AuthorityGroup><Company id="19962">SmithKline Beecham plc</Company><Country id="GB">UK</Country><Drug id="11457">Priorix</Drug><EntityType>Biological</EntityType><HighestDevStatus id="L">Launched</HighestDevStatus><HighestDevStatusForInd id="L">Launched</HighestDevStatusForInd><Indication id="1">Measles virus infection</Indication><IsActiveCompany>true</IsActiveCompany><LatestChange>2012-06-29 00:00:00</LatestChange><ParentCompany id="28355">GlaxoSmithKline plc</ParentCompany><Status id="C3">Phase 3 Clinical</Status><StatusDate>1995-12-14 13:36:39</StatusDate><StatusSortCode>10</StatusSortCode><TherapyArea id="746">Infectious disease</TherapyArea></Row><Row><Action id="12364">Live attenuated viral vaccine</Action><AuthorityGroup>OTHER</AuthorityGroup><Company id="19962">SmithKline Beecham plc</Company><Country id="FR">France</Country><Drug id="11457">Priorix</Drug><EntityType>Biological</EntityType><HighestDevStatus id="L">Launched</HighestDevStatus><HighestDevStatusForInd id="L">Launched</HighestDevStatusForInd><Indication id="1">Measles virus infection</Indication><IsActiveCompany>true</IsActiveCompany><LatestChange>2012-06-29 00:00:00</LatestChange><ParentCompany id="28355">GlaxoSmithKline plc</ParentCompany><Status id="R">Registered</Status><StatusDate>1999-05-25 00:00:00</StatusDate><StatusSortCode>12</StatusSortCode><TherapyArea id="746">Infectious disease</TherapyArea></Row><Row><Action id="12364">Live attenuated viral vaccine</Action><AuthorityGroup>OTHER</AuthorityGroup><Company id="19962">SmithKline Beecham plc</Company><Country id="DK">Denmark</Country><Drug id="11457">Priorix</Drug><EntityType>Biological</EntityType><HighestDevStatus id="L">Launched</HighestDevStatus><HighestDevStatusForInd id="L">Launched</HighestDevStatusForInd><Indication id="1">Measles virus infection</Indication><IsActiveCompany>true</IsActiveCompany><LatestChange>2012-06-29 00:00:00</LatestChange><ParentCompany id="28355">GlaxoSmithKline plc</ParentCompany><Status id="R">Registered</Status><StatusDate>1999-06-10 00:00:00</StatusDate><StatusSortCode>12</StatusSortCode><TherapyArea id="746">Infectious disease</TherapyArea></Row><Row><Action id="12364">Live attenuated viral vaccine</Action><AuthorityGroup>OTHER</AuthorityGroup><Company id="19962">SmithKline Beecham plc</Company><Country id="FR">France</Country><Drug id="11457">Priorix</Drug><EntityType>Biological</EntityType><HighestDevStatus id="L">Launched</HighestDevStatus><HighestDevStatusForInd id="L">Launched</HighestDevStatusForInd><Indication id="1">Measles virus infection</Indication><IsActiveCompany>true</IsActiveCompany><LatestChange>2012-06-29 00:00:00</LatestChange><ParentCompany id="28355">GlaxoSmithKline plc</ParentCompany><Status id="L">Launched</Status><StatusDate>1999-10-13 00:00:00</StatusDate><StatusSortCode>13</StatusSortCode><TherapyArea id="746">Infectious disease</TherapyArea></Row><Row><Action id="12378">Prophylactic vaccine</Action><AuthorityGroup>OTHER</AuthorityGroup><Company id="19962">SmithKline Beecham plc</Company><Country id="BE">Belgium</Country><Drug id="11457">Priorix</Drug><EntityType>Biological</EntityType><HighestDevStatus id="L">Launched</HighestDevStatus><HighestDevStatusForInd id="L">Launched</HighestDevStatusForInd><Indication id="1">Measles virus infection</Indication><IsActiveCompany>true</IsActiveCompany><LatestChange>2012-06-29 00:00:00</LatestChange><ParentCompany id="28355">GlaxoSmithKline plc</ParentCompany><Status id="L">Launched</Status><StatusDate>1999-12-31 00:00:00</StatusDate><StatusSortCode>13</StatusSortCode><TherapyArea id="746">Infectious disease</TherapyArea></Row><Row><Action id="991">Antiviral</Action><AuthorityGroup>LOCAL_AND_MAJOR</AuthorityGroup><Company id="1080922">Guangxi Beisheng Pharmaceutical Co Ltd</Company><Country id="CN">China</Country><Drug id="85734">human immunoglobulin (intramuscular, measles/hepatitis virus infection), Guangxi Beisheng Pharmaceutical</Drug><EntityType>Biological</EntityType><HighestDevStatus id="DX">Discontinued</HighestDevStatus><HighestDevStatusForInd id="DX">Discontinued</HighestDevStatusForInd><Indication id="1">Measles virus infection</Indication><IsActiveCompany>false</IsActiveCompany><LatestChange>2008-11-27 00:00:00</LatestChange><ParentCompany id="1080922">Guangxi Beisheng Pharmaceutical Co Ltd</ParentCompany><Status id="R">Registered</Status><StatusDate>2005-12-31 00:00:00</StatusDate><StatusSortCode>12</StatusSortCode><TherapyArea id="746">Infectious disease</TherapyArea></Row><Row><Action id="393">Immunostimulant</Action><AuthorityGroup>LOCAL_AND_MAJOR</AuthorityGroup><Company id="1080922">Guangxi Beisheng Pharmaceutical Co Ltd</Company><Country id="CN">China</Country><Drug id="85734">human immunoglobulin (intramuscular, measles/hepatitis virus infection), Guangxi Beisheng Pharmaceutical</Drug><EntityType>Biological</EntityType><HighestDevStatus id="DX">Discontinued</HighestDevStatus><HighestDevStatusForInd id="DX">Discontinued</HighestDevStatusForInd><Indication id="1">Measles virus infection</Indication><IsActiveCompany>false</IsActiveCompany><LatestChange>2008-11-27 00:00:00</LatestChange><ParentCompany id="1080922">Guangxi Beisheng Pharmaceutical Co Ltd</ParentCompany><Status id="DX">Discontinued</Status><StatusDate>2008-11-27 00:00:00</StatusDate><StatusSortCode>3</StatusSortCode><TherapyArea id="746">Infectious disease</TherapyArea></Row><Row><Action id="12378">Prophylactic vaccine</Action><AuthorityGroup>LOCAL_AND_MAJOR</AuthorityGroup><Company id="15374">Kaketsuken</Company><Country id="JP">Japan</Country><Drug id="3643">MMR vaccine, Merck &amp; Co</Drug><EntityType>Biological</EntityType><HighestDevStatus id="L">Launched</HighestDevStatus><HighestDevStatusForInd id="L">Launched</HighestDevStatusForInd><Indication id="1">Measles virus infection</Indication><IsActiveCompany>true</IsActiveCompany><LatestChange>2013-05-07 00:00:00</LatestChange><ParentCompany id="15374">Kaketsuken</ParentCompany><Status id="PR">Pre-registration</Status><StatusDate>2013-05-07 00:00:00</StatusDate><StatusSortCode>11</StatusSortCode><TherapyArea id="746">Infectious disease</TherapyArea></Row><Row><Action id="12378">Prophylactic vaccine</Action><AuthorityGroup>OTHER</AuthorityGroup><Company id="18077">Merck &amp; Co Inc</Company><Country id="TW">Taiwan</Country><Drug id="3643">MMR vaccine, Merck &amp; Co</Drug><EntityType>Biological</EntityType><HighestDevStatus id="L">Launched</HighestDevStatus><HighestDevStatusForInd id="L">Launched</HighestDevStatusForInd><Indication id="1">Measles virus infection</Indication><IsActiveCompany>true</IsActiveCompany><LatestChange>2013-05-07 00:00:00</LatestChange><ParentCompany id="18077">Merck &amp; Co Inc</ParentCompany><Status id="R">Registered</Status><StatusDate>1982-04-16 00:00:00</StatusDate><StatusSortCode>12</StatusSortCode><TherapyArea id="746">Infectious disease</TherapyArea></Row><Row><Action id="12378">Prophylactic vaccine</Action><AuthorityGroup>LOCAL_AND_MAJOR</AuthorityGroup><Company id="18077">Merck &amp; Co Inc</Company><Country id="US">US</Country><Drug id="47279">ProQuad</Drug><EntityType>Biological</EntityType><HighestDevStatus id="L">Launched</HighestDevStatus><HighestDevStatusForInd id="L">Launched</HighestDevStatusForInd><Indication id="1">Measles virus infection</Indication><IsActiveCompany>true</IsActiveCompany><LatestChange>2013-01-10 00:00:00</LatestChange><ParentCompany id="18077">Merck &amp; Co Inc</ParentCompany><Status id="C3">Phase 3 Clinical</Status><StatusDate>2003-09-26 00:00:00</StatusDate><StatusSortCode>10</StatusSortCode><TherapyArea id="746">Infectious disease</TherapyArea></Row><Row><Action id="12364">Live attenuated viral vaccine</Action><AuthorityGroup>OTHER</AuthorityGroup><Company id="18077">Merck &amp; Co Inc</Company><Country id="GB">UK</Country><Drug id="47279">ProQuad</Drug><EntityType>Biological</EntityType><HighestDevStatus id="L">Launched</HighestDevStatus><HighestDevStatusForInd id="L">Launched</HighestDevStatusForInd><Indication id="1">Measles virus infection</Indication><IsActiveCompany>true</IsActiveCompany><LatestChange>2013-01-10 00:00:00</LatestChange><ParentCompany id="18077">Merck &amp; Co Inc</ParentCompany><Status id="PR">Pre-registration</Status><StatusDate>2013-01-10 00:00:00</StatusDate><StatusSortCode>11</StatusSortCode><TherapyArea id="746">Infectious disease</TherapyArea></Row><Row><Action id="12364">Live attenuated viral vaccine</Action><AuthorityGroup>OTHER</AuthorityGroup><Company id="23408">Sanofi Pasteur MSD</Company><Country id="ES">Spain</Country><Drug id="47279">ProQuad</Drug><EntityType>Biological</EntityType><HighestDevStatus id="L">Launched</HighestDevStatus><HighestDevStatusForInd id="L">Launched</HighestDevStatusForInd><Indication id="1">Measles virus infection</Indication><IsActiveCompany>true</IsActiveCompany><LatestChange>2013-01-10 00:00:00</LatestChange><ParentCompany id="18077">Merck &amp; Co Inc</ParentCompany><Status id="R">Registered</Status><StatusDate>2006-04-21 00:00:00</StatusDate><StatusSortCode>12</StatusSortCode><TherapyArea id="746">Infectious disease</TherapyArea></Row><Row><Action id="12375">Toxoid vaccine</Action><AuthorityGroup>OTHER</AuthorityGroup><Company id="23408">Sanofi Pasteur MSD</Company><Country id="IS">Iceland</Country><Drug id="47279">ProQuad</Drug><EntityType>Biological</EntityType><HighestDevStatus id="L">Launched</HighestDevStatus><HighestDevStatusForInd id="L">Launched</HighestDevStatusForInd><Indication id="1">Measles virus infection</Indication><IsActiveCompany>true</IsActiveCompany><LatestChange>2013-01-10 00:00:00</LatestChange><ParentCompany id="18077">Merck &amp; Co Inc</ParentCompany><Status id="R">Registered</Status><StatusDate>2006-04-25 00:00:00</StatusDate><StatusSortCode>12</StatusSortCode><TherapyArea id="746">Infectious disease</TherapyArea></Row><Row><Action id="12364">Live attenuated viral vaccine</Action><AuthorityGroup>OTHER</AuthorityGroup><Company id="23408">Sanofi Pasteur MSD</Company><Country id="EE">Estonia</Country><Drug id="47279">ProQuad</Drug><EntityType>Biological</EntityType><HighestDevStatus id="L">Launched</HighestDevStatus><HighestDevStatusForInd id="L">Launched</HighestDevStatusForInd><Indication id="1">Measles virus infection</Indication><IsActiveCompany>true</IsActiveCompany><LatestChange>2013-01-10 00:00:00</LatestChange><ParentCompany id="18077">Merck &amp; Co Inc</ParentCompany><Status id="R">Registered</Status><StatusDate>2006-04-10 00:00:00</StatusDate><StatusSortCode>12</StatusSortCode><TherapyArea id="746">Infectious disease</TherapyArea></Row><Row><Action id="12375">Toxoid vaccine</Action><AuthorityGroup>OTHER</AuthorityGroup><Company id="23408">Sanofi Pasteur MSD</Company><Country id="EE">Estonia</Country><Drug id="47279">ProQuad</Drug><EntityType>Biological</EntityType><HighestDevStatus id="L">Launched</HighestDevStatus><HighestDevStatusForInd id="L">Launched</HighestDevStatusForInd><Indication id="1">Measles virus infection</Indication><IsActiveCompany>true</IsActiveCompany><LatestChange>2013-01-10 00:00:00</LatestChange><ParentCompany id="18077">Merck &amp; Co Inc</ParentCompany><Status id="R">Registered</Status><StatusDate>2006-04-10 00:00:00</StatusDate><StatusSortCode>12</StatusSortCode><TherapyArea id="746">Infectious disease</TherapyArea></Row><Row><Action id="1596">Immunomodulator</Action><AuthorityGroup>LOCAL_AND_MAJOR</AuthorityGroup><Company id="1049660">Hualan Biological Engineering Inc</Company><Country id="CN">China</Country><Drug id="79232">human immunoglobulin (intramuscular, measles/hepatitis virus infection), Hualan Biological Engineering</Drug><EntityType>Biological</EntityType><HighestDevStatus id="L">Launched</HighestDevStatus><HighestDevStatusForInd id="L">Launched</HighestDevStatusForInd><Indication id="1">Measles virus infection</Indication><IsActiveCompany>true</IsActiveCompany><LatestChange>1997-12-31 00:00:00</LatestChange><ParentCompany id="1049660">Hualan Biological Engineering Inc</ParentCompany><Status id="R">Registered</Status><StatusDate>1997-12-31 00:00:00</StatusDate><StatusSortCode>12</StatusSortCode><TherapyArea id="746">Infectious disease</TherapyArea></Row><Row><Action id="1596">Immunomodulator</Action><AuthorityGroup>LOCAL_AND_MAJOR</AuthorityGroup><Company id="1049660">Hualan Biological Engineering Inc</Company><Country id="CN">China</Country><Drug id="79232">human immunoglobulin (intramuscular, measles/hepatitis virus infection), Hualan Biological Engineering</Drug><EntityType>Biological</EntityType><HighestDevStatus id="L">Launched</HighestDevStatus><HighestDevStatusForInd id="L">Launched</HighestDevStatusForInd><Indication id="1">Measles virus infection</Indication><IsActiveCompany>true</IsActiveCompany><LatestChange>1997-12-31 00:00:00</LatestChange><ParentCompany id="1049660">Hualan Biological Engineering Inc</ParentCompany><Status id="L">Launched</Status><StatusDate>1997-12-31 00:00:00</StatusDate><StatusSortCode>13</StatusSortCode><TherapyArea id="746">Infectious disease</TherapyArea></Row><Row><Action id="1594">Antibacterial</Action><AuthorityGroup>LOCAL_AND_MAJOR</AuthorityGroup><Company id="1061250">Lanzhou Institute of Biological Products</Company><Country id="CN">China</Country><Drug id="80205">human immunoglobulin (plasma-derived, intramuscular), Lanzhou Institute of Biological Products</Drug><EntityType>Biological</EntityType><HighestDevStatus id="L">Launched</HighestDevStatus><HighestDevStatusForInd id="L">Launched</HighestDevStatusForInd><Indication id="1">Measles virus infection</Indication><IsActiveCompany>true</IsActiveCompany><LatestChange>2002-12-31 00:00:00</LatestChange><ParentCompany id="1055632">Sinopharm</ParentCompany><Status id="L">Launched</Status><StatusDate>2002-12-31 00:00:00</StatusDate><StatusSortCode>13</StatusSortCode><TherapyArea id="746">Infectious disease</TherapyArea></Row><Row><Action id="12364">Live attenuated viral vaccine</Action><AuthorityGroup>LOCAL_AND_MAJOR</AuthorityGroup><Company id="1027662">Beijing Tiantan Biological Products Co Ltd</Company><Country id="CN">China</Country><Drug id="89450">measles/mumps/rubella/varicella vaccine (live-attenuated), Beijing Tiantan Biological Products</Drug><EntityType>Biological</EntityType><HighestDevStatus id="DR">Discovery</HighestDevStatus><HighestDevStatusForInd id="DR">Discovery</HighestDevStatusForInd><Indication id="1">Measles virus infection</Indication><IsActiveCompany>true</IsActiveCompany><LatestChange>2013-11-12 00:00:00</LatestChange><ParentCompany id="1055632">Sinopharm</ParentCompany><Status id="DR">Discovery</Status><StatusDate>2013-11-12 00:00:00</StatusDate><StatusSortCode>6</StatusSortCode><TherapyArea id="746">Infectious disease</TherapyArea></Row><Row><Action id="12378">Prophylactic vaccine</Action><AuthorityGroup>OTHER</AuthorityGroup><Company id="24166">GlaxoSmithKline Biologicals</Company><Country id="BE">Belgium</Country><Drug id="17141">Priorix-Tetra</Drug><EntityType>Biological</EntityType><HighestDevStatus id="L">Launched</HighestDevStatus><HighestDevStatusForInd id="L">Launched</HighestDevStatusForInd><Indication id="1">Measles virus infection</Indication><IsActiveCompany>false</IsActiveCompany><LatestChange>2008-01-10 00:00:00</LatestChange><ParentCompany id="28355">GlaxoSmithKline plc</ParentCompany><Status id="C3">Phase 3 Clinical</Status><StatusDate>1999-06-16 00:00:00</StatusDate><StatusSortCode>10</StatusSortCode><TherapyArea id="746">Infectious disease</TherapyArea></Row><Row><Action id="12378">Prophylactic vaccine</Action><AuthorityGroup>OTHER</AuthorityGroup><Company id="28355">GlaxoSmithKline plc</Company><Country id="DE">Germany</Country><Drug id="17141">Priorix-Tetra</Drug><EntityType>Biological</EntityType><HighestDevStatus id="L">Launched</HighestDevStatus><HighestDevStatusForInd id="L">Launched</HighestDevStatusForInd><Indication id="1">Measles virus infection</Indication><IsActiveCompany>true</IsActiveCompany><LatestChange>2008-01-10 00:00:00</LatestChange><ParentCompany id="28355">GlaxoSmithKline plc</ParentCompany><Status id="L">Launched</Status><StatusDate>2006-08-31 00:00:00</StatusDate><StatusSortCode>13</StatusSortCode><TherapyArea id="746">Infectious disease</TherapyArea></Row><Row><Action id="12378">Prophylactic vaccine</Action><AuthorityGroup>OTHER</AuthorityGroup><Company id="28355">GlaxoSmithKline plc</Company><Country id="LV">Latvia</Country><Drug id="17141">Priorix-Tetra</Drug><EntityType>Biological</EntityType><HighestDevStatus id="L">Launched</HighestDevStatus><HighestDevStatusForInd id="L">Launched</HighestDevStatusForInd><Indication id="1">Measles virus infection</Indication><IsActiveCompany>true</IsActiveCompany><LatestChange>2008-01-10 00:00:00</LatestChange><ParentCompany id="28355">GlaxoSmithKline plc</ParentCompany><Status id="R">Registered</Status><StatusDate>2007-12-05 00:00:00</StatusDate><StatusSortCode>12</StatusSortCode><TherapyArea id="746">Infectious disease</TherapyArea></Row><Row><Action id="12364">Live attenuated viral vaccine</Action><AuthorityGroup>OTHER</AuthorityGroup><Company id="28355">GlaxoSmithKline plc</Company><Country id="CZ">Czech Republic</Country><Drug id="17141">Priorix-Tetra</Drug><EntityType>Biological</EntityType><HighestDevStatus id="L">Launched</HighestDevStatus><HighestDevStatusForInd id="L">Launched</HighestDevStatusForInd><Indication id="1">Measles virus infection</Indication><IsActiveCompany>true</IsActiveCompany><LatestChange>2008-01-10 00:00:00</LatestChange><ParentCompany id="28355">GlaxoSmithKline plc</ParentCompany><Status id="R">Registered</Status><StatusDate>2007-08-08 00:00:00</StatusDate><StatusSortCode>12</StatusSortCode><TherapyArea id="746">Infectious disease</TherapyArea></Row><Row><Action id="12364">Live attenuated viral vaccine</Action><AuthorityGroup>OTHER</AuthorityGroup><Company id="24766">Crucell Switzerland AG</Company><Country id="CH">Switzerland</Country><Drug id="41069">second-generation MMR vaccine, Berna</Drug><EntityType>Biological</EntityType><HighestDevStatus id="NDR">No Development Reported</HighestDevStatus><HighestDevStatusForInd id="NDR">No Development Reported</HighestDevStatusForInd><Indication id="1">Measles virus infection</Indication><IsActiveCompany>false</IsActiveCompany><LatestChange>2006-03-28 00:00:00</LatestChange><ParentCompany id="17332">Johnson &amp; Johnson</ParentCompany><Status id="C2">Phase 2 Clinical</Status><StatusDate>2002-08-12 00:00:00</StatusDate><StatusSortCode>9</StatusSortCode><TherapyArea id="746">Infectious disease</TherapyArea></Row><Row><Action id="12378">Prophylactic vaccine</Action><AuthorityGroup>OTHER</AuthorityGroup><Company id="24244">Bavarian Nordic A/S</Company><Country id="ZA">South Africa</Country><Drug id="54328">MVA-mBN85B</Drug><EntityType>Biological</EntityType><HighestDevStatus id="NDR">No Development Reported</HighestDevStatus><HighestDevStatusForInd id="NDR">No Development Reported</HighestDevStatusForInd><Indication id="1">Measles virus infection</Indication><IsActiveCompany>false</IsActiveCompany><LatestChange>2011-11-29 00:00:00</LatestChange><ParentCompany id="24244">Bavarian Nordic A/S</ParentCompany><Status id="NDR">No Development Reported</Status><StatusDate>2011-11-29 00:00:00</StatusDate><StatusSortCode>2</StatusSortCode><TherapyArea id="746">Infectious disease</TherapyArea></Row><Row><Action id="12378">Prophylactic vaccine</Action><AuthorityGroup>LOCAL_AND_MAJOR</AuthorityGroup><Company id="24244">Bavarian Nordic A/S</Company><Country id="DK">Denmark</Country><Drug id="54328">MVA-mBN85B</Drug><EntityType>Biological</EntityType><HighestDevStatus id="NDR">No Development Reported</HighestDevStatus><HighestDevStatusForInd id="NDR">No Development Reported</HighestDevStatusForInd><Indication id="1">Measles virus infection</Indication><IsActiveCompany>false</IsActiveCompany><LatestChange>2011-11-29 00:00:00</LatestChange><ParentCompany id="24244">Bavarian Nordic A/S</ParentCompany><Status id="DR">Discovery</Status><StatusDate>2005-03-04 00:00:00</StatusDate><StatusSortCode>6</StatusSortCode><TherapyArea id="746">Infectious disease</TherapyArea></Row><Row><Action id="12370">Recombinant viral vector vaccine</Action><AuthorityGroup>OTHER</AuthorityGroup><Company id="24244">Bavarian Nordic A/S</Company><Country id="ZA">South Africa</Country><Drug id="54328">MVA-mBN85B</Drug><EntityType>Biological</EntityType><HighestDevStatus id="NDR">No Development Reported</HighestDevStatus><HighestDevStatusForInd id="NDR">No Development Reported</HighestDevStatusForInd><Indication id="1">Measles virus infection</Indication><IsActiveCompany>false</IsActiveCompany><LatestChange>2011-11-29 00:00:00</LatestChange><ParentCompany id="24244">Bavarian Nordic A/S</ParentCompany><Status id="C1">Phase 1 Clinical</Status><StatusDate>2007-11-06 00:00:00</StatusDate><StatusSortCode>8</StatusSortCode><TherapyArea id="746">Infectious disease</TherapyArea></Row><Row><Action id="12378">Prophylactic vaccine</Action><AuthorityGroup>OTHER</AuthorityGroup><Company id="1032149">Aktiv-Dry LLC</Company><Country id="IN">India</Country><Drug id="57263">measles vaccine (inhaled dry powder/CAN-BD), Aktiv-Dry</Drug><EntityType>Biological</EntityType><HighestDevStatus id="C1">Phase 1 Clinical</HighestDevStatus><HighestDevStatusForInd id="C1">Phase 1 Clinical</HighestDevStatusForInd><Indication id="1">Measles virus infection</Indication><IsActiveCompany>true</IsActiveCompany><LatestChange>2012-03-28 00:00:00</LatestChange><ParentCompany id="1032149">Aktiv-Dry LLC</ParentCompany><Status id="C1">Phase 1 Clinical</Status><StatusDate>2012-03-28 00:00:00</StatusDate><StatusSortCode>8</StatusSortCode><TherapyArea id="746">Infectious disease</TherapyArea></Row><Row><Action id="12378">Prophylactic vaccine</Action><AuthorityGroup>LOCAL_AND_MAJOR</AuthorityGroup><Company id="26857">Centers for Disease Control and Prevention</Company><Country id="US">US</Country><Drug id="72810">measles vaccine (microneedle patch formulation), Centers for Disease Control and Prevention</Drug><EntityType>Biological</EntityType><HighestDevStatus id="NDR">No Development Reported</HighestDevStatus><HighestDevStatusForInd id="NDR">No Development Reported</HighestDevStatusForInd><Indication id="1">Measles virus infection</Indication><IsActiveCompany>false</IsActiveCompany><LatestChange>2013-09-25 00:00:00</LatestChange><ParentCompany id="20516">US Government</ParentCompany><Status id="DR">Discovery</Status><StatusDate>2011-07-16 00:00:00</StatusDate><StatusSortCode>6</StatusSortCode><TherapyArea id="746">Infectious disease</TherapyArea></Row><Row><Action id="59620">Unspecified drug target</Action><AuthorityGroup>LOCAL_AND_MAJOR</AuthorityGroup><Company id="21028">Bulgarian Academy of Science</Company><Country id="BG">Bulgaria</Country><Drug id="7692">PAMPS</Drug><EntityType>Chemical</EntityType><HighestDevStatus id="NDR">No Development Reported</HighestDevStatus><HighestDevStatusForInd id="NDR">No Development Reported</HighestDevStatusForInd><Indication id="1">Measles virus infection</Indication><IsActiveCompany>false</IsActiveCompany><LatestChange>2008-01-24 00:00:00</LatestChange><ParentCompany id="21028">Bulgarian Academy of Science</ParentCompany><Status id="NDR">No Development Reported</Status><StatusDate>2008-01-24 00:00:00</StatusDate><StatusSortCode>2</StatusSortCode><TherapyArea id="746">Infectious disease</TherapyArea></Row><Row><Action id="12378">Prophylactic vaccine</Action><AuthorityGroup>LOCAL_AND_MAJOR</AuthorityGroup><Company id="1027662">Beijing Tiantan Biological Products Co Ltd</Company><Country id="CN">China</Country><Drug id="79155">measles/rubella vaccine (subcutaneous, live), Beijing Tiantan Biological Products</Drug><EntityType>Biological</EntityType><HighestDevStatus id="L">Launched</HighestDevStatus><HighestDevStatusForInd id="L">Launched</HighestDevStatusForInd><Indication id="1">Measles virus infection</Indication><IsActiveCompany>true</IsActiveCompany><LatestChange>2002-12-31 00:00:00</LatestChange><ParentCompany id="1055632">Sinopharm</ParentCompany><Status id="L">Launched</Status><StatusDate>2002-12-31 00:00:00</StatusDate><StatusSortCode>13</StatusSortCode><TherapyArea id="746">Infectious disease</TherapyArea></Row><Row><Action id="12378">Prophylactic vaccine</Action><AuthorityGroup>LOCAL_AND_MAJOR</AuthorityGroup><Company id="1061252">Wuhan Institute of Biological Products Co Ltd</Company><Country id="CN">China</Country><Drug id="80093">Wu Sheng Si Lin</Drug><EntityType>Biological</EntityType><HighestDevStatus id="L">Launched</HighestDevStatus><HighestDevStatusForInd id="L">Launched</HighestDevStatusForInd><Indication id="1">Measles virus infection</Indication><IsActiveCompany>true</IsActiveCompany><LatestChange>2003-12-31 00:00:00</LatestChange><ParentCompany id="1055632">Sinopharm</ParentCompany><Status id="R">Registered</Status><StatusDate>2003-12-31 00:00:00</StatusDate><StatusSortCode>12</StatusSortCode><TherapyArea id="746">Infectious disease</TherapyArea></Row><Row><Action id="12378">Prophylactic vaccine</Action><AuthorityGroup>LOCAL_AND_MAJOR</AuthorityGroup><Company id="1027662">Beijing Tiantan Biological Products Co Ltd</Company><Country id="CN">China</Country><Drug id="79144">measles/mumps/rubella vaccine (live-attenuated),  Beijing Tiantan Biological Products</Drug><EntityType>Biological</EntityType><HighestDevStatus id="L">Launched</HighestDevStatus><HighestDevStatusForInd id="L">Launched</HighestDevStatusForInd><Indication id="1">Measles virus infection</Indication><IsActiveCompany>true</IsActiveCompany><LatestChange>2002-12-31 00:00:00</LatestChange><ParentCompany id="1055632">Sinopharm</ParentCompany><Status id="L">Launched</Status><StatusDate>2002-12-31 00:00:00</StatusDate><StatusSortCode>13</StatusSortCode><TherapyArea id="746">Infectious disease</TherapyArea></Row><Row><Action id="12378">Prophylactic vaccine</Action><AuthorityGroup>LOCAL_AND_MAJOR</AuthorityGroup><Company id="1027662">Beijing Tiantan Biological Products Co Ltd</Company><Country id="CN">China</Country><Drug id="79144">measles/mumps/rubella vaccine (live-attenuated),  Beijing Tiantan Biological Products</Drug><EntityType>Biological</EntityType><HighestDevStatus id="L">Launched</HighestDevStatus><HighestDevStatusForInd id="L">Launched</HighestDevStatusForInd><Indication id="1">Measles virus infection</Indication><IsActiveCompany>true</IsActiveCompany><LatestChange>2002-12-31 00:00:00</LatestChange><ParentCompany id="1055632">Sinopharm</ParentCompany><Status id="R">Registered</Status><StatusDate>2002-12-31 00:00:00</StatusDate><StatusSortCode>12</StatusSortCode><TherapyArea id="746">Infectious disease</TherapyArea></Row><Row><Action id="2953">Anti-inflammatory</Action><AuthorityGroup>LOCAL_AND_MAJOR</AuthorityGroup><Company id="1061250">Lanzhou Institute of Biological Products</Company><Country id="CN">China</Country><Drug id="80208">human immunoglobulin (pH4, intravenous), Lanzhou Institute of Biological Products</Drug><EntityType>Biological</EntityType><HighestDevStatus id="L">Launched</HighestDevStatus><HighestDevStatusForInd id="L">Launched</HighestDevStatusForInd><Indication id="1">Measles virus infection</Indication><IsActiveCompany>true</IsActiveCompany><LatestChange>2004-12-31 00:00:00</LatestChange><ParentCompany id="1055632">Sinopharm</ParentCompany><Status id="L">Launched</Status><StatusDate>2004-12-31 00:00:00</StatusDate><StatusSortCode>13</StatusSortCode><TherapyArea id="746">Infectious disease</TherapyArea></Row><Row><Action id="991">Antiviral</Action><AuthorityGroup>LOCAL_AND_MAJOR</AuthorityGroup><Company id="1081842">Sichuan Yuanda Shuyang Pharmaceutical Co Ltd</Company><Country id="CN">China</Country><Drug id="84689">human immunoglobulin (intramuscular, measles/hepatitis virus infection), Sichuan Yuanda Shuyang Pharmaceutical</Drug><EntityType>Biological</EntityType><HighestDevStatus id="L">Launched</HighestDevStatus><HighestDevStatusForInd id="L">Launched</HighestDevStatusForInd><Indication id="1">Measles virus infection</Indication><IsActiveCompany>true</IsActiveCompany><LatestChange>1998-12-31 00:00:00</LatestChange><ParentCompany id="1081842">Sichuan Yuanda Shuyang Pharmaceutical Co Ltd</ParentCompany><Status id="R">Registered</Status><StatusDate>1998-12-31 00:00:00</StatusDate><StatusSortCode>12</StatusSortCode><TherapyArea id="746">Infectious disease</TherapyArea></Row><Row><Action id="1596">Immunomodulator</Action><AuthorityGroup>LOCAL_AND_MAJOR</AuthorityGroup><Company id="1077144">Hebei Da'an Pharmaceutical Co Ltd</Company><Country id="CN">China</Country><Drug id="82763">human immunoglobulin (intramuscular, measles/hepatitis virus infection), Hebei Da'an Pharmaceutical</Drug><EntityType>Biological</EntityType><HighestDevStatus id="R">Registered</HighestDevStatus><HighestDevStatusForInd id="R">Registered</HighestDevStatusForInd><Indication id="1">Measles virus infection</Indication><IsActiveCompany>true</IsActiveCompany><LatestChange>2013-10-25 00:00:00</LatestChange><ParentCompany id="1077144">Hebei Da'an Pharmaceutical Co Ltd</ParentCompany><Status id="R">Registered</Status><StatusDate>2013-10-25 00:00:00</StatusDate><StatusSortCode>12</StatusSortCode><TherapyArea id="746">Infectious disease</TherapyArea></Row><Row><Action id="991">Antiviral</Action><AuthorityGroup>LOCAL_AND_MAJOR</AuthorityGroup><Company id="1077144">Hebei Da'an Pharmaceutical Co Ltd</Company><Country id="CN">China</Country><Drug id="82763">human immunoglobulin (intramuscular, measles/hepatitis virus infection), Hebei Da'an Pharmaceutical</Drug><EntityType>Biological</EntityType><HighestDevStatus id="R">Registered</HighestDevStatus><HighestDevStatusForInd id="R">Registered</HighestDevStatusForInd><Indication id="1">Measles virus infection</Indication><IsActiveCompany>true</IsActiveCompany><LatestChange>2013-10-25 00:00:00</LatestChange><ParentCompany id="1077144">Hebei Da'an Pharmaceutical Co Ltd</ParentCompany><Status id="W">Withdrawn</Status><StatusDate>2012-08-03 00:00:00</StatusDate><StatusSortCode>4</StatusSortCode><TherapyArea id="746">Infectious disease</TherapyArea></Row><Row><Action id="991">Antiviral</Action><AuthorityGroup>LOCAL_AND_MAJOR</AuthorityGroup><Company id="1079335">Guangdong Weilun Biological Products Co Ltd</Company><Country id="CN">China</Country><Drug id="84826">human immunoglobulin (intramuscular, measles/hepatitis virus infection), Guangdong Weilun Biological Products</Drug><EntityType>Biological</EntityType><HighestDevStatus id="L">Launched</HighestDevStatus><HighestDevStatusForInd id="L">Launched</HighestDevStatusForInd><Indication id="1">Measles virus infection</Indication><IsActiveCompany>true</IsActiveCompany><LatestChange>2000-12-31 00:00:00</LatestChange><ParentCompany id="1079335">Guangdong Weilun Biological Products Co Ltd</ParentCompany><Status id="L">Launched</Status><StatusDate>2000-12-31 00:00:00</StatusDate><StatusSortCode>13</StatusSortCode><TherapyArea id="746">Infectious disease</TherapyArea></Row><Row><Action id="393">Immunostimulant</Action><AuthorityGroup>LOCAL_AND_MAJOR</AuthorityGroup><Company id="1079335">Guangdong Weilun Biological Products Co Ltd</Company><Country id="CN">China</Country><Drug id="84826">human immunoglobulin (intramuscular, measles/hepatitis virus infection), Guangdong Weilun Biological Products</Drug><EntityType>Biological</EntityType><HighestDevStatus id="L">Launched</HighestDevStatus><HighestDevStatusForInd id="L">Launched</HighestDevStatusForInd><Indication id="1">Measles virus infection</Indication><IsActiveCompany>true</IsActiveCompany><LatestChange>2000-12-31 00:00:00</LatestChange><ParentCompany id="1079335">Guangdong Weilun Biological Products Co Ltd</ParentCompany><Status id="L">Launched</Status><StatusDate>2000-12-31 00:00:00</StatusDate><StatusSortCode>13</StatusSortCode><TherapyArea id="746">Infectious disease</TherapyArea></Row><Row><Action id="2953">Anti-inflammatory</Action><AuthorityGroup>LOCAL_AND_MAJOR</AuthorityGroup><Company id="1079335">Guangdong Weilun Biological Products Co Ltd</Company><Country id="CN">China</Country><Drug id="84826">human immunoglobulin (intramuscular, measles/hepatitis virus infection), Guangdong Weilun Biological Products</Drug><EntityType>Biological</EntityType><HighestDevStatus id="L">Launched</HighestDevStatus><HighestDevStatusForInd id="L">Launched</HighestDevStatusForInd><Indication id="1">Measles virus infection</Indication><IsActiveCompany>true</IsActiveCompany><LatestChange>2000-12-31 00:00:00</LatestChange><ParentCompany id="1079335">Guangdong Weilun Biological Products Co Ltd</ParentCompany><Status id="L">Launched</Status><StatusDate>2000-12-31 00:00:00</StatusDate><StatusSortCode>13</StatusSortCode><TherapyArea id="746">Infectious disease</TherapyArea></Row><Row><Action id="991">Antiviral</Action><AuthorityGroup>LOCAL_AND_MAJOR</AuthorityGroup><Company id="1087965">Guizhou Taibang Biological Products Co Ltd</Company><Country id="CN">China</Country><Drug id="87540">human immunoglobulin (intramuscular, measles/hepatitis virus infection), Guizhou Taibang Biological Products</Drug><EntityType>Biological</EntityType><HighestDevStatus id="L">Launched</HighestDevStatus><HighestDevStatusForInd id="L">Launched</HighestDevStatusForInd><Indication id="1">Measles virus infection</Indication><IsActiveCompany>true</IsActiveCompany><LatestChange>2000-12-31 00:00:00</LatestChange><ParentCompany id="1041423">China Biologic Products Inc</ParentCompany><Status id="L">Launched</Status><StatusDate>2000-12-31 00:00:00</StatusDate><StatusSortCode>13</StatusSortCode><TherapyArea id="746">Infectious disease</TherapyArea></Row><Row><Action id="991">Antiviral</Action><AuthorityGroup>LOCAL_AND_MAJOR</AuthorityGroup><Company id="1076477">Banghe Pharmaceutical Co Ltd</Company><Country id="CN">China</Country><Drug id="85214">human immunoglobulin (intramuscular, measles/hepatitis virus infection), Banghe Pharmaceutical</Drug><EntityType>Biological</EntityType><HighestDevStatus id="L">Launched</HighestDevStatus><HighestDevStatusForInd id="L">Launched</HighestDevStatusForInd><Indication id="1">Measles virus infection</Indication><IsActiveCompany>true</IsActiveCompany><LatestChange>2002-12-31 00:00:00</LatestChange><ParentCompany id="1076477">Banghe Pharmaceutical Co Ltd</ParentCompany><Status id="R">Registered</Status><StatusDate>2002-12-31 00:00:00</StatusDate><StatusSortCode>12</StatusSortCode><TherapyArea id="746">Infectious disease</TherapyArea></Row><Row><Action id="12378">Prophylactic vaccine</Action><AuthorityGroup>LOCAL_AND_MAJOR</AuthorityGroup><Company id="1059311">Bio-Manguinhos/Fiocruz</Company><Country id="BR">Brazil</Country><Drug id="94952">MMR vaccine, Bio-Manguinhos/Fiocruz</Drug><EntityType>Biological</EntityType><HighestDevStatus id="C3">Phase 3 Clinical</HighestDevStatus><HighestDevStatusForInd id="C3">Phase 3 Clinical</HighestDevStatusForInd><Indication id="1">Measles virus infection</Indication><IsActiveCompany>true</IsActiveCompany><LatestChange>2015-04-13 00:00:00</LatestChange><ParentCompany id="16154">Fundacao Oswaldo Cruz (Fiocruz)</ParentCompany><Status id="DR">Discovery</Status><StatusDate>2014-08-08 00:00:00</StatusDate><StatusSortCode>6</StatusSortCode><TherapyArea id="746">Infectious disease</TherapyArea></Row><Row><Action id="12364">Live attenuated viral vaccine</Action><AuthorityGroup>LOCAL_AND_MAJOR</AuthorityGroup><Company id="19962">SmithKline Beecham plc</Company><Country id="GB">UK</Country><Drug id="11457">Priorix</Drug><EntityType>Biological</EntityType><HighestDevStatus id="L">Launched</HighestDevStatus><HighestDevStatusForInd id="L">Launched</HighestDevStatusForInd><Indication id="1">Measles virus infection</Indication><IsActiveCompany>true</IsActiveCompany><LatestChange>2012-06-29 00:00:00</LatestChange><ParentCompany id="28355">GlaxoSmithKline plc</ParentCompany><Status id="R">Registered</Status><StatusDate>1998-03-25 00:00:00</StatusDate><StatusSortCode>12</StatusSortCode><TherapyArea id="746">Infectious disease</TherapyArea></Row><Row><Action id="12364">Live attenuated viral vaccine</Action><AuthorityGroup>OTHER</AuthorityGroup><Company id="19962">SmithKline Beecham plc</Company><Country id="ES">Spain</Country><Drug id="11457">Priorix</Drug><EntityType>Biological</EntityType><HighestDevStatus id="L">Launched</HighestDevStatus><HighestDevStatusForInd id="L">Launched</HighestDevStatusForInd><Indication id="1">Measles virus infection</Indication><IsActiveCompany>true</IsActiveCompany><LatestChange>2012-06-29 00:00:00</LatestChange><ParentCompany id="28355">GlaxoSmithKline plc</ParentCompany><Status id="R">Registered</Status><StatusDate>1999-03-01 00:00:00</StatusDate><StatusSortCode>12</StatusSortCode><TherapyArea id="746">Infectious disease</TherapyArea></Row><Row><Action id="12378">Prophylactic vaccine</Action><AuthorityGroup>OTHER</AuthorityGroup><Company id="19962">SmithKline Beecham plc</Company><Country id="CN">China</Country><Drug id="11457">Priorix</Drug><EntityType>Biological</EntityType><HighestDevStatus id="L">Launched</HighestDevStatus><HighestDevStatusForInd id="L">Launched</HighestDevStatusForInd><Indication id="1">Measles virus infection</Indication><IsActiveCompany>true</IsActiveCompany><LatestChange>2012-06-29 00:00:00</LatestChange><ParentCompany id="28355">GlaxoSmithKline plc</ParentCompany><Status id="L">Launched</Status><StatusDate>1998-12-31 00:00:00</StatusDate><StatusSortCode>13</StatusSortCode><TherapyArea id="746">Infectious disease</TherapyArea></Row><Row><Action id="12364">Live attenuated viral vaccine</Action><AuthorityGroup>OTHER</AuthorityGroup><Company id="28355">GlaxoSmithKline plc</Company><Country id="IS">Iceland</Country><Drug id="11457">Priorix</Drug><EntityType>Biological</EntityType><HighestDevStatus id="L">Launched</HighestDevStatus><HighestDevStatusForInd id="L">Launched</HighestDevStatusForInd><Indication id="1">Measles virus infection</Indication><IsActiveCompany>true</IsActiveCompany><LatestChange>2012-06-29 00:00:00</LatestChange><ParentCompany id="28355">GlaxoSmithKline plc</ParentCompany><Status id="R">Registered</Status><StatusDate>1998-10-07 00:00:00</StatusDate><StatusSortCode>12</StatusSortCode><TherapyArea id="746">Infectious disease</TherapyArea></Row><Row><Action id="12378">Prophylactic vaccine</Action><AuthorityGroup>OTHER</AuthorityGroup><Company id="28355">GlaxoSmithKline plc</Company><Country id="IS">Iceland</Country><Drug id="11457">Priorix</Drug><EntityType>Biological</EntityType><HighestDevStatus id="L">Launched</HighestDevStatus><HighestDevStatusForInd id="L">Launched</HighestDevStatusForInd><Indication id="1">Measles virus infection</Indication><IsActiveCompany>true</IsActiveCompany><LatestChange>2012-06-29 00:00:00</LatestChange><ParentCompany id="28355">GlaxoSmithKline plc</ParentCompany><Status id="R">Registered</Status><StatusDate>1998-10-07 00:00:00</StatusDate><StatusSortCode>12</StatusSortCode><TherapyArea id="746">Infectious disease</TherapyArea></Row><Row><Action id="12378">Prophylactic vaccine</Action><AuthorityGroup>OTHER</AuthorityGroup><Company id="28355">GlaxoSmithKline plc</Company><Country id="TW">Taiwan</Country><Drug id="11457">Priorix</Drug><EntityType>Biological</EntityType><HighestDevStatus id="L">Launched</HighestDevStatus><HighestDevStatusForInd id="L">Launched</HighestDevStatusForInd><Indication id="1">Measles virus infection</Indication><IsActiveCompany>true</IsActiveCompany><LatestChange>2012-06-29 00:00:00</LatestChange><ParentCompany id="28355">GlaxoSmithKline plc</ParentCompany><Status id="R">Registered</Status><StatusDate>1998-12-04 00:00:00</StatusDate><StatusSortCode>12</StatusSortCode><TherapyArea id="746">Infectious disease</TherapyArea></Row><Row><Action id="12378">Prophylactic vaccine</Action><AuthorityGroup>OTHER</AuthorityGroup><Company id="28355">GlaxoSmithKline plc</Company><Country id="LV">Latvia</Country><Drug id="11457">Priorix</Drug><EntityType>Biological</EntityType><HighestDevStatus id="L">Launched</HighestDevStatus><HighestDevStatusForInd id="L">Launched</HighestDevStatusForInd><Indication id="1">Measles virus infection</Indication><IsActiveCompany>true</IsActiveCompany><LatestChange>2012-06-29 00:00:00</LatestChange><ParentCompany id="28355">GlaxoSmithKline plc</ParentCompany><Status id="R">Registered</Status><StatusDate>1999-09-08 00:00:00</StatusDate><StatusSortCode>12</StatusSortCode><TherapyArea id="746">Infectious disease</TherapyArea></Row><Row><Action id="12378">Prophylactic vaccine</Action><AuthorityGroup>OTHER</AuthorityGroup><Company id="28355">GlaxoSmithKline plc</Company><Country id="KR">South Korea</Country><Drug id="11457">Priorix</Drug><EntityType>Biological</EntityType><HighestDevStatus id="L">Launched</HighestDevStatus><HighestDevStatusForInd id="L">Launched</HighestDevStatusForInd><Indication id="1">Measles virus infection</Indication><IsActiveCompany>true</IsActiveCompany><LatestChange>2012-06-29 00:00:00</LatestChange><ParentCompany id="28355">GlaxoSmithKline plc</ParentCompany><Status id="C3">Phase 3 Clinical</Status><StatusDate>2012-06-29 00:00:00</StatusDate><StatusSortCode>10</StatusSortCode><TherapyArea id="746">Infectious disease</TherapyArea></Row><Row><Action id="12378">Prophylactic vaccine</Action><AuthorityGroup>LOCAL_AND_MAJOR</AuthorityGroup><Company id="28355">GlaxoSmithKline plc</Company><Country id="US">US</Country><Drug id="11457">Priorix</Drug><EntityType>Biological</EntityType><HighestDevStatus id="L">Launched</HighestDevStatus><HighestDevStatusForInd id="L">Launched</HighestDevStatusForInd><Indication id="1">Measles virus infection</Indication><IsActiveCompany>true</IsActiveCompany><LatestChange>2012-06-29 00:00:00</LatestChange><ParentCompany id="28355">GlaxoSmithKline plc</ParentCompany><Status id="C3">Phase 3 Clinical</Status><StatusDate>2012-06-29 00:00:00</StatusDate><StatusSortCode>10</StatusSortCode><TherapyArea id="746">Infectious disease</TherapyArea></Row><Row><Action id="12364">Live attenuated viral vaccine</Action><AuthorityGroup>OTHER</AuthorityGroup><Company id="28355">GlaxoSmithKline plc</Company><Country id="TW">Taiwan</Country><Drug id="11457">Priorix</Drug><EntityType>Biological</EntityType><HighestDevStatus id="L">Launched</HighestDevStatus><HighestDevStatusForInd id="L">Launched</HighestDevStatusForInd><Indication id="1">Measles virus infection</Indication><IsActiveCompany>true</IsActiveCompany><LatestChange>2012-06-29 00:00:00</LatestChange><ParentCompany id="28355">GlaxoSmithKline plc</ParentCompany><Status id="L">Launched</Status><StatusDate>1998-12-31 00:00:00</StatusDate><StatusSortCode>13</StatusSortCode><TherapyArea id="746">Infectious disease</TherapyArea></Row><Row><Action id="1532">Viral replication inhibitor</Action><AuthorityGroup>LOCAL_AND_MAJOR</AuthorityGroup><Company id="1051158">Goff Hill Ltd</Company><Country id="CA">Canada</Country><Drug id="65451">antiviral therapeutics (viral infections/measles/multiple sclerosis), Goff Hill</Drug><EntityType>Chemical</EntityType><HighestDevStatus id="CU">Clinical</HighestDevStatus><HighestDevStatusForInd id="CU">Clinical</HighestDevStatusForInd><Indication id="1">Measles virus infection</Indication><IsActiveCompany>true</IsActiveCompany><LatestChange>2014-11-06 00:00:00</LatestChange><ParentCompany id="1051158">Goff Hill Ltd</ParentCompany><Status id="DR">Discovery</Status><StatusDate>2008-06-02 00:00:00</StatusDate><StatusSortCode>6</StatusSortCode><TherapyArea id="746">Infectious disease</TherapyArea></Row><Row><Action id="59620">Unspecified drug target</Action><AuthorityGroup>LOCAL_AND_MAJOR</AuthorityGroup><Company id="1051158">Goff Hill Ltd</Company><Country id="CA">Canada</Country><Drug id="65451">antiviral therapeutics (viral infections/measles/multiple sclerosis), Goff Hill</Drug><EntityType>Chemical</EntityType><HighestDevStatus id="CU">Clinical</HighestDevStatus><HighestDevStatusForInd id="CU">Clinical</HighestDevStatusForInd><Indication id="1">Measles virus infection</Indication><IsActiveCompany>true</IsActiveCompany><LatestChange>2014-11-06 00:00:00</LatestChange><ParentCompany id="1051158">Goff Hill Ltd</ParentCompany><Status id="CU">Clinical</Status><StatusDate>2010-01-27 00:00:00</StatusDate><StatusSortCode>7</StatusSortCode><TherapyArea id="746">Infectious disease</TherapyArea></Row><Row><Action id="12378">Prophylactic vaccine</Action><AuthorityGroup>OTHER</AuthorityGroup><Company id="1078819">Sevapharma Inc</Company><Country id="TH">Thailand</Country><Drug id="83793">Trivivac</Drug><EntityType>Biological</EntityType><HighestDevStatus id="C3">Phase 3 Clinical</HighestDevStatus><HighestDevStatusForInd id="C3">Phase 3 Clinical</HighestDevStatusForInd><Indication id="1">Measles virus infection</Indication><IsActiveCompany>true</IsActiveCompany><LatestChange>2012-09-30 00:00:00</LatestChange><ParentCompany id="1078819">Sevapharma Inc</ParentCompany><Status id="C3">Phase 3 Clinical</Status><StatusDate>2012-09-30 00:00:00</StatusDate><StatusSortCode>10</StatusSortCode><TherapyArea id="746">Infectious disease</TherapyArea></Row><Row><Action id="12364">Live attenuated viral vaccine</Action><AuthorityGroup>LOCAL_AND_MAJOR</AuthorityGroup><Company id="15374">Kaketsuken</Company><Country id="JP">Japan</Country><Drug id="3643">MMR vaccine, Merck &amp; Co</Drug><EntityType>Biological</EntityType><HighestDevStatus id="L">Launched</HighestDevStatus><HighestDevStatusForInd id="L">Launched</HighestDevStatusForInd><Indication id="1">Measles virus infection</Indication><IsActiveCompany>true</IsActiveCompany><LatestChange>2013-05-07 00:00:00</LatestChange><ParentCompany id="15374">Kaketsuken</ParentCompany><Status id="PR">Pre-registration</Status><StatusDate>2013-05-07 00:00:00</StatusDate><StatusSortCode>11</StatusSortCode><TherapyArea id="746">Infectious disease</TherapyArea></Row><Row><Action id="12364">Live attenuated viral vaccine</Action><AuthorityGroup>OTHER</AuthorityGroup><Company id="18077">Merck &amp; Co Inc</Company><Country id="TW">Taiwan</Country><Drug id="3643">MMR vaccine, Merck &amp; Co</Drug><EntityType>Biological</EntityType><HighestDevStatus id="L">Launched</HighestDevStatus><HighestDevStatusForInd id="L">Launched</HighestDevStatusForInd><Indication id="1">Measles virus infection</Indication><IsActiveCompany>true</IsActiveCompany><LatestChange>2013-05-07 00:00:00</LatestChange><ParentCompany id="18077">Merck &amp; Co Inc</ParentCompany><Status id="L">Launched</Status><StatusDate>1982-12-31 00:00:00</StatusDate><StatusSortCode>13</StatusSortCode><TherapyArea id="746">Infectious disease</TherapyArea></Row><Row><Action id="12364">Live attenuated viral vaccine</Action><AuthorityGroup>LOCAL_AND_MAJOR</AuthorityGroup><Company id="18077">Merck &amp; Co Inc</Company><Country id="US">US</Country><Drug id="47279">ProQuad</Drug><EntityType>Biological</EntityType><HighestDevStatus id="L">Launched</HighestDevStatus><HighestDevStatusForInd id="L">Launched</HighestDevStatusForInd><Indication id="1">Measles virus infection</Indication><IsActiveCompany>true</IsActiveCompany><LatestChange>2013-01-10 00:00:00</LatestChange><ParentCompany id="18077">Merck &amp; Co Inc</ParentCompany><Status id="PR">Pre-registration</Status><StatusDate>2004-08-31 00:00:00</StatusDate><StatusSortCode>11</StatusSortCode><TherapyArea id="746">Infectious disease</TherapyArea></Row><Row><Action id="12364">Live attenuated viral vaccine</Action><AuthorityGroup>LOCAL_AND_MAJOR</AuthorityGroup><Company id="18077">Merck &amp; Co Inc</Company><Country id="US">US</Country><Drug id="47279">ProQuad</Drug><EntityType>Biological</EntityType><HighestDevStatus id="L">Launched</HighestDevStatus><HighestDevStatusForInd id="L">Launched</HighestDevStatusForInd><Indication id="1">Measles virus infection</Indication><IsActiveCompany>true</IsActiveCompany><LatestChange>2013-01-10 00:00:00</LatestChange><ParentCompany id="18077">Merck &amp; Co Inc</ParentCompany><Status id="C2">Phase 2 Clinical</Status><StatusDate>1986-12-31 00:00:00</StatusDate><StatusSortCode>9</StatusSortCode><TherapyArea id="746">Infectious disease</TherapyArea></Row><Row><Action id="12375">Toxoid vaccine</Action><AuthorityGroup>LOCAL_AND_MAJOR</AuthorityGroup><Company id="18077">Merck &amp; Co Inc</Company><Country id="US">US</Country><Drug id="47279">ProQuad</Drug><EntityType>Biological</EntityType><HighestDevStatus id="L">Launched</HighestDevStatus><HighestDevStatusForInd id="L">Launched</HighestDevStatusForInd><Indication id="1">Measles virus infection</Indication><IsActiveCompany>true</IsActiveCompany><LatestChange>2013-01-10 00:00:00</LatestChange><ParentCompany id="18077">Merck &amp; Co Inc</ParentCompany><Status id="C2">Phase 2 Clinical</Status><StatusDate>1986-12-31 00:00:00</StatusDate><StatusSortCode>9</StatusSortCode><TherapyArea id="746">Infectious disease</TherapyArea></Row><Row><Action id="12364">Live attenuated viral vaccine</Action><AuthorityGroup>OTHER</AuthorityGroup><Company id="18077">Merck &amp; Co Inc</Company><Country id="KR">South Korea</Country><Drug id="47279">ProQuad</Drug><EntityType>Biological</EntityType><HighestDevStatus id="L">Launched</HighestDevStatus><HighestDevStatusForInd id="L">Launched</HighestDevStatusForInd><Indication id="1">Measles virus infection</Indication><IsActiveCompany>true</IsActiveCompany><LatestChange>2013-01-10 00:00:00</LatestChange><ParentCompany id="18077">Merck &amp; Co Inc</ParentCompany><Status id="L">Launched</Status><StatusDate>2008-02-01 00:00:00</StatusDate><StatusSortCode>13</StatusSortCode><TherapyArea id="746">Infectious disease</TherapyArea></Row><Row><Action id="12364">Live attenuated viral vaccine</Action><AuthorityGroup>LOCAL_AND_MAJOR</AuthorityGroup><Company id="23408">Sanofi Pasteur MSD</Company><Country id="XW">Western Europe</Country><Drug id="47279">ProQuad</Drug><EntityType>Biological</EntityType><HighestDevStatus id="L">Launched</HighestDevStatus><HighestDevStatusForInd id="L">Launched</HighestDevStatusForInd><Indication id="1">Measles virus infection</Indication><IsActiveCompany>true</IsActiveCompany><LatestChange>2013-01-10 00:00:00</LatestChange><ParentCompany id="18077">Merck &amp; Co Inc</ParentCompany><Status id="PR">Pre-registration</Status><StatusDate>2004-10-18 00:00:00</StatusDate><StatusSortCode>11</StatusSortCode><TherapyArea id="746">Infectious disease</TherapyArea></Row><Row><Action id="12364">Live attenuated viral vaccine</Action><AuthorityGroup>OTHER</AuthorityGroup><Company id="23408">Sanofi Pasteur MSD</Company><Country id="BE">Belgium</Country><Drug id="47279">ProQuad</Drug><EntityType>Biological</EntityType><HighestDevStatus id="L">Launched</HighestDevStatus><HighestDevStatusForInd id="L">Launched</HighestDevStatusForInd><Indication id="1">Measles virus infection</Indication><IsActiveCompany>true</IsActiveCompany><LatestChange>2013-01-10 00:00:00</LatestChange><ParentCompany id="18077">Merck &amp; Co Inc</ParentCompany><Status id="R">Registered</Status><StatusDate>2006-04-05 00:00:00</StatusDate><StatusSortCode>12</StatusSortCode><TherapyArea id="746">Infectious disease</TherapyArea></Row><Row><Action id="12375">Toxoid vaccine</Action><AuthorityGroup>OTHER</AuthorityGroup><Company id="23408">Sanofi Pasteur MSD</Company><Country id="ES">Spain</Country><Drug id="47279">ProQuad</Drug><EntityType>Biological</EntityType><HighestDevStatus id="L">Launched</HighestDevStatus><HighestDevStatusForInd id="L">Launched</HighestDevStatusForInd><Indication id="1">Measles virus infection</Indication><IsActiveCompany>true</IsActiveCompany><LatestChange>2013-01-10 00:00:00</LatestChange><ParentCompany id="18077">Merck &amp; Co Inc</ParentCompany><Status id="R">Registered</Status><StatusDate>2006-04-21 00:00:00</StatusDate><StatusSortCode>12</StatusSortCode><TherapyArea id="746">Infectious disease</TherapyArea></Row><Row><Action id="12364">Live attenuated viral vaccine</Action><AuthorityGroup>OTHER</AuthorityGroup><Company id="23408">Sanofi Pasteur MSD</Company><Country id="CZ">Czech Republic</Country><Drug id="47279">ProQuad</Drug><EntityType>Biological</EntityType><HighestDevStatus id="L">Launched</HighestDevStatus><HighestDevStatusForInd id="L">Launched</HighestDevStatusForInd><Indication id="1">Measles virus infection</Indication><IsActiveCompany>true</IsActiveCompany><LatestChange>2013-01-10 00:00:00</LatestChange><ParentCompany id="18077">Merck &amp; Co Inc</ParentCompany><Status id="R">Registered</Status><StatusDate>2006-04-06 00:00:00</StatusDate><StatusSortCode>12</StatusSortCode><TherapyArea id="746">Infectious disease</TherapyArea></Row><Row><Action id="12375">Toxoid vaccine</Action><AuthorityGroup>OTHER</AuthorityGroup><Company id="23408">Sanofi Pasteur MSD</Company><Country id="CZ">Czech Republic</Country><Drug id="47279">ProQuad</Drug><EntityType>Biological</EntityType><HighestDevStatus id="L">Launched</HighestDevStatus><HighestDevStatusForInd id="L">Launched</HighestDevStatusForInd><Indication id="1">Measles virus infection</Indication><IsActiveCompany>true</IsActiveCompany><LatestChange>2013-01-10 00:00:00</LatestChange><ParentCompany id="18077">Merck &amp; Co Inc</ParentCompany><Status id="R">Registered</Status><StatusDate>2006-04-06 00:00:00</StatusDate><StatusSortCode>12</StatusSortCode><TherapyArea id="746">Infectious disease</TherapyArea></Row><Row><Action id="12375">Toxoid vaccine</Action><AuthorityGroup>OTHER</AuthorityGroup><Company id="23408">Sanofi Pasteur MSD</Company><Country id="FR">France</Country><Drug id="47279">ProQuad</Drug><EntityType>Biological</EntityType><HighestDevStatus id="L">Launched</HighestDevStatus><HighestDevStatusForInd id="L">Launched</HighestDevStatusForInd><Indication id="1">Measles virus infection</Indication><IsActiveCompany>true</IsActiveCompany><LatestChange>2013-01-10 00:00:00</LatestChange><ParentCompany id="18077">Merck &amp; Co Inc</ParentCompany><Status id="R">Registered</Status><StatusDate>2006-04-06 00:00:00</StatusDate><StatusSortCode>12</StatusSortCode><TherapyArea id="746">Infectious disease</TherapyArea></Row><Row><Action id="12378">Prophylactic vaccine</Action><AuthorityGroup>OTHER</AuthorityGroup><Company id="23408">Sanofi Pasteur MSD</Company><Country id="FR">France</Country><Drug id="47279">ProQuad</Drug><EntityType>Biological</EntityType><HighestDevStatus id="L">Launched</HighestDevStatus><HighestDevStatusForInd id="L">Launched</HighestDevStatusForInd><Indication id="1">Measles virus infection</Indication><IsActiveCompany>true</IsActiveCompany><LatestChange>2013-01-10 00:00:00</LatestChange><ParentCompany id="18077">Merck &amp; Co Inc</ParentCompany><Status id="R">Registered</Status><StatusDate>2006-04-06 00:00:00</StatusDate><StatusSortCode>12</StatusSortCode><TherapyArea id="746">Infectious disease</TherapyArea></Row><Row><Action id="12364">Live attenuated viral vaccine</Action><AuthorityGroup>OTHER</AuthorityGroup><Company id="23408">Sanofi Pasteur MSD</Company><Country id="IS">Iceland</Country><Drug id="47279">ProQuad</Drug><EntityType>Biological</EntityType><HighestDevStatus id="L">Launched</HighestDevStatus><HighestDevStatusForInd id="L">Launched</HighestDevStatusForInd><Indication id="1">Measles virus infection</Indication><IsActiveCompany>true</IsActiveCompany><LatestChange>2013-01-10 00:00:00</LatestChange><ParentCompany id="18077">Merck &amp; Co Inc</ParentCompany><Status id="R">Registered</Status><StatusDate>2006-04-25 00:00:00</StatusDate><StatusSortCode>12</StatusSortCode><TherapyArea id="746">Infectious disease</TherapyArea></Row><Row><Action id="12364">Live attenuated viral vaccine</Action><AuthorityGroup>OTHER</AuthorityGroup><Company id="23408">Sanofi Pasteur MSD</Company><Country id="NL">Netherlands</Country><Drug id="47279">ProQuad</Drug><EntityType>Biological</EntityType><HighestDevStatus id="L">Launched</HighestDevStatus><HighestDevStatusForInd id="L">Launched</HighestDevStatusForInd><Indication id="1">Measles virus infection</Indication><IsActiveCompany>true</IsActiveCompany><LatestChange>2013-01-10 00:00:00</LatestChange><ParentCompany id="18077">Merck &amp; Co Inc</ParentCompany><Status id="R">Registered</Status><StatusDate>2006-04-06 00:00:00</StatusDate><StatusSortCode>12</StatusSortCode><TherapyArea id="746">Infectious disease</TherapyArea></Row><Row><Action id="59620">Unspecified drug target</Action><AuthorityGroup>LOCAL_AND_MAJOR</AuthorityGroup><Company id="1049660">Hualan Biological Engineering Inc</Company><Country id="CN">China</Country><Drug id="79232">human immunoglobulin (intramuscular, measles/hepatitis virus infection), Hualan Biological Engineering</Drug><EntityType>Biological</EntityType><HighestDevStatus id="L">Launched</HighestDevStatus><HighestDevStatusForInd id="L">Launched</HighestDevStatusForInd><Indication id="1">Measles virus infection</Indication><IsActiveCompany>true</IsActiveCompany><LatestChange>1997-12-31 00:00:00</LatestChange><ParentCompany id="1049660">Hualan Biological Engineering Inc</ParentCompany><Status id="L">Launched</Status><StatusDate>1997-12-31 00:00:00</StatusDate><StatusSortCode>13</StatusSortCode><TherapyArea id="746">Infectious disease</TherapyArea></Row><Row><Action id="991">Antiviral</Action><AuthorityGroup>LOCAL_AND_MAJOR</AuthorityGroup><Company id="1041544">Shenzhen Weiwu Guangming Biological Products Co Ltd</Company><Country id="CN">China</Country><Drug id="84800">human immunoglobulin (intramuscular, measles/hepatitis virus infection), Shenzhen Weiwu Guangming Biological Products</Drug><EntityType>Biological</EntityType><HighestDevStatus id="L">Launched</HighestDevStatus><HighestDevStatusForInd id="L">Launched</HighestDevStatusForInd><Indication id="1">Measles virus infection</Indication><IsActiveCompany>true</IsActiveCompany><LatestChange>1999-12-31 00:00:00</LatestChange><ParentCompany id="1041544">Shenzhen Weiwu Guangming Biological Products Co Ltd</ParentCompany><Status id="R">Registered</Status><StatusDate>1999-12-31 00:00:00</StatusDate><StatusSortCode>12</StatusSortCode><TherapyArea id="746">Infectious disease</TherapyArea></Row><Row><Action id="393">Immunostimulant</Action><AuthorityGroup>LOCAL_AND_MAJOR</AuthorityGroup><Company id="1041544">Shenzhen Weiwu Guangming Biological Products Co Ltd</Company><Country id="CN">China</Country><Drug id="84800">human immunoglobulin (intramuscular, measles/hepatitis virus infection), Shenzhen Weiwu Guangming Biological Products</Drug><EntityType>Biological</EntityType><HighestDevStatus id="L">Launched</HighestDevStatus><HighestDevStatusForInd id="L">Launched</HighestDevStatusForInd><Indication id="1">Measles virus infection</Indication><IsActiveCompany>true</IsActiveCompany><LatestChange>1999-12-31 00:00:00</LatestChange><ParentCompany id="1041544">Shenzhen Weiwu Guangming Biological Products Co Ltd</ParentCompany><Status id="L">Launched</Status><StatusDate>1999-12-31 00:00:00</StatusDate><StatusSortCode>13</StatusSortCode><TherapyArea id="746">Infectious disease</TherapyArea></Row><Row><Action id="59620">Unspecified drug target</Action><AuthorityGroup>LOCAL_AND_MAJOR</AuthorityGroup><Company id="1041544">Shenzhen Weiwu Guangming Biological Products Co Ltd</Company><Country id="CN">China</Country><Drug id="84800">human immunoglobulin (intramuscular, measles/hepatitis virus infection), Shenzhen Weiwu Guangming Biological Products</Drug><EntityType>Biological</EntityType><HighestDevStatus id="L">Launched</HighestDevStatus><HighestDevStatusForInd id="L">Launched</HighestDevStatusForInd><Indication id="1">Measles virus infection</Indication><IsActiveCompany>true</IsActiveCompany><LatestChange>1999-12-31 00:00:00</LatestChange><ParentCompany id="1041544">Shenzhen Weiwu Guangming Biological Products Co Ltd</ParentCompany><Status id="L">Launched</Status><StatusDate>1999-12-31 00:00:00</StatusDate><StatusSortCode>13</StatusSortCode><TherapyArea id="746">Infectious disease</TherapyArea></Row><Row><Action id="1594">Antibacterial</Action><AuthorityGroup>LOCAL_AND_MAJOR</AuthorityGroup><Company id="1061250">Lanzhou Institute of Biological Products</Company><Country id="CN">China</Country><Drug id="80205">human immunoglobulin (plasma-derived, intramuscular), Lanzhou Institute of Biological Products</Drug><EntityType>Biological</EntityType><HighestDevStatus id="L">Launched</HighestDevStatus><HighestDevStatusForInd id="L">Launched</HighestDevStatusForInd><Indication id="1">Measles virus infection</Indication><IsActiveCompany>true</IsActiveCompany><LatestChange>2002-12-31 00:00:00</LatestChange><ParentCompany id="1055632">Sinopharm</ParentCompany><Status id="R">Registered</Status><StatusDate>2002-12-31 00:00:00</StatusDate><StatusSortCode>12</StatusSortCode><TherapyArea id="746">Infectious disease</TherapyArea></Row><Row><Action id="2953">Anti-inflammatory</Action><AuthorityGroup>LOCAL_AND_MAJOR</AuthorityGroup><Company id="1061250">Lanzhou Institute of Biological Products</Company><Country id="CN">China</Country><Drug id="80205">human immunoglobulin (plasma-derived, intramuscular), Lanzhou Institute of Biological Products</Drug><EntityType>Biological</EntityType><HighestDevStatus id="L">Launched</HighestDevStatus><HighestDevStatusForInd id="L">Launched</HighestDevStatusForInd><Indication id="1">Measles virus infection</Indication><IsActiveCompany>true</IsActiveCompany><LatestChange>2002-12-31 00:00:00</LatestChange><ParentCompany id="1055632">Sinopharm</ParentCompany><Status id="R">Registered</Status><StatusDate>2002-12-31 00:00:00</StatusDate><StatusSortCode>12</StatusSortCode><TherapyArea id="746">Infectious disease</TherapyArea></Row><Row><Action id="12378">Prophylactic vaccine</Action><AuthorityGroup>OTHER</AuthorityGroup><Company id="20947">World Health Organization</Company><Country id="MX">Mexico</Country><Drug id="56118">measles vaccine (inhaled aerosol), WHO</Drug><EntityType>Biological</EntityType><HighestDevStatus id="NDR">No Development Reported</HighestDevStatus><HighestDevStatusForInd id="NDR">No Development Reported</HighestDevStatusForInd><Indication id="1">Measles virus infection</Indication><IsActiveCompany>false</IsActiveCompany><LatestChange>2011-12-29 00:00:00</LatestChange><ParentCompany id="20947">World Health Organization</ParentCompany><Status id="NDR">No Development Reported</Status><StatusDate>2011-12-29 00:00:00</StatusDate><StatusSortCode>2</StatusSortCode><TherapyArea id="746">Infectious disease</TherapyArea></Row><Row><Action id="12378">Prophylactic vaccine</Action><AuthorityGroup>LOCAL_AND_MAJOR</AuthorityGroup><Company id="1071897">Shanghai Institute of Biological Products Co Ltd</Company><Country id="CN">China</Country><Drug id="79819">measles/mumps/rubella vaccine (live-attenuated), Shanghai Institute of Biological Products</Drug><EntityType>Biological</EntityType><HighestDevStatus id="L">Launched</HighestDevStatus><HighestDevStatusForInd id="L">Launched</HighestDevStatusForInd><Indication id="1">Measles virus infection</Indication><IsActiveCompany>true</IsActiveCompany><LatestChange>2007-12-31 00:00:00</LatestChange><ParentCompany id="1055632">Sinopharm</ParentCompany><Status id="R">Registered</Status><StatusDate>2007-11-15 00:00:00</StatusDate><StatusSortCode>12</StatusSortCode><TherapyArea id="746">Infectious disease</TherapyArea></Row><Row><Action id="12378">Prophylactic vaccine</Action><AuthorityGroup>LOCAL_AND_MAJOR</AuthorityGroup><Company id="1071897">Shanghai Institute of Biological Products Co Ltd</Company><Country id="CN">China</Country><Drug id="79819">measles/mumps/rubella vaccine (live-attenuated), Shanghai Institute of Biological Products</Drug><EntityType>Biological</EntityType><HighestDevStatus id="L">Launched</HighestDevStatus><HighestDevStatusForInd id="L">Launched</HighestDevStatusForInd><Indication id="1">Measles virus infection</Indication><IsActiveCompany>true</IsActiveCompany><LatestChange>2007-12-31 00:00:00</LatestChange><ParentCompany id="1055632">Sinopharm</ParentCompany><Status id="L">Launched</Status><StatusDate>2007-12-31 00:00:00</StatusDate><StatusSortCode>13</StatusSortCode><TherapyArea id="746">Infectious disease</TherapyArea></Row><Row><Action id="59620">Unspecified drug target</Action><AuthorityGroup>LOCAL_AND_MAJOR</AuthorityGroup><Company id="1072329">Harbin Pacific Biopharmaceutical Co Ltd</Company><Country id="CN">China</Country><Drug id="80551">human immunoglobulin (intramuscular, measles, hepatitis virus infection), Harbin Pacific Biopharmaceutical Co Ltd</Drug><EntityType>Biological</EntityType><HighestDevStatus id="L">Launched</HighestDevStatus><HighestDevStatusForInd id="L">Launched</HighestDevStatusForInd><Indication id="1">Measles virus infection</Indication><IsActiveCompany>true</IsActiveCompany><LatestChange>1998-12-31 00:00:00</LatestChange><ParentCompany id="1072329">Harbin Pacific Biopharmaceutical Co Ltd</ParentCompany><Status id="R">Registered</Status><StatusDate>1998-12-31 00:00:00</StatusDate><StatusSortCode>12</StatusSortCode><TherapyArea id="746">Infectious disease</TherapyArea></Row><Row><Action id="59620">Unspecified drug target</Action><AuthorityGroup>LOCAL_AND_MAJOR</AuthorityGroup><Company id="16450">Gilead Sciences Inc</Company><Country id="US">US</Country><Drug id="9218">GS-438</Drug><EntityType>Chemical</EntityType><HighestDevStatus id="DX">Discontinued</HighestDevStatus><HighestDevStatusForInd id="DX">Discontinued</HighestDevStatusForInd><Indication id="1">Measles virus infection</Indication><IsActiveCompany>false</IsActiveCompany><LatestChange>1997-09-18 00:00:00</LatestChange><ParentCompany id="16450">Gilead Sciences Inc</ParentCompany><Status id="DR">Discovery</Status><StatusDate>1995-09-01 00:00:00</StatusDate><StatusSortCode>6</StatusSortCode><TherapyArea id="746">Infectious disease</TherapyArea></Row><Row><Action id="991">Antiviral</Action><AuthorityGroup>LOCAL_AND_MAJOR</AuthorityGroup><Company id="16450">Gilead Sciences Inc</Company><Country id="US">US</Country><Drug id="9218">GS-438</Drug><EntityType>Chemical</EntityType><HighestDevStatus id="DX">Discontinued</HighestDevStatus><HighestDevStatusForInd id="DX">Discontinued</HighestDevStatusForInd><Indication id="1">Measles virus infection</Indication><IsActiveCompany>false</IsActiveCompany><LatestChange>1997-09-18 00:00:00</LatestChange><ParentCompany id="16450">Gilead Sciences Inc</ParentCompany><Status id="DX">Discontinued</Status><StatusDate>1997-09-18 00:00:00</StatusDate><StatusSortCode>3</StatusSortCode><TherapyArea id="746">Infectious disease</TherapyArea></Row><Row><Action id="12364">Live attenuated viral vaccine</Action><AuthorityGroup>OTHER</AuthorityGroup><Company id="28355">GlaxoSmithKline plc</Company><Country id="DE">Germany</Country><Drug id="17141">Priorix-Tetra</Drug><EntityType>Biological</EntityType><HighestDevStatus id="L">Launched</HighestDevStatus><HighestDevStatusForInd id="L">Launched</HighestDevStatusForInd><Indication id="1">Measles virus infection</Indication><IsActiveCompany>true</IsActiveCompany><LatestChange>2008-01-10 00:00:00</LatestChange><ParentCompany id="28355">GlaxoSmithKline plc</ParentCompany><Status id="L">Launched</Status><StatusDate>2006-08-31 00:00:00</StatusDate><StatusSortCode>13</StatusSortCode><TherapyArea id="746">Infectious disease</TherapyArea></Row><Row><Action id="12364">Live attenuated viral vaccine</Action><AuthorityGroup>OTHER</AuthorityGroup><Company id="28355">GlaxoSmithKline plc</Company><Country id="LT">Lithuania</Country><Drug id="17141">Priorix-Tetra</Drug><EntityType>Biological</EntityType><HighestDevStatus id="L">Launched</HighestDevStatus><HighestDevStatusForInd id="L">Launched</HighestDevStatusForInd><Indication id="1">Measles virus infection</Indication><IsActiveCompany>true</IsActiveCompany><LatestChange>2008-01-10 00:00:00</LatestChange><ParentCompany id="28355">GlaxoSmithKline plc</ParentCompany><Status id="R">Registered</Status><StatusDate>2007-10-03 00:00:00</StatusDate><StatusSortCode>12</StatusSortCode><TherapyArea id="746">Infectious disease</TherapyArea></Row><Row><Action id="12378">Prophylactic vaccine</Action><AuthorityGroup>OTHER</AuthorityGroup><Company id="28355">GlaxoSmithKline plc</Company><Country id="DK">Denmark</Country><Drug id="17141">Priorix-Tetra</Drug><EntityType>Biological</EntityType><HighestDevStatus id="L">Launched</HighestDevStatus><HighestDevStatusForInd id="L">Launched</HighestDevStatusForInd><Indication id="1">Measles virus infection</Indication><IsActiveCompany>true</IsActiveCompany><LatestChange>2008-01-10 00:00:00</LatestChange><ParentCompany id="28355">GlaxoSmithKline plc</ParentCompany><Status id="R">Registered</Status><StatusDate>2007-08-07 00:00:00</StatusDate><StatusSortCode>12</StatusSortCode><TherapyArea id="746">Infectious disease</TherapyArea></Row><Row><Action id="59620">Unspecified drug target</Action><AuthorityGroup>LOCAL_AND_MAJOR</AuthorityGroup><Company id="25282">University of Catania</Company><Country id="IT">Italy</Country><Drug id="16787">ON-1</Drug><EntityType>Chemical</EntityType><HighestDevStatus id="NDR">No Development Reported</HighestDevStatus><HighestDevStatusForInd id="NDR">No Development Reported</HighestDevStatusForInd><Indication id="1">Measles virus infection</Indication><IsActiveCompany>false</IsActiveCompany><LatestChange>2008-08-07 00:00:00</LatestChange><ParentCompany id="25282">University of Catania</ParentCompany><Status id="DR">Discovery</Status><StatusDate>1999-03-31 00:00:00</StatusDate><StatusSortCode>6</StatusSortCode><TherapyArea id="746">Infectious disease</TherapyArea></Row><Row><Action id="12378">Prophylactic vaccine</Action><AuthorityGroup>OTHER</AuthorityGroup><Company id="28355">GlaxoSmithKline plc</Company><Country id="CZ">Czech Republic</Country><Drug id="17141">Priorix-Tetra</Drug><EntityType>Biological</EntityType><HighestDevStatus id="L">Launched</HighestDevStatus><HighestDevStatusForInd id="L">Launched</HighestDevStatusForInd><Indication id="1">Measles virus infection</Indication><IsActiveCompany>true</IsActiveCompany><LatestChange>2008-01-10 00:00:00</LatestChange><ParentCompany id="28355">GlaxoSmithKline plc</ParentCompany><Status id="R">Registered</Status><StatusDate>2007-08-08 00:00:00</StatusDate><StatusSortCode>12</StatusSortCode><TherapyArea id="746">Infectious disease</TherapyArea></Row><Row><Action id="1532">Viral replication inhibitor</Action><AuthorityGroup>LOCAL_AND_MAJOR</AuthorityGroup><Company id="20691">Utah State University</Company><Country id="US">US</Country><Drug id="29239">KS-753</Drug><EntityType>Chemical</EntityType><HighestDevStatus id="NDR">No Development Reported</HighestDevStatus><HighestDevStatusForInd id="NDR">No Development Reported</HighestDevStatusForInd><Indication id="1">Measles virus infection</Indication><IsActiveCompany>false</IsActiveCompany><LatestChange>2008-02-12 00:00:00</LatestChange><ParentCompany id="20691">Utah State University</ParentCompany><Status id="NDR">No Development Reported</Status><StatusDate>2008-02-12 00:00:00</StatusDate><StatusSortCode>2</StatusSortCode><TherapyArea id="746">Infectious disease</TherapyArea></Row><Row><Action id="59620">Unspecified drug target</Action><AuthorityGroup>LOCAL_AND_MAJOR</AuthorityGroup><Company id="20691">Utah State University</Company><Country id="US">US</Country><Drug id="29239">KS-753</Drug><EntityType>Chemical</EntityType><HighestDevStatus id="NDR">No Development Reported</HighestDevStatus><HighestDevStatusForInd id="NDR">No Development Reported</HighestDevStatusForInd><Indication id="1">Measles virus infection</Indication><IsActiveCompany>false</IsActiveCompany><LatestChange>2008-02-12 00:00:00</LatestChange><ParentCompany id="20691">Utah State University</ParentCompany><Status id="DR">Discovery</Status><StatusDate>2000-06-19 00:00:00</StatusDate><StatusSortCode>6</StatusSortCode><TherapyArea id="746">Infectious disease</TherapyArea></Row><Row><Action id="12364">Live attenuated viral vaccine</Action><AuthorityGroup>OTHER</AuthorityGroup><Company id="24766">Crucell Switzerland AG</Company><Country id="CH">Switzerland</Country><Drug id="41069">second-generation MMR vaccine, Berna</Drug><EntityType>Biological</EntityType><HighestDevStatus id="NDR">No Development Reported</HighestDevStatus><HighestDevStatusForInd id="NDR">No Development Reported</HighestDevStatusForInd><Indication id="1">Measles virus infection</Indication><IsActiveCompany>false</IsActiveCompany><LatestChange>2006-03-28 00:00:00</LatestChange><ParentCompany id="17332">Johnson &amp; Johnson</ParentCompany><Status id="C3">Phase 3 Clinical</Status><StatusDate>2004-08-31 00:00:00</StatusDate><StatusSortCode>10</StatusSortCode><TherapyArea id="746">Infectious disease</TherapyArea></Row><Row><Action id="12370">Recombinant viral vector vaccine</Action><AuthorityGroup>OTHER</AuthorityGroup><Company id="24244">Bavarian Nordic A/S</Company><Country id="ZA">South Africa</Country><Drug id="54328">MVA-mBN85B</Drug><EntityType>Biological</EntityType><HighestDevStatus id="NDR">No Development Reported</HighestDevStatus><HighestDevStatusForInd id="NDR">No Development Reported</HighestDevStatusForInd><Indication id="1">Measles virus infection</Indication><IsActiveCompany>false</IsActiveCompany><LatestChange>2011-11-29 00:00:00</LatestChange><ParentCompany id="24244">Bavarian Nordic A/S</ParentCompany><Status id="NDR">No Development Reported</Status><StatusDate>2011-11-29 00:00:00</StatusDate><StatusSortCode>2</StatusSortCode><TherapyArea id="746">Infectious disease</TherapyArea></Row><Row><Action id="1879">DNA vaccine</Action><AuthorityGroup>LOCAL_AND_MAJOR</AuthorityGroup><Company id="20743">Vical Inc</Company><Country id="US">US</Country><Drug id="57445">DNA vaccine (measles, Vaxfectin), Vical/Johns Hopkins University</Drug><EntityType>Biological</EntityType><HighestDevStatus id="NDR">No Development Reported</HighestDevStatus><HighestDevStatusForInd id="NDR">No Development Reported</HighestDevStatusForInd><Indication id="1">Measles virus infection</Indication><IsActiveCompany>false</IsActiveCompany><LatestChange>2012-11-30 00:00:00</LatestChange><ParentCompany id="20743">Vical Inc</ParentCompany><Status id="DR">Discovery</Status><StatusDate>2007-05-31 00:00:00</StatusDate><StatusSortCode>6</StatusSortCode><TherapyArea id="746">Infectious disease</TherapyArea></Row><Row><Action id="12378">Prophylactic vaccine</Action><AuthorityGroup>LOCAL_AND_MAJOR</AuthorityGroup><Company id="1002892">VBI Vaccines</Company><Country id="CA">Canada</Country><Drug id="70445">thermostable prophylactic MMR vaccine (intramuscular, measles/mumps/rubella infections), VBI Vaccines</Drug><EntityType>Biological</EntityType><HighestDevStatus id="DR">Discovery</HighestDevStatus><HighestDevStatusForInd id="DR">Discovery</HighestDevStatusForInd><Indication id="1">Measles virus infection</Indication><IsActiveCompany>true</IsActiveCompany><LatestChange>2014-04-29 00:00:00</LatestChange><ParentCompany id="1002892">VBI Vaccines</ParentCompany><Status id="DR">Discovery</Status><StatusDate>2010-11-30 00:00:00</StatusDate><StatusSortCode>6</StatusSortCode><TherapyArea id="746">Infectious disease</TherapyArea></Row><Row><Action id="12378">Prophylactic vaccine</Action><AuthorityGroup>LOCAL_AND_MAJOR</AuthorityGroup><Company id="1061252">Wuhan Institute of Biological Products Co Ltd</Company><Country id="CN">China</Country><Drug id="80093">Wu Sheng Si Lin</Drug><EntityType>Biological</EntityType><HighestDevStatus id="L">Launched</HighestDevStatus><HighestDevStatusForInd id="L">Launched</HighestDevStatusForInd><Indication id="1">Measles virus infection</Indication><IsActiveCompany>true</IsActiveCompany><LatestChange>2003-12-31 00:00:00</LatestChange><ParentCompany id="1055632">Sinopharm</ParentCompany><Status id="L">Launched</Status><StatusDate>2003-12-31 00:00:00</StatusDate><StatusSortCode>13</StatusSortCode><TherapyArea id="746">Infectious disease</TherapyArea></Row><Row><Action id="12364">Live attenuated viral vaccine</Action><AuthorityGroup>LOCAL_AND_MAJOR</AuthorityGroup><Company id="1061252">Wuhan Institute of Biological Products Co Ltd</Company><Country id="CN">China</Country><Drug id="80093">Wu Sheng Si Lin</Drug><EntityType>Biological</EntityType><HighestDevStatus id="L">Launched</HighestDevStatus><HighestDevStatusForInd id="L">Launched</HighestDevStatusForInd><Indication id="1">Measles virus infection</Indication><IsActiveCompany>true</IsActiveCompany><LatestChange>2003-12-31 00:00:00</LatestChange><ParentCompany id="1055632">Sinopharm</ParentCompany><Status id="L">Launched</Status><StatusDate>2003-12-31 00:00:00</StatusDate><StatusSortCode>13</StatusSortCode><TherapyArea id="746">Infectious disease</TherapyArea></Row><Row><Action id="12378">Prophylactic vaccine</Action><AuthorityGroup>LOCAL_AND_MAJOR</AuthorityGroup><Company id="1052048">Sinovac (Dalian) Vaccine Technology Co Ltd</Company><Country id="CN">China</Country><Drug id="80163">measles vaccine, Sinovac Dalian</Drug><EntityType>Biological</EntityType><HighestDevStatus id="NDR">No Development Reported</HighestDevStatus><HighestDevStatusForInd id="NDR">No Development Reported</HighestDevStatusForInd><Indication id="1">Measles virus infection</Indication><IsActiveCompany>false</IsActiveCompany><LatestChange>2014-07-07 00:00:00</LatestChange><ParentCompany id="1005255">Sinovac Biotech Ltd</ParentCompany><Status id="DR">Discovery</Status><StatusDate>2011-05-31 00:00:00</StatusDate><StatusSortCode>6</StatusSortCode><TherapyArea id="746">Infectious disease</TherapyArea></Row><Row><Action id="1594">Antibacterial</Action><AuthorityGroup>LOCAL_AND_MAJOR</AuthorityGroup><Company id="1061250">Lanzhou Institute of Biological Products</Company><Country id="CN">China</Country><Drug id="80208">human immunoglobulin (pH4, intravenous), Lanzhou Institute of Biological Products</Drug><EntityType>Biological</EntityType><HighestDevStatus id="L">Launched</HighestDevStatus><HighestDevStatusForInd id="L">Launched</HighestDevStatusForInd><Indication id="1">Measles virus infection</Indication><IsActiveCompany>true</IsActiveCompany><LatestChange>2004-12-31 00:00:00</LatestChange><ParentCompany id="1055632">Sinopharm</ParentCompany><Status id="L">Launched</Status><StatusDate>2004-12-31 00:00:00</StatusDate><StatusSortCode>13</StatusSortCode><TherapyArea id="746">Infectious disease</TherapyArea></Row><Row><Action id="1594">Antibacterial</Action><AuthorityGroup>LOCAL_AND_MAJOR</AuthorityGroup><Company id="1061250">Lanzhou Institute of Biological Products</Company><Country id="CN">China</Country><Drug id="80208">human immunoglobulin (pH4, intravenous), Lanzhou Institute of Biological Products</Drug><EntityType>Biological</EntityType><HighestDevStatus id="L">Launched</HighestDevStatus><HighestDevStatusForInd id="L">Launched</HighestDevStatusForInd><Indication id="1">Measles virus infection</Indication><IsActiveCompany>true</IsActiveCompany><LatestChange>2004-12-31 00:00:00</LatestChange><ParentCompany id="1055632">Sinopharm</ParentCompany><Status id="R">Registered</Status><StatusDate>2004-12-31 00:00:00</StatusDate><StatusSortCode>12</StatusSortCode><TherapyArea id="746">Infectious disease</TherapyArea></Row><Row><Action id="12378">Prophylactic vaccine</Action><AuthorityGroup>LOCAL_AND_MAJOR</AuthorityGroup><Company id="1056577">Beijing Minhai Biotechnology Co Ltd</Company><Country id="CN">China</Country><Drug id="82024">measles/rubella vaccine (subcutaneous, live), Beijing Minhai Biotechnology</Drug><EntityType>Biological</EntityType><HighestDevStatus id="L">Launched</HighestDevStatus><HighestDevStatusForInd id="L">Launched</HighestDevStatusForInd><Indication id="1">Measles virus infection</Indication><IsActiveCompany>true</IsActiveCompany><LatestChange>2014-10-24 00:00:00</LatestChange><ParentCompany id="1071345">Kangtai Biological Products Co Ltd</ParentCompany><Status id="R">Registered</Status><StatusDate>2012-10-30 00:00:00</StatusDate><StatusSortCode>12</StatusSortCode><TherapyArea id="746">Infectious disease</TherapyArea></Row><Row><Action id="2953">Anti-inflammatory</Action><AuthorityGroup>LOCAL_AND_MAJOR</AuthorityGroup><Company id="1076477">Banghe Pharmaceutical Co Ltd</Company><Country id="CN">China</Country><Drug id="85214">human immunoglobulin (intramuscular, measles/hepatitis virus infection), Banghe Pharmaceutical</Drug><EntityType>Biological</EntityType><HighestDevStatus id="L">Launched</HighestDevStatus><HighestDevStatusForInd id="L">Launched</HighestDevStatusForInd><Indication id="1">Measles virus infection</Indication><IsActiveCompany>true</IsActiveCompany><LatestChange>2002-12-31 00:00:00</LatestChange><ParentCompany id="1076477">Banghe Pharmaceutical Co Ltd</ParentCompany><Status id="L">Launched</Status><StatusDate>2002-12-31 00:00:00</StatusDate><StatusSortCode>13</StatusSortCode><TherapyArea id="746">Infectious disease</TherapyArea></Row><Row><Action id="59620">Unspecified drug target</Action><AuthorityGroup>LOCAL_AND_MAJOR</AuthorityGroup><Company id="1077144">Hebei Da'an Pharmaceutical Co Ltd</Company><Country id="CN">China</Country><Drug id="82763">human immunoglobulin (intramuscular, measles/hepatitis virus infection), Hebei Da'an Pharmaceutical</Drug><EntityType>Biological</EntityType><HighestDevStatus id="R">Registered</HighestDevStatus><HighestDevStatusForInd id="R">Registered</HighestDevStatusForInd><Indication id="1">Measles virus infection</Indication><IsActiveCompany>true</IsActiveCompany><LatestChange>2013-10-25 00:00:00</LatestChange><ParentCompany id="1077144">Hebei Da'an Pharmaceutical Co Ltd</ParentCompany><Status id="R">Registered</Status><StatusDate>2013-10-25 00:00:00</StatusDate><StatusSortCode>12</StatusSortCode><TherapyArea id="746">Infectious disease</TherapyArea></Row><Row><Action id="12364">Live attenuated viral vaccine</Action><AuthorityGroup>LOCAL_AND_MAJOR</AuthorityGroup><Company id="1061252">Wuhan Institute of Biological Products Co Ltd</Company><Country id="CN">China</Country><Drug id="87292">measles/Japanese encephalitis vaccine (live attenuated), Wuhan Institute of Biological Products</Drug><EntityType>Biological</EntityType><HighestDevStatus id="DR">Discovery</HighestDevStatus><HighestDevStatusForInd id="DR">Discovery</HighestDevStatusForInd><Indication id="1">Measles virus infection</Indication><IsActiveCompany>true</IsActiveCompany><LatestChange>2008-10-31 00:00:00</LatestChange><ParentCompany id="1055632">Sinopharm</ParentCompany><Status id="DR">Discovery</Status><StatusDate>2008-10-31 00:00:00</StatusDate><StatusSortCode>6</StatusSortCode><TherapyArea id="746">Infectious disease</TherapyArea></Row><Row><Action id="991">Antiviral</Action><AuthorityGroup>LOCAL_AND_MAJOR</AuthorityGroup><Company id="1051158">Goff Hill Ltd</Company><Country id="CA">Canada</Country><Drug id="65451">antiviral therapeutics (viral infections/measles/multiple sclerosis), Goff Hill</Drug><EntityType>Chemical</EntityType><HighestDevStatus id="CU">Clinical</HighestDevStatus><HighestDevStatusForInd id="CU">Clinical</HighestDevStatusForInd><Indication id="1">Measles virus infection</Indication><IsActiveCompany>true</IsActiveCompany><LatestChange>2014-11-06 00:00:00</LatestChange><ParentCompany id="1051158">Goff Hill Ltd</ParentCompany><Status id="CU">Clinical</Status><StatusDate>2010-01-27 00:00:00</StatusDate><StatusSortCode>7</StatusSortCode><TherapyArea id="746">Infectious disease</TherapyArea></Row><Row><Action id="12364">Live attenuated viral vaccine</Action><AuthorityGroup>OTHER</AuthorityGroup><Company id="28355">GlaxoSmithKline plc</Company><Country id="TW">Taiwan</Country><Drug id="11457">Priorix</Drug><EntityType>Biological</EntityType><HighestDevStatus id="L">Launched</HighestDevStatus><HighestDevStatusForInd id="L">Launched</HighestDevStatusForInd><Indication id="1">Measles virus infection</Indication><IsActiveCompany>true</IsActiveCompany><LatestChange>2012-06-29 00:00:00</LatestChange><ParentCompany id="28355">GlaxoSmithKline plc</ParentCompany><Status id="R">Registered</Status><StatusDate>1998-12-04 00:00:00</StatusDate><StatusSortCode>12</StatusSortCode><TherapyArea id="746">Infectious disease</TherapyArea></Row><Row><Action id="12364">Live attenuated viral vaccine</Action><AuthorityGroup>OTHER</AuthorityGroup><Company id="28355">GlaxoSmithKline plc</Company><Country id="CZ">Czech Republic</Country><Drug id="11457">Priorix</Drug><EntityType>Biological</EntityType><HighestDevStatus id="L">Launched</HighestDevStatus><HighestDevStatusForInd id="L">Launched</HighestDevStatusForInd><Indication id="1">Measles virus infection</Indication><IsActiveCompany>true</IsActiveCompany><LatestChange>2012-06-29 00:00:00</LatestChange><ParentCompany id="28355">GlaxoSmithKline plc</ParentCompany><Status id="R">Registered</Status><StatusDate>1999-11-03 00:00:00</StatusDate><StatusSortCode>12</StatusSortCode><TherapyArea id="746">Infectious disease</TherapyArea></Row><Row><Action id="12364">Live attenuated viral vaccine</Action><AuthorityGroup>OTHER</AuthorityGroup><Company id="28355">GlaxoSmithKline plc</Company><Country id="GR">Greece</Country><Drug id="11457">Priorix</Drug><EntityType>Biological</EntityType><HighestDevStatus id="L">Launched</HighestDevStatus><HighestDevStatusForInd id="L">Launched</HighestDevStatusForInd><Indication id="1">Measles virus infection</Indication><IsActiveCompany>true</IsActiveCompany><LatestChange>2012-06-29 00:00:00</LatestChange><ParentCompany id="28355">GlaxoSmithKline plc</ParentCompany><Status id="R">Registered</Status><StatusDate>1998-11-02 00:00:00</StatusDate><StatusSortCode>12</StatusSortCode><TherapyArea id="746">Infectious disease</TherapyArea></Row><Row><Action id="12378">Prophylactic vaccine</Action><AuthorityGroup>OTHER</AuthorityGroup><Company id="28355">GlaxoSmithKline plc</Company><Country id="PR">Puerto Rico</Country><Drug id="11457">Priorix</Drug><EntityType>Biological</EntityType><HighestDevStatus id="L">Launched</HighestDevStatus><HighestDevStatusForInd id="L">Launched</HighestDevStatusForInd><Indication id="1">Measles virus infection</Indication><IsActiveCompany>true</IsActiveCompany><LatestChange>2012-06-29 00:00:00</LatestChange><ParentCompany id="28355">GlaxoSmithKline plc</ParentCompany><Status id="C3">Phase 3 Clinical</Status><StatusDate>2012-06-29 00:00:00</StatusDate><StatusSortCode>10</StatusSortCode><TherapyArea id="746">Infectious disease</TherapyArea></Row><Row><Action id="12378">Prophylactic vaccine</Action><AuthorityGroup>OTHER</AuthorityGroup><Company id="28355">GlaxoSmithKline plc</Company><Country id="LT">Lithuania</Country><Drug id="11457">Priorix</Drug><EntityType>Biological</EntityType><HighestDevStatus id="L">Launched</HighestDevStatus><HighestDevStatusForInd id="L">Launched</HighestDevStatusForInd><Indication id="1">Measles virus infection</Indication><IsActiveCompany>true</IsActiveCompany><LatestChange>2012-06-29 00:00:00</LatestChange><ParentCompany id="28355">GlaxoSmithKline plc</ParentCompany><Status id="R">Registered</Status><StatusDate>1999-07-02 00:00:00</StatusDate><StatusSortCode>12</StatusSortCode><TherapyArea id="746">Infectious disease</TherapyArea></Row><Row><Action id="12378">Prophylactic vaccine</Action><AuthorityGroup>LOCAL_AND_MAJOR</AuthorityGroup><Company id="15374">Kaketsuken</Company><Country id="JP">Japan</Country><Drug id="3643">MMR vaccine, Merck &amp; Co</Drug><EntityType>Biological</EntityType><HighestDevStatus id="L">Launched</HighestDevStatus><HighestDevStatusForInd id="L">Launched</HighestDevStatusForInd><Indication id="1">Measles virus infection</Indication><IsActiveCompany>true</IsActiveCompany><LatestChange>2013-05-07 00:00:00</LatestChange><ParentCompany id="15374">Kaketsuken</ParentCompany><Status id="DR">Discovery</Status><StatusDate>1993-12-01 00:00:00</StatusDate><StatusSortCode>6</StatusSortCode><TherapyArea id="746">Infectious disease</TherapyArea></Row><Row><Action id="12378">Prophylactic vaccine</Action><AuthorityGroup>OTHER</AuthorityGroup><Company id="18077">Merck &amp; Co Inc</Company><Country id="EU">EU</Country><Drug id="3643">MMR vaccine, Merck &amp; Co</Drug><EntityType>Biological</EntityType><HighestDevStatus id="L">Launched</HighestDevStatus><HighestDevStatusForInd id="L">Launched</HighestDevStatusForInd><Indication id="1">Measles virus infection</Indication><IsActiveCompany>true</IsActiveCompany><LatestChange>2013-05-07 00:00:00</LatestChange><ParentCompany id="18077">Merck &amp; Co Inc</ParentCompany><Status id="L">Launched</Status><StatusDate>2001-01-09 00:00:00</StatusDate><StatusSortCode>13</StatusSortCode><TherapyArea id="746">Infectious disease</TherapyArea></Row><Row><Action id="59620">Unspecified drug target</Action><AuthorityGroup>LOCAL_AND_MAJOR</AuthorityGroup><Company id="1080922">Guangxi Beisheng Pharmaceutical Co Ltd</Company><Country id="CN">China</Country><Drug id="85734">human immunoglobulin (intramuscular, measles/hepatitis virus infection), Guangxi Beisheng Pharmaceutical</Drug><EntityType>Biological</EntityType><HighestDevStatus id="DX">Discontinued</HighestDevStatus><HighestDevStatusForInd id="DX">Discontinued</HighestDevStatusForInd><Indication id="1">Measles virus infection</Indication><IsActiveCompany>false</IsActiveCompany><LatestChange>2008-11-27 00:00:00</LatestChange><ParentCompany id="1080922">Guangxi Beisheng Pharmaceutical Co Ltd</ParentCompany><Status id="R">Registered</Status><StatusDate>2005-12-31 00:00:00</StatusDate><StatusSortCode>12</StatusSortCode><TherapyArea id="746">Infectious disease</TherapyArea></Row><Row><Action id="12378">Prophylactic vaccine</Action><AuthorityGroup>LOCAL_AND_MAJOR</AuthorityGroup><Company id="18077">Merck &amp; Co Inc</Company><Country id="US">US</Country><Drug id="47279">ProQuad</Drug><EntityType>Biological</EntityType><HighestDevStatus id="L">Launched</HighestDevStatus><HighestDevStatusForInd id="L">Launched</HighestDevStatusForInd><Indication id="1">Measles virus infection</Indication><IsActiveCompany>true</IsActiveCompany><LatestChange>2013-01-10 00:00:00</LatestChange><ParentCompany id="18077">Merck &amp; Co Inc</ParentCompany><Status id="PR">Pre-registration</Status><StatusDate>2004-08-31 00:00:00</StatusDate><StatusSortCode>11</StatusSortCode><TherapyArea id="746">Infectious disease</TherapyArea></Row><Row><Action id="12378">Prophylactic vaccine</Action><AuthorityGroup>LOCAL_AND_MAJOR</AuthorityGroup><Company id="18077">Merck &amp; Co Inc</Company><Country id="US">US</Country><Drug id="47279">ProQuad</Drug><EntityType>Biological</EntityType><HighestDevStatus id="L">Launched</HighestDevStatus><HighestDevStatusForInd id="L">Launched</HighestDevStatusForInd><Indication id="1">Measles virus infection</Indication><IsActiveCompany>true</IsActiveCompany><LatestChange>2013-01-10 00:00:00</LatestChange><ParentCompany id="18077">Merck &amp; Co Inc</ParentCompany><Status id="R">Registered</Status><StatusDate>2005-09-06 00:00:00</StatusDate><StatusSortCode>12</StatusSortCode><TherapyArea id="746">Infectious disease</TherapyArea></Row><Row><Action id="12364">Live attenuated viral vaccine</Action><AuthorityGroup>LOCAL_AND_MAJOR</AuthorityGroup><Company id="18077">Merck &amp; Co Inc</Company><Country id="US">US</Country><Drug id="47279">ProQuad</Drug><EntityType>Biological</EntityType><HighestDevStatus id="L">Launched</HighestDevStatus><HighestDevStatusForInd id="L">Launched</HighestDevStatusForInd><Indication id="1">Measles virus infection</Indication><IsActiveCompany>true</IsActiveCompany><LatestChange>2013-01-10 00:00:00</LatestChange><ParentCompany id="18077">Merck &amp; Co Inc</ParentCompany><Status id="C3">Phase 3 Clinical</Status><StatusDate>2003-09-26 00:00:00</StatusDate><StatusSortCode>10</StatusSortCode><TherapyArea id="746">Infectious disease</TherapyArea></Row><Row><Action id="12364">Live attenuated viral vaccine</Action><AuthorityGroup>OTHER</AuthorityGroup><Company id="18077">Merck &amp; Co Inc</Company><Country id="KR">South Korea</Country><Drug id="47279">ProQuad</Drug><EntityType>Biological</EntityType><HighestDevStatus id="L">Launched</HighestDevStatus><HighestDevStatusForInd id="L">Launched</HighestDevStatusForInd><Indication id="1">Measles virus infection</Indication><IsActiveCompany>true</IsActiveCompany><LatestChange>2013-01-10 00:00:00</LatestChange><ParentCompany id="18077">Merck &amp; Co Inc</ParentCompany><Status id="R">Registered</Status><StatusDate>2008-01-31 00:00:00</StatusDate><StatusSortCode>12</StatusSortCode><TherapyArea id="746">Infectious disease</TherapyArea></Row><Row><Action id="12375">Toxoid vaccine</Action><AuthorityGroup>OTHER</AuthorityGroup><Company id="18077">Merck &amp; Co Inc</Company><Country id="KR">South Korea</Country><Drug id="47279">ProQuad</Drug><EntityType>Biological</EntityType><HighestDevStatus id="L">Launched</HighestDevStatus><HighestDevStatusForInd id="L">Launched</HighestDevStatusForInd><Indication id="1">Measles virus infection</Indication><IsActiveCompany>true</IsActiveCompany><LatestChange>2013-01-10 00:00:00</LatestChange><ParentCompany id="18077">Merck &amp; Co Inc</ParentCompany><Status id="R">Registered</Status><StatusDate>2008-01-31 00:00:00</StatusDate><StatusSortCode>12</StatusSortCode><TherapyArea id="746">Infectious disease</TherapyArea></Row><Row><Action id="12375">Toxoid vaccine</Action><AuthorityGroup>LOCAL_AND_MAJOR</AuthorityGroup><Company id="18077">Merck &amp; Co Inc</Company><Country id="US">US</Country><Drug id="47279">ProQuad</Drug><EntityType>Biological</EntityType><HighestDevStatus id="L">Launched</HighestDevStatus><HighestDevStatusForInd id="L">Launched</HighestDevStatusForInd><Indication id="1">Measles virus infection</Indication><IsActiveCompany>true</IsActiveCompany><LatestChange>2013-01-10 00:00:00</LatestChange><ParentCompany id="18077">Merck &amp; Co Inc</ParentCompany><Status id="L">Launched</Status><StatusDate>2005-09-30 00:00:00</StatusDate><StatusSortCode>13</StatusSortCode><TherapyArea id="746">Infectious disease</TherapyArea></Row><Row><Action id="12375">Toxoid vaccine</Action><AuthorityGroup>OTHER</AuthorityGroup><Company id="18077">Merck &amp; Co Inc</Company><Country id="GB">UK</Country><Drug id="47279">ProQuad</Drug><EntityType>Biological</EntityType><HighestDevStatus id="L">Launched</HighestDevStatus><HighestDevStatusForInd id="L">Launched</HighestDevStatusForInd><Indication id="1">Measles virus infection</Indication><IsActiveCompany>true</IsActiveCompany><LatestChange>2013-01-10 00:00:00</LatestChange><ParentCompany id="18077">Merck &amp; Co Inc</ParentCompany><Status id="PR">Pre-registration</Status><StatusDate>2013-01-10 00:00:00</StatusDate><StatusSortCode>11</StatusSortCode><TherapyArea id="746">Infectious disease</TherapyArea></Row><Row><Action id="12364">Live attenuated viral vaccine</Action><AuthorityGroup>OTHER</AuthorityGroup><Company id="23408">Sanofi Pasteur MSD</Company><Country id="EU">EU</Country><Drug id="47279">ProQuad</Drug><EntityType>Biological</EntityType><HighestDevStatus id="L">Launched</HighestDevStatus><HighestDevStatusForInd id="L">Launched</HighestDevStatusForInd><Indication id="1">Measles virus infection</Indication><IsActiveCompany>true</IsActiveCompany><LatestChange>2013-01-10 00:00:00</LatestChange><ParentCompany id="18077">Merck &amp; Co Inc</ParentCompany><Status id="L">Launched</Status><StatusDate>2006-04-30 00:00:00</StatusDate><StatusSortCode>13</StatusSortCode><TherapyArea id="746">Infectious disease</TherapyArea></Row><Row><Action id="12378">Prophylactic vaccine</Action><AuthorityGroup>OTHER</AuthorityGroup><Company id="23408">Sanofi Pasteur MSD</Company><Country id="EU">EU</Country><Drug id="47279">ProQuad</Drug><EntityType>Biological</EntityType><HighestDevStatus id="L">Launched</HighestDevStatus><HighestDevStatusForInd id="L">Launched</HighestDevStatusForInd><Indication id="1">Measles virus infection</Indication><IsActiveCompany>true</IsActiveCompany><LatestChange>2013-01-10 00:00:00</LatestChange><ParentCompany id="18077">Merck &amp; Co Inc</ParentCompany><Status id="L">Launched</Status><StatusDate>2006-04-30 00:00:00</StatusDate><StatusSortCode>13</StatusSortCode><TherapyArea id="746">Infectious disease</TherapyArea></Row><Row><Action id="12378">Prophylactic vaccine</Action><AuthorityGroup>OTHER</AuthorityGroup><Company id="23408">Sanofi Pasteur MSD</Company><Country id="IS">Iceland</Country><Drug id="47279">ProQuad</Drug><EntityType>Biological</EntityType><HighestDevStatus id="L">Launched</HighestDevStatus><HighestDevStatusForInd id="L">Launched</HighestDevStatusForInd><Indication id="1">Measles virus infection</Indication><IsActiveCompany>true</IsActiveCompany><LatestChange>2013-01-10 00:00:00</LatestChange><ParentCompany id="18077">Merck &amp; Co Inc</ParentCompany><Status id="R">Registered</Status><StatusDate>2006-04-25 00:00:00</StatusDate><StatusSortCode>12</StatusSortCode><TherapyArea id="746">Infectious disease</TherapyArea></Row><Row><Action id="991">Antiviral</Action><AuthorityGroup>LOCAL_AND_MAJOR</AuthorityGroup><Company id="1061250">Lanzhou Institute of Biological Products</Company><Country id="CN">China</Country><Drug id="80205">human immunoglobulin (plasma-derived, intramuscular), Lanzhou Institute of Biological Products</Drug><EntityType>Biological</EntityType><HighestDevStatus id="L">Launched</HighestDevStatus><HighestDevStatusForInd id="L">Launched</HighestDevStatusForInd><Indication id="1">Measles virus infection</Indication><IsActiveCompany>true</IsActiveCompany><LatestChange>2002-12-31 00:00:00</LatestChange><ParentCompany id="1055632">Sinopharm</ParentCompany><Status id="R">Registered</Status><StatusDate>2002-12-31 00:00:00</StatusDate><StatusSortCode>12</StatusSortCode><TherapyArea id="746">Infectious disease</TherapyArea></Row><Row><Action id="991">Antiviral</Action><AuthorityGroup>LOCAL_AND_MAJOR</AuthorityGroup><Company id="16450">Gilead Sciences Inc</Company><Country id="US">US</Country><Drug id="9218">GS-438</Drug><EntityType>Chemical</EntityType><HighestDevStatus id="DX">Discontinued</HighestDevStatus><HighestDevStatusForInd id="DX">Discontinued</HighestDevStatusForInd><Indication id="1">Measles virus infection</Indication><IsActiveCompany>false</IsActiveCompany><LatestChange>1997-09-18 00:00:00</LatestChange><ParentCompany id="16450">Gilead Sciences Inc</ParentCompany><Status id="DR">Discovery</Status><StatusDate>1995-09-01 00:00:00</StatusDate><StatusSortCode>6</StatusSortCode><TherapyArea id="746">Infectious disease</TherapyArea></Row><Row><Action id="2953">Anti-inflammatory</Action><AuthorityGroup>LOCAL_AND_MAJOR</AuthorityGroup><Company id="1072329">Harbin Pacific Biopharmaceutical Co Ltd</Company><Country id="CN">China</Country><Drug id="80551">human immunoglobulin (intramuscular, measles, hepatitis virus infection), Harbin Pacific Biopharmaceutical Co Ltd</Drug><EntityType>Biological</EntityType><HighestDevStatus id="L">Launched</HighestDevStatus><HighestDevStatusForInd id="L">Launched</HighestDevStatusForInd><Indication id="1">Measles virus infection</Indication><IsActiveCompany>true</IsActiveCompany><LatestChange>1998-12-31 00:00:00</LatestChange><ParentCompany id="1072329">Harbin Pacific Biopharmaceutical Co Ltd</ParentCompany><Status id="R">Registered</Status><StatusDate>1998-12-31 00:00:00</StatusDate><StatusSortCode>12</StatusSortCode><TherapyArea id="746">Infectious disease</TherapyArea></Row><Row><Action id="12380">Unspecified vaccine</Action><AuthorityGroup>LOCAL_AND_MAJOR</AuthorityGroup><Company id="1056577">Beijing Minhai Biotechnology Co Ltd</Company><Country id="CN">China</Country><Drug id="93309">measles/rubella/varicella Vaccine, Beijing Minhai Biotechnology</Drug><EntityType>Biological</EntityType><HighestDevStatus id="DR">Discovery</HighestDevStatus><HighestDevStatusForInd id="DR">Discovery</HighestDevStatusForInd><Indication id="1">Measles virus infection</Indication><IsActiveCompany>true</IsActiveCompany><LatestChange>2014-10-24 00:00:00</LatestChange><ParentCompany id="1071345">Kangtai Biological Products Co Ltd</ParentCompany><Status id="DR">Discovery</Status><StatusDate>2014-10-24 00:00:00</StatusDate><StatusSortCode>6</StatusSortCode><TherapyArea id="746">Infectious disease</TherapyArea></Row><Row><Action id="1532">Viral replication inhibitor</Action><AuthorityGroup>LOCAL_AND_MAJOR</AuthorityGroup><Company id="20573">Emory University</Company><Country id="US">US</Country><Drug id="77538">non-nucleoside RDRP inhibitors (measles virus infection), Emory University</Drug><EntityType>Chemical</EntityType><HighestDevStatus id="DR">Discovery</HighestDevStatus><HighestDevStatusForInd id="DR">Discovery</HighestDevStatusForInd><Indication id="1">Measles virus infection</Indication><IsActiveCompany>true</IsActiveCompany><LatestChange>2012-01-27 00:00:00</LatestChange><ParentCompany id="20573">Emory University</ParentCompany><Status id="DR">Discovery</Status><StatusDate>2007-02-27 00:00:00</StatusDate><StatusSortCode>6</StatusSortCode><TherapyArea id="746">Infectious disease</TherapyArea></Row><Row><Action id="1532">Viral replication inhibitor</Action><AuthorityGroup>LOCAL_AND_MAJOR</AuthorityGroup><Company id="20691">Utah State University</Company><Country id="US">US</Country><Drug id="38853">coumarin analogs (measles virus), MediChem/Utah State</Drug><EntityType>Chemical</EntityType><HighestDevStatus id="NDR">No Development Reported</HighestDevStatus><HighestDevStatusForInd id="NDR">No Development Reported</HighestDevStatusForInd><Indication id="1">Measles virus infection</Indication><IsActiveCompany>false</IsActiveCompany><LatestChange>2008-02-12 00:00:00</LatestChange><ParentCompany id="20691">Utah State University</ParentCompany><Status id="DR">Discovery</Status><StatusDate>2002-03-21 00:00:00</StatusDate><StatusSortCode>6</StatusSortCode><TherapyArea id="746">Infectious disease</TherapyArea></Row><Row><Action id="59620">Unspecified drug target</Action><AuthorityGroup>LOCAL_AND_MAJOR</AuthorityGroup><Company id="25282">University of Catania</Company><Country id="IT">Italy</Country><Drug id="16787">ON-1</Drug><EntityType>Chemical</EntityType><HighestDevStatus id="NDR">No Development Reported</HighestDevStatus><HighestDevStatusForInd id="NDR">No Development Reported</HighestDevStatusForInd><Indication id="1">Measles virus infection</Indication><IsActiveCompany>false</IsActiveCompany><LatestChange>2008-08-07 00:00:00</LatestChange><ParentCompany id="25282">University of Catania</ParentCompany><Status id="NDR">No Development Reported</Status><StatusDate>2008-08-07 00:00:00</StatusDate><StatusSortCode>2</StatusSortCode><TherapyArea id="746">Infectious disease</TherapyArea></Row><Row><Action id="12364">Live attenuated viral vaccine</Action><AuthorityGroup>OTHER</AuthorityGroup><Company id="28355">GlaxoSmithKline plc</Company><Country id="EU">EU</Country><Drug id="17141">Priorix-Tetra</Drug><EntityType>Biological</EntityType><HighestDevStatus id="L">Launched</HighestDevStatus><HighestDevStatusForInd id="L">Launched</HighestDevStatusForInd><Indication id="1">Measles virus infection</Indication><IsActiveCompany>true</IsActiveCompany><LatestChange>2008-01-10 00:00:00</LatestChange><ParentCompany id="28355">GlaxoSmithKline plc</ParentCompany><Status id="R">Registered</Status><StatusDate>2006-07-31 00:00:00</StatusDate><StatusSortCode>12</StatusSortCode><TherapyArea id="746">Infectious disease</TherapyArea></Row><Row><Action id="12364">Live attenuated viral vaccine</Action><AuthorityGroup>OTHER</AuthorityGroup><Company id="28355">GlaxoSmithKline plc</Company><Country id="NL">Netherlands</Country><Drug id="17141">Priorix-Tetra</Drug><EntityType>Biological</EntityType><HighestDevStatus id="L">Launched</HighestDevStatus><HighestDevStatusForInd id="L">Launched</HighestDevStatusForInd><Indication id="1">Measles virus infection</Indication><IsActiveCompany>true</IsActiveCompany><LatestChange>2008-01-10 00:00:00</LatestChange><ParentCompany id="28355">GlaxoSmithKline plc</ParentCompany><Status id="R">Registered</Status><StatusDate>2007-08-13 00:00:00</StatusDate><StatusSortCode>12</StatusSortCode><TherapyArea id="746">Infectious disease</TherapyArea></Row><Row><Action id="12378">Prophylactic vaccine</Action><AuthorityGroup>OTHER</AuthorityGroup><Company id="28355">GlaxoSmithKline plc</Company><Country id="LT">Lithuania</Country><Drug id="17141">Priorix-Tetra</Drug><EntityType>Biological</EntityType><HighestDevStatus id="L">Launched</HighestDevStatus><HighestDevStatusForInd id="L">Launched</HighestDevStatusForInd><Indication id="1">Measles virus infection</Indication><IsActiveCompany>true</IsActiveCompany><LatestChange>2008-01-10 00:00:00</LatestChange><ParentCompany id="28355">GlaxoSmithKline plc</ParentCompany><Status id="R">Registered</Status><StatusDate>2007-10-03 00:00:00</StatusDate><StatusSortCode>12</StatusSortCode><TherapyArea id="746">Infectious disease</TherapyArea></Row><Row><Action id="12378">Prophylactic vaccine</Action><AuthorityGroup>OTHER</AuthorityGroup><Company id="28355">GlaxoSmithKline plc</Company><Country id="FR">France</Country><Drug id="17141">Priorix-Tetra</Drug><EntityType>Biological</EntityType><HighestDevStatus id="L">Launched</HighestDevStatus><HighestDevStatusForInd id="L">Launched</HighestDevStatusForInd><Indication id="1">Measles virus infection</Indication><IsActiveCompany>true</IsActiveCompany><LatestChange>2008-01-10 00:00:00</LatestChange><ParentCompany id="28355">GlaxoSmithKline plc</ParentCompany><Status id="R">Registered</Status><StatusDate>2008-01-10 00:00:00</StatusDate><StatusSortCode>12</StatusSortCode><TherapyArea id="746">Infectious disease</TherapyArea></Row><Row><Action id="12378">Prophylactic vaccine</Action><AuthorityGroup>OTHER</AuthorityGroup><Company id="24766">Crucell Switzerland AG</Company><Country id="CH">Switzerland</Country><Drug id="41069">second-generation MMR vaccine, Berna</Drug><EntityType>Biological</EntityType><HighestDevStatus id="NDR">No Development Reported</HighestDevStatus><HighestDevStatusForInd id="NDR">No Development Reported</HighestDevStatusForInd><Indication id="1">Measles virus infection</Indication><IsActiveCompany>false</IsActiveCompany><LatestChange>2006-03-28 00:00:00</LatestChange><ParentCompany id="17332">Johnson &amp; Johnson</ParentCompany><Status id="NDR">No Development Reported</Status><StatusDate>2006-03-28 00:00:00</StatusDate><StatusSortCode>2</StatusSortCode><TherapyArea id="746">Infectious disease</TherapyArea></Row><Row><Action id="1879">DNA vaccine</Action><AuthorityGroup>LOCAL_AND_MAJOR</AuthorityGroup><Company id="20743">Vical Inc</Company><Country id="US">US</Country><Drug id="57445">DNA vaccine (measles, Vaxfectin), Vical/Johns Hopkins University</Drug><EntityType>Biological</EntityType><HighestDevStatus id="NDR">No Development Reported</HighestDevStatus><HighestDevStatusForInd id="NDR">No Development Reported</HighestDevStatusForInd><Indication id="1">Measles virus infection</Indication><IsActiveCompany>false</IsActiveCompany><LatestChange>2012-11-30 00:00:00</LatestChange><ParentCompany id="20743">Vical Inc</ParentCompany><Status id="NDR">No Development Reported</Status><StatusDate>2012-11-30 00:00:00</StatusDate><StatusSortCode>2</StatusSortCode><TherapyArea id="746">Infectious disease</TherapyArea></Row><Row><Action id="12378">Prophylactic vaccine</Action><AuthorityGroup>LOCAL_AND_MAJOR</AuthorityGroup><Company id="1032149">Aktiv-Dry LLC</Company><Country id="US">US</Country><Drug id="57263">measles vaccine (inhaled dry powder/CAN-BD), Aktiv-Dry</Drug><EntityType>Biological</EntityType><HighestDevStatus id="C1">Phase 1 Clinical</HighestDevStatus><HighestDevStatusForInd id="C1">Phase 1 Clinical</HighestDevStatusForInd><Indication id="1">Measles virus infection</Indication><IsActiveCompany>true</IsActiveCompany><LatestChange>2012-03-28 00:00:00</LatestChange><ParentCompany id="1032149">Aktiv-Dry LLC</ParentCompany><Status id="DR">Discovery</Status><StatusDate>2005-09-30 00:00:00</StatusDate><StatusSortCode>6</StatusSortCode><TherapyArea id="746">Infectious disease</TherapyArea></Row><Row><Action id="12364">Live attenuated viral vaccine</Action><AuthorityGroup>LOCAL_AND_MAJOR</AuthorityGroup><Company id="20315">Tanabe Seiyaku Co Ltd</Company><Country id="JP">Japan</Country><Drug id="66592">Mearubik</Drug><EntityType>Biological</EntityType><HighestDevStatus id="L">Launched</HighestDevStatus><HighestDevStatusForInd id="L">Launched</HighestDevStatusForInd><Indication id="1">Measles virus infection</Indication><IsActiveCompany>true</IsActiveCompany><LatestChange>2005-12-31 00:00:00</LatestChange><ParentCompany id="1022450">Mitsubishi Chemical Holdings Corp</ParentCompany><Status id="L">Launched</Status><StatusDate>2005-12-31 00:00:00</StatusDate><StatusSortCode>13</StatusSortCode><TherapyArea id="746">Infectious disease</TherapyArea></Row><Row><Action id="12378">Prophylactic vaccine</Action><AuthorityGroup>LOCAL_AND_MAJOR</AuthorityGroup><Company id="1027662">Beijing Tiantan Biological Products Co Ltd</Company><Country id="CN">China</Country><Drug id="79155">measles/rubella vaccine (subcutaneous, live), Beijing Tiantan Biological Products</Drug><EntityType>Biological</EntityType><HighestDevStatus id="L">Launched</HighestDevStatus><HighestDevStatusForInd id="L">Launched</HighestDevStatusForInd><Indication id="1">Measles virus infection</Indication><IsActiveCompany>true</IsActiveCompany><LatestChange>2002-12-31 00:00:00</LatestChange><ParentCompany id="1055632">Sinopharm</ParentCompany><Status id="R">Registered</Status><StatusDate>2002-12-31 00:00:00</StatusDate><StatusSortCode>12</StatusSortCode><TherapyArea id="746">Infectious disease</TherapyArea></Row><Row><Action id="12378">Prophylactic vaccine</Action><AuthorityGroup>LOCAL_AND_MAJOR</AuthorityGroup><Company id="1052048">Sinovac (Dalian) Vaccine Technology Co Ltd</Company><Country id="CN">China</Country><Drug id="80163">measles vaccine, Sinovac Dalian</Drug><EntityType>Biological</EntityType><HighestDevStatus id="NDR">No Development Reported</HighestDevStatus><HighestDevStatusForInd id="NDR">No Development Reported</HighestDevStatusForInd><Indication id="1">Measles virus infection</Indication><IsActiveCompany>false</IsActiveCompany><LatestChange>2014-07-07 00:00:00</LatestChange><ParentCompany id="1005255">Sinovac Biotech Ltd</ParentCompany><Status id="NDR">No Development Reported</Status><StatusDate>2014-07-07 00:00:00</StatusDate><StatusSortCode>2</StatusSortCode><TherapyArea id="746">Infectious disease</TherapyArea></Row><Row><Action id="991">Antiviral</Action><AuthorityGroup>LOCAL_AND_MAJOR</AuthorityGroup><Company id="1071897">Shanghai Institute of Biological Products Co Ltd</Company><Country id="CN">China</Country><Drug id="80171">human immunoglobulin (intramuscular), Shanghai Institute of Biological Products</Drug><EntityType>Biological</EntityType><HighestDevStatus id="L">Launched</HighestDevStatus><HighestDevStatusForInd id="L">Launched</HighestDevStatusForInd><Indication id="1">Measles virus infection</Indication><IsActiveCompany>true</IsActiveCompany><LatestChange>1997-12-31 00:00:00</LatestChange><ParentCompany id="1055632">Sinopharm</ParentCompany><Status id="L">Launched</Status><StatusDate>1997-12-31 00:00:00</StatusDate><StatusSortCode>13</StatusSortCode><TherapyArea id="746">Infectious disease</TherapyArea></Row><Row><Action id="12378">Prophylactic vaccine</Action><AuthorityGroup>LOCAL_AND_MAJOR</AuthorityGroup><Company id="1049946">BioNet-Asia Co Ltd</Company><Country id="TH">Thailand</Country><Drug id="81219">measles vaccine, BioNet-Asia</Drug><EntityType>Biological</EntityType><HighestDevStatus id="L">Launched</HighestDevStatus><HighestDevStatusForInd id="L">Launched</HighestDevStatusForInd><Indication id="1">Measles virus infection</Indication><IsActiveCompany>true</IsActiveCompany><LatestChange>2012-08-30 00:00:00</LatestChange><ParentCompany id="1049946">BioNet-Asia Co Ltd</ParentCompany><Status id="L">Launched</Status><StatusDate>2012-08-30 00:00:00</StatusDate><StatusSortCode>13</StatusSortCode><TherapyArea id="746">Infectious disease</TherapyArea></Row><Row><Action id="1720">Virus uptake inhibitor</Action><AuthorityGroup>LOCAL_AND_MAJOR</AuthorityGroup><Company id="21028">Bulgarian Academy of Science</Company><Country id="BG">Bulgaria</Country><Drug id="7692">PAMPS</Drug><EntityType>Chemical</EntityType><HighestDevStatus id="NDR">No Development Reported</HighestDevStatus><HighestDevStatusForInd id="NDR">No Development Reported</HighestDevStatusForInd><Indication id="1">Measles virus infection</Indication><IsActiveCompany>false</IsActiveCompany><LatestChange>2008-01-24 00:00:00</LatestChange><ParentCompany id="21028">Bulgarian Academy of Science</ParentCompany><Status id="DR">Discovery</Status><StatusDate>2000-05-02 00:00:00</StatusDate><StatusSortCode>6</StatusSortCode><TherapyArea id="746">Infectious disease</TherapyArea></Row><Row><Action id="991">Antiviral</Action><AuthorityGroup>LOCAL_AND_MAJOR</AuthorityGroup><Company id="1081842">Sichuan Yuanda Shuyang Pharmaceutical Co Ltd</Company><Country id="CN">China</Country><Drug id="84689">human immunoglobulin (intramuscular, measles/hepatitis virus infection), Sichuan Yuanda Shuyang Pharmaceutical</Drug><EntityType>Biological</EntityType><HighestDevStatus id="L">Launched</HighestDevStatus><HighestDevStatusForInd id="L">Launched</HighestDevStatusForInd><Indication id="1">Measles virus infection</Indication><IsActiveCompany>true</IsActiveCompany><LatestChange>1998-12-31 00:00:00</LatestChange><ParentCompany id="1081842">Sichuan Yuanda Shuyang Pharmaceutical Co Ltd</ParentCompany><Status id="L">Launched</Status><StatusDate>1998-12-31 00:00:00</StatusDate><StatusSortCode>13</StatusSortCode><TherapyArea id="746">Infectious disease</TherapyArea></Row><Row><Action id="991">Antiviral</Action><AuthorityGroup>LOCAL_AND_MAJOR</AuthorityGroup><Company id="1087965">Guizhou Taibang Biological Products Co Ltd</Company><Country id="CN">China</Country><Drug id="87540">human immunoglobulin (intramuscular, measles/hepatitis virus infection), Guizhou Taibang Biological Products</Drug><EntityType>Biological</EntityType><HighestDevStatus id="L">Launched</HighestDevStatus><HighestDevStatusForInd id="L">Launched</HighestDevStatusForInd><Indication id="1">Measles virus infection</Indication><IsActiveCompany>true</IsActiveCompany><LatestChange>2000-12-31 00:00:00</LatestChange><ParentCompany id="1041423">China Biologic Products Inc</ParentCompany><Status id="R">Registered</Status><StatusDate>2000-12-31 00:00:00</StatusDate><StatusSortCode>12</StatusSortCode><TherapyArea id="746">Infectious disease</TherapyArea></Row><Row><Action id="991">Antiviral</Action><AuthorityGroup>LOCAL_AND_MAJOR</AuthorityGroup><Company id="1077144">Hebei Da'an Pharmaceutical Co Ltd</Company><Country id="CN">China</Country><Drug id="82763">human immunoglobulin (intramuscular, measles/hepatitis virus infection), Hebei Da'an Pharmaceutical</Drug><EntityType>Biological</EntityType><HighestDevStatus id="R">Registered</HighestDevStatus><HighestDevStatusForInd id="R">Registered</HighestDevStatusForInd><Indication id="1">Measles virus infection</Indication><IsActiveCompany>true</IsActiveCompany><LatestChange>2013-10-25 00:00:00</LatestChange><ParentCompany id="1077144">Hebei Da'an Pharmaceutical Co Ltd</ParentCompany><Status id="L">Launched</Status><StatusDate>2006-12-31 00:00:00</StatusDate><StatusSortCode>13</StatusSortCode><TherapyArea id="746">Infectious disease</TherapyArea></Row><Row><Action id="59620">Unspecified drug target</Action><AuthorityGroup>LOCAL_AND_MAJOR</AuthorityGroup><Company id="1077144">Hebei Da'an Pharmaceutical Co Ltd</Company><Country id="CN">China</Country><Drug id="82763">human immunoglobulin (intramuscular, measles/hepatitis virus infection), Hebei Da'an Pharmaceutical</Drug><EntityType>Biological</EntityType><HighestDevStatus id="R">Registered</HighestDevStatus><HighestDevStatusForInd id="R">Registered</HighestDevStatusForInd><Indication id="1">Measles virus infection</Indication><IsActiveCompany>true</IsActiveCompany><LatestChange>2013-10-25 00:00:00</LatestChange><ParentCompany id="1077144">Hebei Da'an Pharmaceutical Co Ltd</ParentCompany><Status id="L">Launched</Status><StatusDate>2006-12-31 00:00:00</StatusDate><StatusSortCode>13</StatusSortCode><TherapyArea id="746">Infectious disease</TherapyArea></Row><Row><Action id="12364">Live attenuated viral vaccine</Action><AuthorityGroup>OTHER</AuthorityGroup><Company id="19962">SmithKline Beecham plc</Company><Country id="CN">China</Country><Drug id="11457">Priorix</Drug><EntityType>Biological</EntityType><HighestDevStatus id="L">Launched</HighestDevStatus><HighestDevStatusForInd id="L">Launched</HighestDevStatusForInd><Indication id="1">Measles virus infection</Indication><IsActiveCompany>true</IsActiveCompany><LatestChange>2012-06-29 00:00:00</LatestChange><ParentCompany id="28355">GlaxoSmithKline plc</ParentCompany><Status id="R">Registered</Status><StatusDate>1998-12-25 00:00:00</StatusDate><StatusSortCode>12</StatusSortCode><TherapyArea id="746">Infectious disease</TherapyArea></Row><Row><Action id="12378">Prophylactic vaccine</Action><AuthorityGroup>OTHER</AuthorityGroup><Company id="19962">SmithKline Beecham plc</Company><Country id="ES">Spain</Country><Drug id="11457">Priorix</Drug><EntityType>Biological</EntityType><HighestDevStatus id="L">Launched</HighestDevStatus><HighestDevStatusForInd id="L">Launched</HighestDevStatusForInd><Indication id="1">Measles virus infection</Indication><IsActiveCompany>true</IsActiveCompany><LatestChange>2012-06-29 00:00:00</LatestChange><ParentCompany id="28355">GlaxoSmithKline plc</ParentCompany><Status id="R">Registered</Status><StatusDate>1999-03-01 00:00:00</StatusDate><StatusSortCode>12</StatusSortCode><TherapyArea id="746">Infectious disease</TherapyArea></Row><Row><Action id="12364">Live attenuated viral vaccine</Action><AuthorityGroup>OTHER</AuthorityGroup><Company id="19962">SmithKline Beecham plc</Company><Country id="BE">Belgium</Country><Drug id="11457">Priorix</Drug><EntityType>Biological</EntityType><HighestDevStatus id="L">Launched</HighestDevStatus><HighestDevStatusForInd id="L">Launched</HighestDevStatusForInd><Indication id="1">Measles virus infection</Indication><IsActiveCompany>true</IsActiveCompany><LatestChange>2012-06-29 00:00:00</LatestChange><ParentCompany id="28355">GlaxoSmithKline plc</ParentCompany><Status id="L">Launched</Status><StatusDate>1999-12-31 00:00:00</StatusDate><StatusSortCode>13</StatusSortCode><TherapyArea id="746">Infectious disease</TherapyArea></Row><Row><Action id="12364">Live attenuated viral vaccine</Action><AuthorityGroup>LOCAL_AND_MAJOR</AuthorityGroup><Company id="19962">SmithKline Beecham plc</Company><Country id="GB">UK</Country><Drug id="11457">Priorix</Drug><EntityType>Biological</EntityType><HighestDevStatus id="L">Launched</HighestDevStatus><HighestDevStatusForInd id="L">Launched</HighestDevStatusForInd><Indication id="1">Measles virus infection</Indication><IsActiveCompany>true</IsActiveCompany><LatestChange>2012-06-29 00:00:00</LatestChange><ParentCompany id="28355">GlaxoSmithKline plc</ParentCompany><Status id="L">Launched</Status><StatusDate>1998-05-22 00:00:00</StatusDate><StatusSortCode>13</StatusSortCode><TherapyArea id="746">Infectious disease</TherapyArea></Row><Row><Action id="12364">Live attenuated viral vaccine</Action><AuthorityGroup>OTHER</AuthorityGroup><Company id="19962">SmithKline Beecham plc</Company><Country id="DE">Germany</Country><Drug id="11457">Priorix</Drug><EntityType>Biological</EntityType><HighestDevStatus id="L">Launched</HighestDevStatus><HighestDevStatusForInd id="L">Launched</HighestDevStatusForInd><Indication id="1">Measles virus infection</Indication><IsActiveCompany>true</IsActiveCompany><LatestChange>2012-06-29 00:00:00</LatestChange><ParentCompany id="28355">GlaxoSmithKline plc</ParentCompany><Status id="L">Launched</Status><StatusDate>1998-03-25 00:00:00</StatusDate><StatusSortCode>13</StatusSortCode><TherapyArea id="746">Infectious disease</TherapyArea></Row><Row><Action id="12378">Prophylactic vaccine</Action><AuthorityGroup>OTHER</AuthorityGroup><Company id="28355">GlaxoSmithKline plc</Company><Country id="CZ">Czech Republic</Country><Drug id="11457">Priorix</Drug><EntityType>Biological</EntityType><HighestDevStatus id="L">Launched</HighestDevStatus><HighestDevStatusForInd id="L">Launched</HighestDevStatusForInd><Indication id="1">Measles virus infection</Indication><IsActiveCompany>true</IsActiveCompany><LatestChange>2012-06-29 00:00:00</LatestChange><ParentCompany id="28355">GlaxoSmithKline plc</ParentCompany><Status id="R">Registered</Status><StatusDate>1999-11-03 00:00:00</StatusDate><StatusSortCode>12</StatusSortCode><TherapyArea id="746">Infectious disease</TherapyArea></Row><Row><Action id="12364">Live attenuated viral vaccine</Action><AuthorityGroup>OTHER</AuthorityGroup><Company id="28355">GlaxoSmithKline plc</Company><Country id="LV">Latvia</Country><Drug id="11457">Priorix</Drug><EntityType>Biological</EntityType><HighestDevStatus id="L">Launched</HighestDevStatus><HighestDevStatusForInd id="L">Launched</HighestDevStatusForInd><Indication id="1">Measles virus infection</Indication><IsActiveCompany>true</IsActiveCompany><LatestChange>2012-06-29 00:00:00</LatestChange><ParentCompany id="28355">GlaxoSmithKline plc</ParentCompany><Status id="R">Registered</Status><StatusDate>1999-09-08 00:00:00</StatusDate><StatusSortCode>12</StatusSortCode><TherapyArea id="746">Infectious disease</TherapyArea></Row><Row><Action id="12378">Prophylactic vaccine</Action><AuthorityGroup>OTHER</AuthorityGroup><Company id="28355">GlaxoSmithKline plc</Company><Country id="TW">Taiwan</Country><Drug id="11457">Priorix</Drug><EntityType>Biological</EntityType><HighestDevStatus id="L">Launched</HighestDevStatus><HighestDevStatusForInd id="L">Launched</HighestDevStatusForInd><Indication id="1">Measles virus infection</Indication><IsActiveCompany>true</IsActiveCompany><LatestChange>2012-06-29 00:00:00</LatestChange><ParentCompany id="28355">GlaxoSmithKline plc</ParentCompany><Status id="L">Launched</Status><StatusDate>1998-12-31 00:00:00</StatusDate><StatusSortCode>13</StatusSortCode><TherapyArea id="746">Infectious disease</TherapyArea></Row><Row><Action id="59620">Unspecified drug target</Action><AuthorityGroup>LOCAL_AND_MAJOR</AuthorityGroup><Company id="1051158">Goff Hill Ltd</Company><Country id="CA">Canada</Country><Drug id="65451">antiviral therapeutics (viral infections/measles/multiple sclerosis), Goff Hill</Drug><EntityType>Chemical</EntityType><HighestDevStatus id="CU">Clinical</HighestDevStatus><HighestDevStatusForInd id="CU">Clinical</HighestDevStatusForInd><Indication id="1">Measles virus infection</Indication><IsActiveCompany>true</IsActiveCompany><LatestChange>2014-11-06 00:00:00</LatestChange><ParentCompany id="1051158">Goff Hill Ltd</ParentCompany><Status id="DR">Discovery</Status><StatusDate>2008-06-02 00:00:00</StatusDate><StatusSortCode>6</StatusSortCode><TherapyArea id="746">Infectious disease</TherapyArea></Row><Row><Action id="59620">Unspecified drug target</Action><AuthorityGroup>LOCAL_AND_MAJOR</AuthorityGroup><Company id="1054697">Shanxi Kangbao Biological Products Co Ltd</Company><Country id="CN">China</Country><Drug id="81711">human immunoglobulin (im, hepatitis, measles), Shanxi Kangbao Biological Products</Drug><EntityType>Biological</EntityType><HighestDevStatus id="L">Launched</HighestDevStatus><HighestDevStatusForInd id="L">Launched</HighestDevStatusForInd><Indication id="1">Measles virus infection</Indication><IsActiveCompany>true</IsActiveCompany><LatestChange>1998-12-31 00:00:00</LatestChange><ParentCompany id="1054697">Shanxi Kangbao Biological Products Co Ltd</ParentCompany><Status id="L">Launched</Status><StatusDate>1998-12-31 00:00:00</StatusDate><StatusSortCode>13</StatusSortCode><TherapyArea id="746">Infectious disease</TherapyArea></Row><Row><Action id="59620">Unspecified drug target</Action><AuthorityGroup>LOCAL_AND_MAJOR</AuthorityGroup><Company id="1080922">Guangxi Beisheng Pharmaceutical Co Ltd</Company><Country id="CN">China</Country><Drug id="85734">human immunoglobulin (intramuscular, measles/hepatitis virus infection), Guangxi Beisheng Pharmaceutical</Drug><EntityType>Biological</EntityType><HighestDevStatus id="DX">Discontinued</HighestDevStatus><HighestDevStatusForInd id="DX">Discontinued</HighestDevStatusForInd><Indication id="1">Measles virus infection</Indication><IsActiveCompany>false</IsActiveCompany><LatestChange>2008-11-27 00:00:00</LatestChange><ParentCompany id="1080922">Guangxi Beisheng Pharmaceutical Co Ltd</ParentCompany><Status id="L">Launched</Status><StatusDate>2005-12-31 00:00:00</StatusDate><StatusSortCode>13</StatusSortCode><TherapyArea id="746">Infectious disease</TherapyArea></Row><Row><Action id="59620">Unspecified drug target</Action><AuthorityGroup>LOCAL_AND_MAJOR</AuthorityGroup><Company id="1080922">Guangxi Beisheng Pharmaceutical Co Ltd</Company><Country id="CN">China</Country><Drug id="85734">human immunoglobulin (intramuscular, measles/hepatitis virus infection), Guangxi Beisheng Pharmaceutical</Drug><EntityType>Biological</EntityType><HighestDevStatus id="DX">Discontinued</HighestDevStatus><HighestDevStatusForInd id="DX">Discontinued</HighestDevStatusForInd><Indication id="1">Measles virus infection</Indication><IsActiveCompany>false</IsActiveCompany><LatestChange>2008-11-27 00:00:00</LatestChange><ParentCompany id="1080922">Guangxi Beisheng Pharmaceutical Co Ltd</ParentCompany><Status id="DX">Discontinued</Status><StatusDate>2008-11-27 00:00:00</StatusDate><StatusSortCode>3</StatusSortCode><TherapyArea id="746">Infectious disease</TherapyArea></Row><Row><Action id="12364">Live attenuated viral vaccine</Action><AuthorityGroup>LOCAL_AND_MAJOR</AuthorityGroup><Company id="15374">Kaketsuken</Company><Country id="JP">Japan</Country><Drug id="3643">MMR vaccine, Merck &amp; Co</Drug><EntityType>Biological</EntityType><HighestDevStatus id="L">Launched</HighestDevStatus><HighestDevStatusForInd id="L">Launched</HighestDevStatusForInd><Indication id="1">Measles virus infection</Indication><IsActiveCompany>true</IsActiveCompany><LatestChange>2013-05-07 00:00:00</LatestChange><ParentCompany id="15374">Kaketsuken</ParentCompany><Status id="DR">Discovery</Status><StatusDate>1993-12-01 00:00:00</StatusDate><StatusSortCode>6</StatusSortCode><TherapyArea id="746">Infectious disease</TherapyArea></Row><Row><Action id="12375">Toxoid vaccine</Action><AuthorityGroup>LOCAL_AND_MAJOR</AuthorityGroup><Company id="18077">Merck &amp; Co Inc</Company><Country id="US">US</Country><Drug id="47279">ProQuad</Drug><EntityType>Biological</EntityType><HighestDevStatus id="L">Launched</HighestDevStatus><HighestDevStatusForInd id="L">Launched</HighestDevStatusForInd><Indication id="1">Measles virus infection</Indication><IsActiveCompany>true</IsActiveCompany><LatestChange>2013-01-10 00:00:00</LatestChange><ParentCompany id="18077">Merck &amp; Co Inc</ParentCompany><Status id="R">Registered</Status><StatusDate>2005-09-06 00:00:00</StatusDate><StatusSortCode>12</StatusSortCode><TherapyArea id="746">Infectious disease</TherapyArea></Row><Row><Action id="12375">Toxoid vaccine</Action><AuthorityGroup>LOCAL_AND_MAJOR</AuthorityGroup><Company id="18077">Merck &amp; Co Inc</Company><Country id="US">US</Country><Drug id="47279">ProQuad</Drug><EntityType>Biological</EntityType><HighestDevStatus id="L">Launched</HighestDevStatus><HighestDevStatusForInd id="L">Launched</HighestDevStatusForInd><Indication id="1">Measles virus infection</Indication><IsActiveCompany>true</IsActiveCompany><LatestChange>2013-01-10 00:00:00</LatestChange><ParentCompany id="18077">Merck &amp; Co Inc</ParentCompany><Status id="C3">Phase 3 Clinical</Status><StatusDate>2003-09-26 00:00:00</StatusDate><StatusSortCode>10</StatusSortCode><TherapyArea id="746">Infectious disease</TherapyArea></Row><Row><Action id="12375">Toxoid vaccine</Action><AuthorityGroup>OTHER</AuthorityGroup><Company id="18077">Merck &amp; Co Inc</Company><Country id="KR">South Korea</Country><Drug id="47279">ProQuad</Drug><EntityType>Biological</EntityType><HighestDevStatus id="L">Launched</HighestDevStatus><HighestDevStatusForInd id="L">Launched</HighestDevStatusForInd><Indication id="1">Measles virus infection</Indication><IsActiveCompany>true</IsActiveCompany><LatestChange>2013-01-10 00:00:00</LatestChange><ParentCompany id="18077">Merck &amp; Co Inc</ParentCompany><Status id="L">Launched</Status><StatusDate>2008-02-01 00:00:00</StatusDate><StatusSortCode>13</StatusSortCode><TherapyArea id="746">Infectious disease</TherapyArea></Row><Row><Action id="12375">Toxoid vaccine</Action><AuthorityGroup>OTHER</AuthorityGroup><Company id="23408">Sanofi Pasteur MSD</Company><Country id="FR">France</Country><Drug id="47279">ProQuad</Drug><EntityType>Biological</EntityType><HighestDevStatus id="L">Launched</HighestDevStatus><HighestDevStatusForInd id="L">Launched</HighestDevStatusForInd><Indication id="1">Measles virus infection</Indication><IsActiveCompany>true</IsActiveCompany><LatestChange>2013-01-10 00:00:00</LatestChange><ParentCompany id="18077">Merck &amp; Co Inc</ParentCompany><Status id="C3">Phase 3 Clinical</Status><StatusDate>2003-09-26 00:00:00</StatusDate><StatusSortCode>10</StatusSortCode><TherapyArea id="746">Infectious disease</TherapyArea></Row><Row><Action id="12378">Prophylactic vaccine</Action><AuthorityGroup>LOCAL_AND_MAJOR</AuthorityGroup><Company id="23408">Sanofi Pasteur MSD</Company><Country id="XW">Western Europe</Country><Drug id="47279">ProQuad</Drug><EntityType>Biological</EntityType><HighestDevStatus id="L">Launched</HighestDevStatus><HighestDevStatusForInd id="L">Launched</HighestDevStatusForInd><Indication id="1">Measles virus infection</Indication><IsActiveCompany>true</IsActiveCompany><LatestChange>2013-01-10 00:00:00</LatestChange><ParentCompany id="18077">Merck &amp; Co Inc</ParentCompany><Status id="PR">Pre-registration</Status><StatusDate>2004-10-18 00:00:00</StatusDate><StatusSortCode>11</StatusSortCode><TherapyArea id="746">Infectious disease</TherapyArea></Row><Row><Action id="12378">Prophylactic vaccine</Action><AuthorityGroup>OTHER</AuthorityGroup><Company id="23408">Sanofi Pasteur MSD</Company><Country id="BE">Belgium</Country><Drug id="47279">ProQuad</Drug><EntityType>Biological</EntityType><HighestDevStatus id="L">Launched</HighestDevStatus><HighestDevStatusForInd id="L">Launched</HighestDevStatusForInd><Indication id="1">Measles virus infection</Indication><IsActiveCompany>true</IsActiveCompany><LatestChange>2013-01-10 00:00:00</LatestChange><ParentCompany id="18077">Merck &amp; Co Inc</ParentCompany><Status id="R">Registered</Status><StatusDate>2006-04-05 00:00:00</StatusDate><StatusSortCode>12</StatusSortCode><TherapyArea id="746">Infectious disease</TherapyArea></Row><Row><Action id="12364">Live attenuated viral vaccine</Action><AuthorityGroup>OTHER</AuthorityGroup><Company id="23408">Sanofi Pasteur MSD</Company><Country id="FR">France</Country><Drug id="47279">ProQuad</Drug><EntityType>Biological</EntityType><HighestDevStatus id="L">Launched</HighestDevStatus><HighestDevStatusForInd id="L">Launched</HighestDevStatusForInd><Indication id="1">Measles virus infection</Indication><IsActiveCompany>true</IsActiveCompany><LatestChange>2013-01-10 00:00:00</LatestChange><ParentCompany id="18077">Merck &amp; Co Inc</ParentCompany><Status id="R">Registered</Status><StatusDate>2006-04-06 00:00:00</StatusDate><StatusSortCode>12</StatusSortCode><TherapyArea id="746">Infectious disease</TherapyArea></Row><Row><Action id="12378">Prophylactic vaccine</Action><AuthorityGroup>OTHER</AuthorityGroup><Company id="23408">Sanofi Pasteur MSD</Company><Country id="EE">Estonia</Country><Drug id="47279">ProQuad</Drug><EntityType>Biological</EntityType><HighestDevStatus id="L">Launched</HighestDevStatus><HighestDevStatusForInd id="L">Launched</HighestDevStatusForInd><Indication id="1">Measles virus infection</Indication><IsActiveCompany>true</IsActiveCompany><LatestChange>2013-01-10 00:00:00</LatestChange><ParentCompany id="18077">Merck &amp; Co Inc</ParentCompany><Status id="R">Registered</Status><StatusDate>2006-04-10 00:00:00</StatusDate><StatusSortCode>12</StatusSortCode><TherapyArea id="746">Infectious disease</TherapyArea></Row><Row><Action id="12364">Live attenuated viral vaccine</Action><AuthorityGroup>OTHER</AuthorityGroup><Company id="20947">World Health Organization</Company><Country id="MX">Mexico</Country><Drug id="56118">measles vaccine (inhaled aerosol), WHO</Drug><EntityType>Biological</EntityType><HighestDevStatus id="NDR">No Development Reported</HighestDevStatus><HighestDevStatusForInd id="NDR">No Development Reported</HighestDevStatusForInd><Indication id="1">Measles virus infection</Indication><IsActiveCompany>false</IsActiveCompany><LatestChange>2011-12-29 00:00:00</LatestChange><ParentCompany id="20947">World Health Organization</ParentCompany><Status id="NDR">No Development Reported</Status><StatusDate>2011-12-29 00:00:00</StatusDate><StatusSortCode>2</StatusSortCode><TherapyArea id="746">Infectious disease</TherapyArea></Row><Row><Action id="12364">Live attenuated viral vaccine</Action><AuthorityGroup>OTHER</AuthorityGroup><Company id="22127">Sanofi Pasteur</Company><Country id="EU">EU</Country><Drug id="89684">M-M-RvaxPRO</Drug><EntityType>Biological</EntityType><HighestDevStatus id="L">Launched</HighestDevStatus><HighestDevStatusForInd id="L">Launched</HighestDevStatusForInd><Indication id="1">Measles virus infection</Indication><IsActiveCompany>true</IsActiveCompany><LatestChange>2008-06-01 00:00:00</LatestChange><ParentCompany id="1009547">Sanofi</ParentCompany><Status id="PR">Pre-registration</Status><StatusDate>2004-06-04 00:00:00</StatusDate><StatusSortCode>11</StatusSortCode><TherapyArea id="746">Infectious disease</TherapyArea></Row><Row><Action id="12378">Prophylactic vaccine</Action><AuthorityGroup>OTHER</AuthorityGroup><Company id="22127">Sanofi Pasteur</Company><Country id="EU">EU</Country><Drug id="89684">M-M-RvaxPRO</Drug><EntityType>Biological</EntityType><HighestDevStatus id="L">Launched</HighestDevStatus><HighestDevStatusForInd id="L">Launched</HighestDevStatusForInd><Indication id="1">Measles virus infection</Indication><IsActiveCompany>true</IsActiveCompany><LatestChange>2008-06-01 00:00:00</LatestChange><ParentCompany id="1009547">Sanofi</ParentCompany><Status id="PR">Pre-registration</Status><StatusDate>2004-06-04 00:00:00</StatusDate><StatusSortCode>11</StatusSortCode><TherapyArea id="746">Infectious disease</TherapyArea></Row><Row><Action id="12364">Live attenuated viral vaccine</Action><AuthorityGroup>OTHER</AuthorityGroup><Company id="22127">Sanofi Pasteur</Company><Country id="EU">EU</Country><Drug id="89684">M-M-RvaxPRO</Drug><EntityType>Biological</EntityType><HighestDevStatus id="L">Launched</HighestDevStatus><HighestDevStatusForInd id="L">Launched</HighestDevStatusForInd><Indication id="1">Measles virus infection</Indication><IsActiveCompany>true</IsActiveCompany><LatestChange>2008-06-01 00:00:00</LatestChange><ParentCompany id="1009547">Sanofi</ParentCompany><Status id="L">Launched</Status><StatusDate>2006-11-05 00:00:00</StatusDate><StatusSortCode>13</StatusSortCode><TherapyArea id="746">Infectious disease</TherapyArea></Row><Row><Action id="59620">Unspecified drug target</Action><AuthorityGroup>LOCAL_AND_MAJOR</AuthorityGroup><Company id="1072329">Harbin Pacific Biopharmaceutical Co Ltd</Company><Country id="CN">China</Country><Drug id="80551">human immunoglobulin (intramuscular, measles, hepatitis virus infection), Harbin Pacific Biopharmaceutical Co Ltd</Drug><EntityType>Biological</EntityType><HighestDevStatus id="L">Launched</HighestDevStatus><HighestDevStatusForInd id="L">Launched</HighestDevStatusForInd><Indication id="1">Measles virus infection</Indication><IsActiveCompany>true</IsActiveCompany><LatestChange>1998-12-31 00:00:00</LatestChange><ParentCompany id="1072329">Harbin Pacific Biopharmaceutical Co Ltd</ParentCompany><Status id="L">Launched</Status><StatusDate>1998-12-31 00:00:00</StatusDate><StatusSortCode>13</StatusSortCode><TherapyArea id="746">Infectious disease</TherapyArea></Row><Row><Action id="12364">Live attenuated viral vaccine</Action><AuthorityGroup>OTHER</AuthorityGroup><Company id="28355">GlaxoSmithKline plc</Company><Country id="IS">Iceland</Country><Drug id="17141">Priorix-Tetra</Drug><EntityType>Biological</EntityType><HighestDevStatus id="L">Launched</HighestDevStatus><HighestDevStatusForInd id="L">Launched</HighestDevStatusForInd><Indication id="1">Measles virus infection</Indication><IsActiveCompany>true</IsActiveCompany><LatestChange>2008-01-10 00:00:00</LatestChange><ParentCompany id="28355">GlaxoSmithKline plc</ParentCompany><Status id="R">Registered</Status><StatusDate>2007-08-23 00:00:00</StatusDate><StatusSortCode>12</StatusSortCode><TherapyArea id="746">Infectious disease</TherapyArea></Row><Row><Action id="12378">Prophylactic vaccine</Action><AuthorityGroup>OTHER</AuthorityGroup><Company id="28355">GlaxoSmithKline plc</Company><Country id="NL">Netherlands</Country><Drug id="17141">Priorix-Tetra</Drug><EntityType>Biological</EntityType><HighestDevStatus id="L">Launched</HighestDevStatus><HighestDevStatusForInd id="L">Launched</HighestDevStatusForInd><Indication id="1">Measles virus infection</Indication><IsActiveCompany>true</IsActiveCompany><LatestChange>2008-01-10 00:00:00</LatestChange><ParentCompany id="28355">GlaxoSmithKline plc</ParentCompany><Status id="R">Registered</Status><StatusDate>2007-08-13 00:00:00</StatusDate><StatusSortCode>12</StatusSortCode><TherapyArea id="746">Infectious disease</TherapyArea></Row><Row><Action id="12364">Live attenuated viral vaccine</Action><AuthorityGroup>OTHER</AuthorityGroup><Company id="28355">GlaxoSmithKline plc</Company><Country id="BE">Belgium</Country><Drug id="17141">Priorix-Tetra</Drug><EntityType>Biological</EntityType><HighestDevStatus id="L">Launched</HighestDevStatus><HighestDevStatusForInd id="L">Launched</HighestDevStatusForInd><Indication id="1">Measles virus infection</Indication><IsActiveCompany>true</IsActiveCompany><LatestChange>2008-01-10 00:00:00</LatestChange><ParentCompany id="28355">GlaxoSmithKline plc</ParentCompany><Status id="C3">Phase 3 Clinical</Status><StatusDate>2001-03-01 00:00:00</StatusDate><StatusSortCode>10</StatusSortCode><TherapyArea id="746">Infectious disease</TherapyArea></Row><Row><Action id="1532">Viral replication inhibitor</Action><AuthorityGroup>LOCAL_AND_MAJOR</AuthorityGroup><Company id="20691">Utah State University</Company><Country id="US">US</Country><Drug id="29239">KS-753</Drug><EntityType>Chemical</EntityType><HighestDevStatus id="NDR">No Development Reported</HighestDevStatus><HighestDevStatusForInd id="NDR">No Development Reported</HighestDevStatusForInd><Indication id="1">Measles virus infection</Indication><IsActiveCompany>false</IsActiveCompany><LatestChange>2008-02-12 00:00:00</LatestChange><ParentCompany id="20691">Utah State University</ParentCompany><Status id="DR">Discovery</Status><StatusDate>2000-06-19 00:00:00</StatusDate><StatusSortCode>6</StatusSortCode><TherapyArea id="746">Infectious disease</TherapyArea></Row><Row><Action id="12364">Live attenuated viral vaccine</Action><AuthorityGroup>OTHER</AuthorityGroup><Company id="1032149">Aktiv-Dry LLC</Company><Country id="IN">India</Country><Drug id="57263">measles vaccine (inhaled dry powder/CAN-BD), Aktiv-Dry</Drug><EntityType>Biological</EntityType><HighestDevStatus id="C1">Phase 1 Clinical</HighestDevStatus><HighestDevStatusForInd id="C1">Phase 1 Clinical</HighestDevStatusForInd><Indication id="1">Measles virus infection</Indication><IsActiveCompany>true</IsActiveCompany><LatestChange>2012-03-28 00:00:00</LatestChange><ParentCompany id="1032149">Aktiv-Dry LLC</ParentCompany><Status id="C1">Phase 1 Clinical</Status><StatusDate>2012-03-28 00:00:00</StatusDate><StatusSortCode>8</StatusSortCode><TherapyArea id="746">Infectious disease</TherapyArea></Row><Row><Action id="12364">Live attenuated viral vaccine</Action><AuthorityGroup>LOCAL_AND_MAJOR</AuthorityGroup><Company id="26857">Centers for Disease Control and Prevention</Company><Country id="US">US</Country><Drug id="72810">measles vaccine (microneedle patch formulation), Centers for Disease Control and Prevention</Drug><EntityType>Biological</EntityType><HighestDevStatus id="NDR">No Development Reported</HighestDevStatus><HighestDevStatusForInd id="NDR">No Development Reported</HighestDevStatusForInd><Indication id="1">Measles virus infection</Indication><IsActiveCompany>false</IsActiveCompany><LatestChange>2013-09-25 00:00:00</LatestChange><ParentCompany id="20516">US Government</ParentCompany><Status id="NDR">No Development Reported</Status><StatusDate>2013-09-25 00:00:00</StatusDate><StatusSortCode>2</StatusSortCode><TherapyArea id="746">Infectious disease</TherapyArea></Row><Row><Action id="12364">Live attenuated viral vaccine</Action><AuthorityGroup>LOCAL_AND_MAJOR</AuthorityGroup><Company id="1071897">Shanghai Institute of Biological Products Co Ltd</Company><Country id="CN">China</Country><Drug id="80154">measles/mumps vaccine (live attenuated), Shanghai Institute of Biological Product</Drug><EntityType>Biological</EntityType><HighestDevStatus id="L">Launched</HighestDevStatus><HighestDevStatusForInd id="L">Launched</HighestDevStatusForInd><Indication id="1">Measles virus infection</Indication><IsActiveCompany>true</IsActiveCompany><LatestChange>2012-08-16 00:00:00</LatestChange><ParentCompany id="1055632">Sinopharm</ParentCompany><Status id="R">Registered</Status><StatusDate>2012-08-16 00:00:00</StatusDate><StatusSortCode>12</StatusSortCode><TherapyArea id="746">Infectious disease</TherapyArea></Row><Row><Action id="12364">Live attenuated viral vaccine</Action><AuthorityGroup>LOCAL_AND_MAJOR</AuthorityGroup><Company id="1052048">Sinovac (Dalian) Vaccine Technology Co Ltd</Company><Country id="CN">China</Country><Drug id="80163">measles vaccine, Sinovac Dalian</Drug><EntityType>Biological</EntityType><HighestDevStatus id="NDR">No Development Reported</HighestDevStatus><HighestDevStatusForInd id="NDR">No Development Reported</HighestDevStatusForInd><Indication id="1">Measles virus infection</Indication><IsActiveCompany>false</IsActiveCompany><LatestChange>2014-07-07 00:00:00</LatestChange><ParentCompany id="1005255">Sinovac Biotech Ltd</ParentCompany><Status id="DR">Discovery</Status><StatusDate>2011-05-31 00:00:00</StatusDate><StatusSortCode>6</StatusSortCode><TherapyArea id="746">Infectious disease</TherapyArea></Row><Row><Action id="991">Antiviral</Action><AuthorityGroup>LOCAL_AND_MAJOR</AuthorityGroup><Company id="1061250">Lanzhou Institute of Biological Products</Company><Country id="CN">China</Country><Drug id="80208">human immunoglobulin (pH4, intravenous), Lanzhou Institute of Biological Products</Drug><EntityType>Biological</EntityType><HighestDevStatus id="L">Launched</HighestDevStatus><HighestDevStatusForInd id="L">Launched</HighestDevStatusForInd><Indication id="1">Measles virus infection</Indication><IsActiveCompany>true</IsActiveCompany><LatestChange>2004-12-31 00:00:00</LatestChange><ParentCompany id="1055632">Sinopharm</ParentCompany><Status id="R">Registered</Status><StatusDate>2004-12-31 00:00:00</StatusDate><StatusSortCode>12</StatusSortCode><TherapyArea id="746">Infectious disease</TherapyArea></Row><Row><Action id="59620">Unspecified drug target</Action><AuthorityGroup>LOCAL_AND_MAJOR</AuthorityGroup><Company id="1061250">Lanzhou Institute of Biological Products</Company><Country id="CN">China</Country><Drug id="80208">human immunoglobulin (pH4, intravenous), Lanzhou Institute of Biological Products</Drug><EntityType>Biological</EntityType><HighestDevStatus id="L">Launched</HighestDevStatus><HighestDevStatusForInd id="L">Launched</HighestDevStatusForInd><Indication id="1">Measles virus infection</Indication><IsActiveCompany>true</IsActiveCompany><LatestChange>2004-12-31 00:00:00</LatestChange><ParentCompany id="1055632">Sinopharm</ParentCompany><Status id="R">Registered</Status><StatusDate>2004-12-31 00:00:00</StatusDate><StatusSortCode>12</StatusSortCode><TherapyArea id="746">Infectious disease</TherapyArea></Row><Row><Action id="1720">Virus uptake inhibitor</Action><AuthorityGroup>LOCAL_AND_MAJOR</AuthorityGroup><Company id="21028">Bulgarian Academy of Science</Company><Country id="BG">Bulgaria</Country><Drug id="7692">PAMPS</Drug><EntityType>Chemical</EntityType><HighestDevStatus id="NDR">No Development Reported</HighestDevStatus><HighestDevStatusForInd id="NDR">No Development Reported</HighestDevStatusForInd><Indication id="1">Measles virus infection</Indication><IsActiveCompany>false</IsActiveCompany><LatestChange>2008-01-24 00:00:00</LatestChange><ParentCompany id="21028">Bulgarian Academy of Science</ParentCompany><Status id="NDR">No Development Reported</Status><StatusDate>2008-01-24 00:00:00</StatusDate><StatusSortCode>2</StatusSortCode><TherapyArea id="746">Infectious disease</TherapyArea></Row><Row><Action id="59620">Unspecified drug target</Action><AuthorityGroup>LOCAL_AND_MAJOR</AuthorityGroup><Company id="21028">Bulgarian Academy of Science</Company><Country id="BG">Bulgaria</Country><Drug id="7692">PAMPS</Drug><EntityType>Chemical</EntityType><HighestDevStatus id="NDR">No Development Reported</HighestDevStatus><HighestDevStatusForInd id="NDR">No Development Reported</HighestDevStatusForInd><Indication id="1">Measles virus infection</Indication><IsActiveCompany>false</IsActiveCompany><LatestChange>2008-01-24 00:00:00</LatestChange><ParentCompany id="21028">Bulgarian Academy of Science</ParentCompany><Status id="DR">Discovery</Status><StatusDate>2000-05-02 00:00:00</StatusDate><StatusSortCode>6</StatusSortCode><TherapyArea id="746">Infectious disease</TherapyArea></Row><Row><Action id="1596">Immunomodulator</Action><AuthorityGroup>LOCAL_AND_MAJOR</AuthorityGroup><Company id="1077144">Hebei Da'an Pharmaceutical Co Ltd</Company><Country id="CN">China</Country><Drug id="82763">human immunoglobulin (intramuscular, measles/hepatitis virus infection), Hebei Da'an Pharmaceutical</Drug><EntityType>Biological</EntityType><HighestDevStatus id="R">Registered</HighestDevStatus><HighestDevStatusForInd id="R">Registered</HighestDevStatusForInd><Indication id="1">Measles virus infection</Indication><IsActiveCompany>true</IsActiveCompany><LatestChange>2013-10-25 00:00:00</LatestChange><ParentCompany id="1077144">Hebei Da'an Pharmaceutical Co Ltd</ParentCompany><Status id="W">Withdrawn</Status><StatusDate>2012-08-03 00:00:00</StatusDate><StatusSortCode>4</StatusSortCode><TherapyArea id="746">Infectious disease</TherapyArea></Row><Row><Action id="991">Antiviral</Action><AuthorityGroup>LOCAL_AND_MAJOR</AuthorityGroup><Company id="1077144">Hebei Da'an Pharmaceutical Co Ltd</Company><Country id="CN">China</Country><Drug id="82763">human immunoglobulin (intramuscular, measles/hepatitis virus infection), Hebei Da'an Pharmaceutical</Drug><EntityType>Biological</EntityType><HighestDevStatus id="R">Registered</HighestDevStatus><HighestDevStatusForInd id="R">Registered</HighestDevStatusForInd><Indication id="1">Measles virus infection</Indication><IsActiveCompany>true</IsActiveCompany><LatestChange>2013-10-25 00:00:00</LatestChange><ParentCompany id="1077144">Hebei Da'an Pharmaceutical Co Ltd</ParentCompany><Status id="PR">Pre-registration</Status><StatusDate>2012-08-03 00:00:00</StatusDate><StatusSortCode>11</StatusSortCode><TherapyArea id="746">Infectious disease</TherapyArea></Row><Row><Action id="59620">Unspecified drug target</Action><AuthorityGroup>LOCAL_AND_MAJOR</AuthorityGroup><Company id="1077144">Hebei Da'an Pharmaceutical Co Ltd</Company><Country id="CN">China</Country><Drug id="82763">human immunoglobulin (intramuscular, measles/hepatitis virus infection), Hebei Da'an Pharmaceutical</Drug><EntityType>Biological</EntityType><HighestDevStatus id="R">Registered</HighestDevStatus><HighestDevStatusForInd id="R">Registered</HighestDevStatusForInd><Indication id="1">Measles virus infection</Indication><IsActiveCompany>true</IsActiveCompany><LatestChange>2013-10-25 00:00:00</LatestChange><ParentCompany id="1077144">Hebei Da'an Pharmaceutical Co Ltd</ParentCompany><Status id="PR">Pre-registration</Status><StatusDate>2012-08-03 00:00:00</StatusDate><StatusSortCode>11</StatusSortCode><TherapyArea id="746">Infectious disease</TherapyArea></Row><Row><Action id="1596">Immunomodulator</Action><AuthorityGroup>LOCAL_AND_MAJOR</AuthorityGroup><Company id="1077144">Hebei Da'an Pharmaceutical Co Ltd</Company><Country id="CN">China</Country><Drug id="82763">human immunoglobulin (intramuscular, measles/hepatitis virus infection), Hebei Da'an Pharmaceutical</Drug><EntityType>Biological</EntityType><HighestDevStatus id="R">Registered</HighestDevStatus><HighestDevStatusForInd id="R">Registered</HighestDevStatusForInd><Indication id="1">Measles virus infection</Indication><IsActiveCompany>true</IsActiveCompany><LatestChange>2013-10-25 00:00:00</LatestChange><ParentCompany id="1077144">Hebei Da'an Pharmaceutical Co Ltd</ParentCompany><Status id="PR">Pre-registration</Status><StatusDate>2012-08-03 00:00:00</StatusDate><StatusSortCode>11</StatusSortCode><TherapyArea id="746">Infectious disease</TherapyArea></Row><Row><Action id="12364">Live attenuated viral vaccine</Action><AuthorityGroup>LOCAL_AND_MAJOR</AuthorityGroup><Company id="1027662">Beijing Tiantan Biological Products Co Ltd</Company><Country id="CN">China</Country><Drug id="79144">measles/mumps/rubella vaccine (live-attenuated),  Beijing Tiantan Biological Products</Drug><EntityType>Biological</EntityType><HighestDevStatus id="L">Launched</HighestDevStatus><HighestDevStatusForInd id="L">Launched</HighestDevStatusForInd><Indication id="1">Measles virus infection</Indication><IsActiveCompany>true</IsActiveCompany><LatestChange>2002-12-31 00:00:00</LatestChange><ParentCompany id="1055632">Sinopharm</ParentCompany><Status id="L">Launched</Status><StatusDate>2002-12-31 00:00:00</StatusDate><StatusSortCode>13</StatusSortCode><TherapyArea id="746">Infectious disease</TherapyArea></Row><Row><Action id="12364">Live attenuated viral vaccine</Action><AuthorityGroup>LOCAL_AND_MAJOR</AuthorityGroup><Company id="1027662">Beijing Tiantan Biological Products Co Ltd</Company><Country id="CN">China</Country><Drug id="79155">measles/rubella vaccine (subcutaneous, live), Beijing Tiantan Biological Products</Drug><EntityType>Biological</EntityType><HighestDevStatus id="L">Launched</HighestDevStatus><HighestDevStatusForInd id="L">Launched</HighestDevStatusForInd><Indication id="1">Measles virus infection</Indication><IsActiveCompany>true</IsActiveCompany><LatestChange>2002-12-31 00:00:00</LatestChange><ParentCompany id="1055632">Sinopharm</ParentCompany><Status id="L">Launched</Status><StatusDate>2002-12-31 00:00:00</StatusDate><StatusSortCode>13</StatusSortCode><TherapyArea id="746">Infectious disease</TherapyArea></Row><Row><Action id="991">Antiviral</Action><AuthorityGroup>LOCAL_AND_MAJOR</AuthorityGroup><Company id="1076477">Banghe Pharmaceutical Co Ltd</Company><Country id="CN">China</Country><Drug id="85214">human immunoglobulin (intramuscular, measles/hepatitis virus infection), Banghe Pharmaceutical</Drug><EntityType>Biological</EntityType><HighestDevStatus id="L">Launched</HighestDevStatus><HighestDevStatusForInd id="L">Launched</HighestDevStatusForInd><Indication id="1">Measles virus infection</Indication><IsActiveCompany>true</IsActiveCompany><LatestChange>2002-12-31 00:00:00</LatestChange><ParentCompany id="1076477">Banghe Pharmaceutical Co Ltd</ParentCompany><Status id="L">Launched</Status><StatusDate>2002-12-31 00:00:00</StatusDate><StatusSortCode>13</StatusSortCode><TherapyArea id="746">Infectious disease</TherapyArea></Row><Row><Action id="59620">Unspecified drug target</Action><AuthorityGroup>LOCAL_AND_MAJOR</AuthorityGroup><Company id="1076477">Banghe Pharmaceutical Co Ltd</Company><Country id="CN">China</Country><Drug id="85214">human immunoglobulin (intramuscular, measles/hepatitis virus infection), Banghe Pharmaceutical</Drug><EntityType>Biological</EntityType><HighestDevStatus id="L">Launched</HighestDevStatus><HighestDevStatusForInd id="L">Launched</HighestDevStatusForInd><Indication id="1">Measles virus infection</Indication><IsActiveCompany>true</IsActiveCompany><LatestChange>2002-12-31 00:00:00</LatestChange><ParentCompany id="1076477">Banghe Pharmaceutical Co Ltd</ParentCompany><Status id="L">Launched</Status><StatusDate>2002-12-31 00:00:00</StatusDate><StatusSortCode>13</StatusSortCode><TherapyArea id="746">Infectious disease</TherapyArea></Row><Row><Action id="393">Immunostimulant</Action><AuthorityGroup>LOCAL_AND_MAJOR</AuthorityGroup><Company id="1076477">Banghe Pharmaceutical Co Ltd</Company><Country id="CN">China</Country><Drug id="85214">human immunoglobulin (intramuscular, measles/hepatitis virus infection), Banghe Pharmaceutical</Drug><EntityType>Biological</EntityType><HighestDevStatus id="L">Launched</HighestDevStatus><HighestDevStatusForInd id="L">Launched</HighestDevStatusForInd><Indication id="1">Measles virus infection</Indication><IsActiveCompany>true</IsActiveCompany><LatestChange>2002-12-31 00:00:00</LatestChange><ParentCompany id="1076477">Banghe Pharmaceutical Co Ltd</ParentCompany><Status id="L">Launched</Status><StatusDate>2002-12-31 00:00:00</StatusDate><StatusSortCode>13</StatusSortCode><TherapyArea id="746">Infectious disease</TherapyArea></Row><Row><Action id="2953">Anti-inflammatory</Action><AuthorityGroup>LOCAL_AND_MAJOR</AuthorityGroup><Company id="1076477">Banghe Pharmaceutical Co Ltd</Company><Country id="CN">China</Country><Drug id="85214">human immunoglobulin (intramuscular, measles/hepatitis virus infection), Banghe Pharmaceutical</Drug><EntityType>Biological</EntityType><HighestDevStatus id="L">Launched</HighestDevStatus><HighestDevStatusForInd id="L">Launched</HighestDevStatusForInd><Indication id="1">Measles virus infection</Indication><IsActiveCompany>true</IsActiveCompany><LatestChange>2002-12-31 00:00:00</LatestChange><ParentCompany id="1076477">Banghe Pharmaceutical Co Ltd</ParentCompany><Status id="R">Registered</Status><StatusDate>2002-12-31 00:00:00</StatusDate><StatusSortCode>12</StatusSortCode><TherapyArea id="746">Infectious disease</TherapyArea></Row><Row><Action id="1596">Immunomodulator</Action><AuthorityGroup>LOCAL_AND_MAJOR</AuthorityGroup><Company id="1081842">Sichuan Yuanda Shuyang Pharmaceutical Co Ltd</Company><Country id="CN">China</Country><Drug id="84689">human immunoglobulin (intramuscular, measles/hepatitis virus infection), Sichuan Yuanda Shuyang Pharmaceutical</Drug><EntityType>Biological</EntityType><HighestDevStatus id="L">Launched</HighestDevStatus><HighestDevStatusForInd id="L">Launched</HighestDevStatusForInd><Indication id="1">Measles virus infection</Indication><IsActiveCompany>true</IsActiveCompany><LatestChange>1998-12-31 00:00:00</LatestChange><ParentCompany id="1081842">Sichuan Yuanda Shuyang Pharmaceutical Co Ltd</ParentCompany><Status id="L">Launched</Status><StatusDate>1998-12-31 00:00:00</StatusDate><StatusSortCode>13</StatusSortCode><TherapyArea id="746">Infectious disease</TherapyArea></Row><Row><Action id="991">Antiviral</Action><AuthorityGroup>LOCAL_AND_MAJOR</AuthorityGroup><Company id="1079335">Guangdong Weilun Biological Products Co Ltd</Company><Country id="CN">China</Country><Drug id="84826">human immunoglobulin (intramuscular, measles/hepatitis virus infection), Guangdong Weilun Biological Products</Drug><EntityType>Biological</EntityType><HighestDevStatus id="L">Launched</HighestDevStatus><HighestDevStatusForInd id="L">Launched</HighestDevStatusForInd><Indication id="1">Measles virus infection</Indication><IsActiveCompany>true</IsActiveCompany><LatestChange>2000-12-31 00:00:00</LatestChange><ParentCompany id="1079335">Guangdong Weilun Biological Products Co Ltd</ParentCompany><Status id="R">Registered</Status><StatusDate>2000-12-31 00:00:00</StatusDate><StatusSortCode>12</StatusSortCode><TherapyArea id="746">Infectious disease</TherapyArea></Row><Row><Action id="2953">Anti-inflammatory</Action><AuthorityGroup>LOCAL_AND_MAJOR</AuthorityGroup><Company id="1079335">Guangdong Weilun Biological Products Co Ltd</Company><Country id="CN">China</Country><Drug id="84826">human immunoglobulin (intramuscular, measles/hepatitis virus infection), Guangdong Weilun Biological Products</Drug><EntityType>Biological</EntityType><HighestDevStatus id="L">Launched</HighestDevStatus><HighestDevStatusForInd id="L">Launched</HighestDevStatusForInd><Indication id="1">Measles virus infection</Indication><IsActiveCompany>true</IsActiveCompany><LatestChange>2000-12-31 00:00:00</LatestChange><ParentCompany id="1079335">Guangdong Weilun Biological Products Co Ltd</ParentCompany><Status id="R">Registered</Status><StatusDate>2000-12-31 00:00:00</StatusDate><StatusSortCode>12</StatusSortCode><TherapyArea id="746">Infectious disease</TherapyArea></Row><Row><Action id="12364">Live attenuated viral vaccine</Action><AuthorityGroup>LOCAL_AND_MAJOR</AuthorityGroup><Company id="1016340">Chengdu Institute of Biological Products</Company><Country id="CN">China</Country><Drug id="83455">measles/Japanese encephalitis conjugate attenuated vaccine, Chengdu Institute of Biological Products</Drug><EntityType>Biological</EntityType><HighestDevStatus id="DR">Discovery</HighestDevStatus><HighestDevStatusForInd id="DR">Discovery</HighestDevStatusForInd><Indication id="1">Measles virus infection</Indication><IsActiveCompany>true</IsActiveCompany><LatestChange>2011-11-09 00:00:00</LatestChange><ParentCompany id="1055632">Sinopharm</ParentCompany><Status id="DR">Discovery</Status><StatusDate>2011-11-09 00:00:00</StatusDate><StatusSortCode>6</StatusSortCode><TherapyArea id="746">Infectious disease</TherapyArea></Row><Row><Action id="12378">Prophylactic vaccine</Action><AuthorityGroup>LOCAL_AND_MAJOR</AuthorityGroup><Company id="1016340">Chengdu Institute of Biological Products</Company><Country id="CN">China</Country><Drug id="83455">measles/Japanese encephalitis conjugate attenuated vaccine, Chengdu Institute of Biological Products</Drug><EntityType>Biological</EntityType><HighestDevStatus id="DR">Discovery</HighestDevStatus><HighestDevStatusForInd id="DR">Discovery</HighestDevStatusForInd><Indication id="1">Measles virus infection</Indication><IsActiveCompany>true</IsActiveCompany><LatestChange>2011-11-09 00:00:00</LatestChange><ParentCompany id="1055632">Sinopharm</ParentCompany><Status id="DR">Discovery</Status><StatusDate>2011-11-09 00:00:00</StatusDate><StatusSortCode>6</StatusSortCode><TherapyArea id="746">Infectious disease</TherapyArea></Row><Row><Action id="12364">Live attenuated viral vaccine</Action><AuthorityGroup>OTHER</AuthorityGroup><Company id="1078819">Sevapharma Inc</Company><Country id="TH">Thailand</Country><Drug id="83793">Trivivac</Drug><EntityType>Biological</EntityType><HighestDevStatus id="C3">Phase 3 Clinical</HighestDevStatus><HighestDevStatusForInd id="C3">Phase 3 Clinical</HighestDevStatusForInd><Indication id="1">Measles virus infection</Indication><IsActiveCompany>true</IsActiveCompany><LatestChange>2012-09-30 00:00:00</LatestChange><ParentCompany id="1078819">Sevapharma Inc</ParentCompany><Status id="C3">Phase 3 Clinical</Status><StatusDate>2012-09-30 00:00:00</StatusDate><StatusSortCode>10</StatusSortCode><TherapyArea id="746">Infectious disease</TherapyArea></Row><Row><Action id="12378">Prophylactic vaccine</Action><AuthorityGroup>LOCAL_AND_MAJOR</AuthorityGroup><Company id="19962">SmithKline Beecham plc</Company><Country id="GB">UK</Country><Drug id="11457">Priorix</Drug><EntityType>Biological</EntityType><HighestDevStatus id="L">Launched</HighestDevStatus><HighestDevStatusForInd id="L">Launched</HighestDevStatusForInd><Indication id="1">Measles virus infection</Indication><IsActiveCompany>true</IsActiveCompany><LatestChange>2012-06-29 00:00:00</LatestChange><ParentCompany id="28355">GlaxoSmithKline plc</ParentCompany><Status id="C3">Phase 3 Clinical</Status><StatusDate>1995-12-14 13:36:39</StatusDate><StatusSortCode>10</StatusSortCode><TherapyArea id="746">Infectious disease</TherapyArea></Row><Row><Action id="12378">Prophylactic vaccine</Action><AuthorityGroup>OTHER</AuthorityGroup><Company id="19962">SmithKline Beecham plc</Company><Country id="FR">France</Country><Drug id="11457">Priorix</Drug><EntityType>Biological</EntityType><HighestDevStatus id="L">Launched</HighestDevStatus><HighestDevStatusForInd id="L">Launched</HighestDevStatusForInd><Indication id="1">Measles virus infection</Indication><IsActiveCompany>true</IsActiveCompany><LatestChange>2012-06-29 00:00:00</LatestChange><ParentCompany id="28355">GlaxoSmithKline plc</ParentCompany><Status id="R">Registered</Status><StatusDate>1999-05-25 00:00:00</StatusDate><StatusSortCode>12</StatusSortCode><TherapyArea id="746">Infectious disease</TherapyArea></Row><Row><Action id="12364">Live attenuated viral vaccine</Action><AuthorityGroup>OTHER</AuthorityGroup><Company id="28355">GlaxoSmithKline plc</Company><Country id="LT">Lithuania</Country><Drug id="11457">Priorix</Drug><EntityType>Biological</EntityType><HighestDevStatus id="L">Launched</HighestDevStatus><HighestDevStatusForInd id="L">Launched</HighestDevStatusForInd><Indication id="1">Measles virus infection</Indication><IsActiveCompany>true</IsActiveCompany><LatestChange>2012-06-29 00:00:00</LatestChange><ParentCompany id="28355">GlaxoSmithKline plc</ParentCompany><Status id="R">Registered</Status><StatusDate>1999-07-02 00:00:00</StatusDate><StatusSortCode>12</StatusSortCode><TherapyArea id="746">Infectious disease</TherapyArea></Row><Row><Action id="991">Antiviral</Action><AuthorityGroup>LOCAL_AND_MAJOR</AuthorityGroup><Company id="1080922">Guangxi Beisheng Pharmaceutical Co Ltd</Company><Country id="CN">China</Country><Drug id="85734">human immunoglobulin (intramuscular, measles/hepatitis virus infection), Guangxi Beisheng Pharmaceutical</Drug><EntityType>Biological</EntityType><HighestDevStatus id="DX">Discontinued</HighestDevStatus><HighestDevStatusForInd id="DX">Discontinued</HighestDevStatusForInd><Indication id="1">Measles virus infection</Indication><IsActiveCompany>false</IsActiveCompany><LatestChange>2008-11-27 00:00:00</LatestChange><ParentCompany id="1080922">Guangxi Beisheng Pharmaceutical Co Ltd</ParentCompany><Status id="L">Launched</Status><StatusDate>2005-12-31 00:00:00</StatusDate><StatusSortCode>13</StatusSortCode><TherapyArea id="746">Infectious disease</TherapyArea></Row><Row><Action id="991">Antiviral</Action><AuthorityGroup>LOCAL_AND_MAJOR</AuthorityGroup><Company id="1049660">Hualan Biological Engineering Inc</Company><Country id="CN">China</Country><Drug id="79232">human immunoglobulin (intramuscular, measles/hepatitis virus infection), Hualan Biological Engineering</Drug><EntityType>Biological</EntityType><HighestDevStatus id="L">Launched</HighestDevStatus><HighestDevStatusForInd id="L">Launched</HighestDevStatusForInd><Indication id="1">Measles virus infection</Indication><IsActiveCompany>true</IsActiveCompany><LatestChange>1997-12-31 00:00:00</LatestChange><ParentCompany id="1049660">Hualan Biological Engineering Inc</ParentCompany><Status id="R">Registered</Status><StatusDate>1997-12-31 00:00:00</StatusDate><StatusSortCode>12</StatusSortCode><TherapyArea id="746">Infectious disease</TherapyArea></Row><Row><Action id="393">Immunostimulant</Action><AuthorityGroup>LOCAL_AND_MAJOR</AuthorityGroup><Company id="1061250">Lanzhou Institute of Biological Products</Company><Country id="CN">China</Country><Drug id="80205">human immunoglobulin (plasma-derived, intramuscular), Lanzhou Institute of Biological Products</Drug><EntityType>Biological</EntityType><HighestDevStatus id="L">Launched</HighestDevStatus><HighestDevStatusForInd id="L">Launched</HighestDevStatusForInd><Indication id="1">Measles virus infection</Indication><IsActiveCompany>true</IsActiveCompany><LatestChange>2002-12-31 00:00:00</LatestChange><ParentCompany id="1055632">Sinopharm</ParentCompany><Status id="R">Registered</Status><StatusDate>2002-12-31 00:00:00</StatusDate><StatusSortCode>12</StatusSortCode><TherapyArea id="746">Infectious disease</TherapyArea></Row><Row><Action id="2953">Anti-inflammatory</Action><AuthorityGroup>LOCAL_AND_MAJOR</AuthorityGroup><Company id="1061250">Lanzhou Institute of Biological Products</Company><Country id="CN">China</Country><Drug id="80205">human immunoglobulin (plasma-derived, intramuscular), Lanzhou Institute of Biological Products</Drug><EntityType>Biological</EntityType><HighestDevStatus id="L">Launched</HighestDevStatus><HighestDevStatusForInd id="L">Launched</HighestDevStatusForInd><Indication id="1">Measles virus infection</Indication><IsActiveCompany>true</IsActiveCompany><LatestChange>2002-12-31 00:00:00</LatestChange><ParentCompany id="1055632">Sinopharm</ParentCompany><Status id="L">Launched</Status><StatusDate>2002-12-31 00:00:00</StatusDate><StatusSortCode>13</StatusSortCode><TherapyArea id="746">Infectious disease</TherapyArea></Row><Row><Action id="393">Immunostimulant</Action><AuthorityGroup>LOCAL_AND_MAJOR</AuthorityGroup><Company id="1061250">Lanzhou Institute of Biological Products</Company><Country id="CN">China</Country><Drug id="80205">human immunoglobulin (plasma-derived, intramuscular), Lanzhou Institute of Biological Products</Drug><EntityType>Biological</EntityType><HighestDevStatus id="L">Launched</HighestDevStatus><HighestDevStatusForInd id="L">Launched</HighestDevStatusForInd><Indication id="1">Measles virus infection</Indication><IsActiveCompany>true</IsActiveCompany><LatestChange>2002-12-31 00:00:00</LatestChange><ParentCompany id="1055632">Sinopharm</ParentCompany><Status id="L">Launched</Status><StatusDate>2002-12-31 00:00:00</StatusDate><StatusSortCode>13</StatusSortCode><TherapyArea id="746">Infectious disease</TherapyArea></Row><Row><Action id="991">Antiviral</Action><AuthorityGroup>LOCAL_AND_MAJOR</AuthorityGroup><Company id="1061250">Lanzhou Institute of Biological Products</Company><Country id="CN">China</Country><Drug id="80205">human immunoglobulin (plasma-derived, intramuscular), Lanzhou Institute of Biological Products</Drug><EntityType>Biological</EntityType><HighestDevStatus id="L">Launched</HighestDevStatus><HighestDevStatusForInd id="L">Launched</HighestDevStatusForInd><Indication id="1">Measles virus infection</Indication><IsActiveCompany>true</IsActiveCompany><LatestChange>2002-12-31 00:00:00</LatestChange><ParentCompany id="1055632">Sinopharm</ParentCompany><Status id="L">Launched</Status><StatusDate>2002-12-31 00:00:00</StatusDate><StatusSortCode>13</StatusSortCode><TherapyArea id="746">Infectious disease</TherapyArea></Row><Row><Action id="12364">Live attenuated viral vaccine</Action><AuthorityGroup>LOCAL_AND_MAJOR</AuthorityGroup><Company id="18077">Merck &amp; Co Inc</Company><Country id="US">US</Country><Drug id="47279">ProQuad</Drug><EntityType>Biological</EntityType><HighestDevStatus id="L">Launched</HighestDevStatus><HighestDevStatusForInd id="L">Launched</HighestDevStatusForInd><Indication id="1">Measles virus infection</Indication><IsActiveCompany>true</IsActiveCompany><LatestChange>2013-01-10 00:00:00</LatestChange><ParentCompany id="18077">Merck &amp; Co Inc</ParentCompany><Status id="L">Launched</Status><StatusDate>2005-09-30 00:00:00</StatusDate><StatusSortCode>13</StatusSortCode><TherapyArea id="746">Infectious disease</TherapyArea></Row><Row><Action id="12364">Live attenuated viral vaccine</Action><AuthorityGroup>OTHER</AuthorityGroup><Company id="23408">Sanofi Pasteur MSD</Company><Country id="FR">France</Country><Drug id="47279">ProQuad</Drug><EntityType>Biological</EntityType><HighestDevStatus id="L">Launched</HighestDevStatus><HighestDevStatusForInd id="L">Launched</HighestDevStatusForInd><Indication id="1">Measles virus infection</Indication><IsActiveCompany>true</IsActiveCompany><LatestChange>2013-01-10 00:00:00</LatestChange><ParentCompany id="18077">Merck &amp; Co Inc</ParentCompany><Status id="C3">Phase 3 Clinical</Status><StatusDate>2003-09-26 00:00:00</StatusDate><StatusSortCode>10</StatusSortCode><TherapyArea id="746">Infectious disease</TherapyArea></Row><Row><Action id="12378">Prophylactic vaccine</Action><AuthorityGroup>OTHER</AuthorityGroup><Company id="23408">Sanofi Pasteur MSD</Company><Country id="FR">France</Country><Drug id="47279">ProQuad</Drug><EntityType>Biological</EntityType><HighestDevStatus id="L">Launched</HighestDevStatus><HighestDevStatusForInd id="L">Launched</HighestDevStatusForInd><Indication id="1">Measles virus infection</Indication><IsActiveCompany>true</IsActiveCompany><LatestChange>2013-01-10 00:00:00</LatestChange><ParentCompany id="18077">Merck &amp; Co Inc</ParentCompany><Status id="C3">Phase 3 Clinical</Status><StatusDate>2003-09-26 00:00:00</StatusDate><StatusSortCode>10</StatusSortCode><TherapyArea id="746">Infectious disease</TherapyArea></Row><Row><Action id="12378">Prophylactic vaccine</Action><AuthorityGroup>OTHER</AuthorityGroup><Company id="23408">Sanofi Pasteur MSD</Company><Country id="CZ">Czech Republic</Country><Drug id="47279">ProQuad</Drug><EntityType>Biological</EntityType><HighestDevStatus id="L">Launched</HighestDevStatus><HighestDevStatusForInd id="L">Launched</HighestDevStatusForInd><Indication id="1">Measles virus infection</Indication><IsActiveCompany>true</IsActiveCompany><LatestChange>2013-01-10 00:00:00</LatestChange><ParentCompany id="18077">Merck &amp; Co Inc</ParentCompany><Status id="R">Registered</Status><StatusDate>2006-04-06 00:00:00</StatusDate><StatusSortCode>12</StatusSortCode><TherapyArea id="746">Infectious disease</TherapyArea></Row><Row><Action id="12378">Prophylactic vaccine</Action><AuthorityGroup>OTHER</AuthorityGroup><Company id="22127">Sanofi Pasteur</Company><Country id="EU">EU</Country><Drug id="89684">M-M-RvaxPRO</Drug><EntityType>Biological</EntityType><HighestDevStatus id="L">Launched</HighestDevStatus><HighestDevStatusForInd id="L">Launched</HighestDevStatusForInd><Indication id="1">Measles virus infection</Indication><IsActiveCompany>true</IsActiveCompany><LatestChange>2008-06-01 00:00:00</LatestChange><ParentCompany id="1009547">Sanofi</ParentCompany><Status id="L">Launched</Status><StatusDate>2006-11-05 00:00:00</StatusDate><StatusSortCode>13</StatusSortCode><TherapyArea id="746">Infectious disease</TherapyArea></Row><Row><Action id="12364">Live attenuated viral vaccine</Action><AuthorityGroup>LOCAL_AND_MAJOR</AuthorityGroup><Company id="18077">Merck &amp; Co Inc</Company><Country id="US">US</Country><Drug id="3643">MMR vaccine, Merck &amp; Co</Drug><EntityType>Biological</EntityType><HighestDevStatus id="L">Launched</HighestDevStatus><HighestDevStatusForInd id="L">Launched</HighestDevStatusForInd><Indication id="1">Measles virus infection</Indication><IsActiveCompany>true</IsActiveCompany><LatestChange>2013-05-07 00:00:00</LatestChange><ParentCompany id="18077">Merck &amp; Co Inc</ParentCompany><Status id="L">Launched</Status><StatusDate>1978-12-31 00:00:00</StatusDate><StatusSortCode>13</StatusSortCode><TherapyArea id="746">Infectious disease</TherapyArea></Row><Row><Action id="12378">Prophylactic vaccine</Action><AuthorityGroup>OTHER</AuthorityGroup><Company id="18077">Merck &amp; Co Inc</Company><Country id="TW">Taiwan</Country><Drug id="3643">MMR vaccine, Merck &amp; Co</Drug><EntityType>Biological</EntityType><HighestDevStatus id="L">Launched</HighestDevStatus><HighestDevStatusForInd id="L">Launched</HighestDevStatusForInd><Indication id="1">Measles virus infection</Indication><IsActiveCompany>true</IsActiveCompany><LatestChange>2013-05-07 00:00:00</LatestChange><ParentCompany id="18077">Merck &amp; Co Inc</ParentCompany><Status id="L">Launched</Status><StatusDate>1982-12-31 00:00:00</StatusDate><StatusSortCode>13</StatusSortCode><TherapyArea id="746">Infectious disease</TherapyArea></Row><Row><Action id="12364">Live attenuated viral vaccine</Action><AuthorityGroup>OTHER</AuthorityGroup><Company id="20947">World Health Organization</Company><Country id="MX">Mexico</Country><Drug id="56118">measles vaccine (inhaled aerosol), WHO</Drug><EntityType>Biological</EntityType><HighestDevStatus id="NDR">No Development Reported</HighestDevStatus><HighestDevStatusForInd id="NDR">No Development Reported</HighestDevStatusForInd><Indication id="1">Measles virus infection</Indication><IsActiveCompany>false</IsActiveCompany><LatestChange>2011-12-29 00:00:00</LatestChange><ParentCompany id="20947">World Health Organization</ParentCompany><Status id="C2">Phase 2 Clinical</Status><StatusDate>2006-09-06 00:00:00</StatusDate><StatusSortCode>9</StatusSortCode><TherapyArea id="746">Infectious disease</TherapyArea></Row><Row><Action id="12378">Prophylactic vaccine</Action><AuthorityGroup>OTHER</AuthorityGroup><Company id="20947">World Health Organization</Company><Country id="MX">Mexico</Country><Drug id="56118">measles vaccine (inhaled aerosol), WHO</Drug><EntityType>Biological</EntityType><HighestDevStatus id="NDR">No Development Reported</HighestDevStatus><HighestDevStatusForInd id="NDR">No Development Reported</HighestDevStatusForInd><Indication id="1">Measles virus infection</Indication><IsActiveCompany>false</IsActiveCompany><LatestChange>2011-12-29 00:00:00</LatestChange><ParentCompany id="20947">World Health Organization</ParentCompany><Status id="CU">Clinical</Status><StatusDate>2002-10-31 00:00:00</StatusDate><StatusSortCode>7</StatusSortCode><TherapyArea id="746">Infectious disease</TherapyArea></Row><Row><Action id="991">Antiviral</Action><AuthorityGroup>LOCAL_AND_MAJOR</AuthorityGroup><Company id="1072329">Harbin Pacific Biopharmaceutical Co Ltd</Company><Country id="CN">China</Country><Drug id="80551">human immunoglobulin (intramuscular, measles, hepatitis virus infection), Harbin Pacific Biopharmaceutical Co Ltd</Drug><EntityType>Biological</EntityType><HighestDevStatus id="L">Launched</HighestDevStatus><HighestDevStatusForInd id="L">Launched</HighestDevStatusForInd><Indication id="1">Measles virus infection</Indication><IsActiveCompany>true</IsActiveCompany><LatestChange>1998-12-31 00:00:00</LatestChange><ParentCompany id="1072329">Harbin Pacific Biopharmaceutical Co Ltd</ParentCompany><Status id="L">Launched</Status><StatusDate>1998-12-31 00:00:00</StatusDate><StatusSortCode>13</StatusSortCode><TherapyArea id="746">Infectious disease</TherapyArea></Row><Row><Action id="1532">Viral replication inhibitor</Action><AuthorityGroup>LOCAL_AND_MAJOR</AuthorityGroup><Company id="20691">Utah State University</Company><Country id="US">US</Country><Drug id="38853">coumarin analogs (measles virus), MediChem/Utah State</Drug><EntityType>Chemical</EntityType><HighestDevStatus id="NDR">No Development Reported</HighestDevStatus><HighestDevStatusForInd id="NDR">No Development Reported</HighestDevStatusForInd><Indication id="1">Measles virus infection</Indication><IsActiveCompany>false</IsActiveCompany><LatestChange>2008-02-12 00:00:00</LatestChange><ParentCompany id="20691">Utah State University</ParentCompany><Status id="NDR">No Development Reported</Status><StatusDate>2008-02-12 00:00:00</StatusDate><StatusSortCode>2</StatusSortCode><TherapyArea id="746">Infectious disease</TherapyArea></Row><Row><Action id="12378">Prophylactic vaccine</Action><AuthorityGroup>LOCAL_AND_MAJOR</AuthorityGroup><Company id="18630">State Research Center of Virology and Biotechnology VECTOR</Company><Country id="RU">Russian Federation</Country><Drug id="12671">measles vaccine, NPO Vector</Drug><EntityType>Biological</EntityType><HighestDevStatus id="L">Launched</HighestDevStatus><HighestDevStatusForInd id="L">Launched</HighestDevStatusForInd><Indication id="1">Measles virus infection</Indication><IsActiveCompany>true</IsActiveCompany><LatestChange>2000-03-17 00:00:00</LatestChange><ParentCompany id="18630">State Research Center of Virology and Biotechnology VECTOR</ParentCompany><Status id="PR">Pre-registration</Status><StatusDate>1996-07-02 00:00:00</StatusDate><StatusSortCode>11</StatusSortCode><TherapyArea id="746">Infectious disease</TherapyArea></Row><Row><Action id="12364">Live attenuated viral vaccine</Action><AuthorityGroup>OTHER</AuthorityGroup><Company id="28355">GlaxoSmithKline plc</Company><Country id="FR">France</Country><Drug id="17141">Priorix-Tetra</Drug><EntityType>Biological</EntityType><HighestDevStatus id="L">Launched</HighestDevStatus><HighestDevStatusForInd id="L">Launched</HighestDevStatusForInd><Indication id="1">Measles virus infection</Indication><IsActiveCompany>true</IsActiveCompany><LatestChange>2008-01-10 00:00:00</LatestChange><ParentCompany id="28355">GlaxoSmithKline plc</ParentCompany><Status id="R">Registered</Status><StatusDate>2008-01-10 00:00:00</StatusDate><StatusSortCode>12</StatusSortCode><TherapyArea id="746">Infectious disease</TherapyArea></Row><Row><Action id="12378">Prophylactic vaccine</Action><AuthorityGroup>OTHER</AuthorityGroup><Company id="28355">GlaxoSmithKline plc</Company><Country id="BE">Belgium</Country><Drug id="17141">Priorix-Tetra</Drug><EntityType>Biological</EntityType><HighestDevStatus id="L">Launched</HighestDevStatus><HighestDevStatusForInd id="L">Launched</HighestDevStatusForInd><Indication id="1">Measles virus infection</Indication><IsActiveCompany>true</IsActiveCompany><LatestChange>2008-01-10 00:00:00</LatestChange><ParentCompany id="28355">GlaxoSmithKline plc</ParentCompany><Status id="C3">Phase 3 Clinical</Status><StatusDate>2001-03-01 00:00:00</StatusDate><StatusSortCode>10</StatusSortCode><TherapyArea id="746">Infectious disease</TherapyArea></Row><Row><Action id="12378">Prophylactic vaccine</Action><AuthorityGroup>OTHER</AuthorityGroup><Company id="24244">Bavarian Nordic A/S</Company><Country id="ZA">South Africa</Country><Drug id="54328">MVA-mBN85B</Drug><EntityType>Biological</EntityType><HighestDevStatus id="NDR">No Development Reported</HighestDevStatus><HighestDevStatusForInd id="NDR">No Development Reported</HighestDevStatusForInd><Indication id="1">Measles virus infection</Indication><IsActiveCompany>false</IsActiveCompany><LatestChange>2011-11-29 00:00:00</LatestChange><ParentCompany id="24244">Bavarian Nordic A/S</ParentCompany><Status id="C1">Phase 1 Clinical</Status><StatusDate>2007-11-06 00:00:00</StatusDate><StatusSortCode>8</StatusSortCode><TherapyArea id="746">Infectious disease</TherapyArea></Row><Row><Action id="12378">Prophylactic vaccine</Action><AuthorityGroup>LOCAL_AND_MAJOR</AuthorityGroup><Company id="20596">Johns Hopkins University</Company><Country id="US">US</Country><Drug id="57445">DNA vaccine (measles, Vaxfectin), Vical/Johns Hopkins University</Drug><EntityType>Biological</EntityType><HighestDevStatus id="NDR">No Development Reported</HighestDevStatus><HighestDevStatusForInd id="NDR">No Development Reported</HighestDevStatusForInd><Indication id="1">Measles virus infection</Indication><IsActiveCompany>false</IsActiveCompany><LatestChange>2012-11-30 00:00:00</LatestChange><ParentCompany id="20596">Johns Hopkins University</ParentCompany><Status id="NDR">No Development Reported</Status><StatusDate>2012-11-30 00:00:00</StatusDate><StatusSortCode>2</StatusSortCode><TherapyArea id="746">Infectious disease</TherapyArea></Row><Row><Action id="1879">DNA vaccine</Action><AuthorityGroup>LOCAL_AND_MAJOR</AuthorityGroup><Company id="20596">Johns Hopkins University</Company><Country id="US">US</Country><Drug id="57445">DNA vaccine (measles, Vaxfectin), Vical/Johns Hopkins University</Drug><EntityType>Biological</EntityType><HighestDevStatus id="NDR">No Development Reported</HighestDevStatus><HighestDevStatusForInd id="NDR">No Development Reported</HighestDevStatusForInd><Indication id="1">Measles virus infection</Indication><IsActiveCompany>false</IsActiveCompany><LatestChange>2012-11-30 00:00:00</LatestChange><ParentCompany id="20596">Johns Hopkins University</ParentCompany><Status id="DR">Discovery</Status><StatusDate>1997-06-30 00:00:00</StatusDate><StatusSortCode>6</StatusSortCode><TherapyArea id="746">Infectious disease</TherapyArea></Row><Row><Action id="12378">Prophylactic vaccine</Action><AuthorityGroup>LOCAL_AND_MAJOR</AuthorityGroup><Company id="20743">Vical Inc</Company><Country id="US">US</Country><Drug id="57445">DNA vaccine (measles, Vaxfectin), Vical/Johns Hopkins University</Drug><EntityType>Biological</EntityType><HighestDevStatus id="NDR">No Development Reported</HighestDevStatus><HighestDevStatusForInd id="NDR">No Development Reported</HighestDevStatusForInd><Indication id="1">Measles virus infection</Indication><IsActiveCompany>false</IsActiveCompany><LatestChange>2012-11-30 00:00:00</LatestChange><ParentCompany id="20743">Vical Inc</ParentCompany><Status id="NDR">No Development Reported</Status><StatusDate>2012-11-30 00:00:00</StatusDate><StatusSortCode>2</StatusSortCode><TherapyArea id="746">Infectious disease</TherapyArea></Row><Row><Action id="12364">Live attenuated viral vaccine</Action><AuthorityGroup>LOCAL_AND_MAJOR</AuthorityGroup><Company id="30063">BIKEN</Company><Country id="JP">Japan</Country><Drug id="66592">Mearubik</Drug><EntityType>Biological</EntityType><HighestDevStatus id="L">Launched</HighestDevStatus><HighestDevStatusForInd id="L">Launched</HighestDevStatusForInd><Indication id="1">Measles virus infection</Indication><IsActiveCompany>true</IsActiveCompany><LatestChange>2005-12-31 00:00:00</LatestChange><ParentCompany id="20653">Osaka University</ParentCompany><Status id="L">Launched</Status><StatusDate>2005-12-31 00:00:00</StatusDate><StatusSortCode>13</StatusSortCode><TherapyArea id="746">Infectious disease</TherapyArea></Row><Row><Action id="12378">Prophylactic vaccine</Action><AuthorityGroup>LOCAL_AND_MAJOR</AuthorityGroup><Company id="20315">Tanabe Seiyaku Co Ltd</Company><Country id="JP">Japan</Country><Drug id="66592">Mearubik</Drug><EntityType>Biological</EntityType><HighestDevStatus id="L">Launched</HighestDevStatus><HighestDevStatusForInd id="L">Launched</HighestDevStatusForInd><Indication id="1">Measles virus infection</Indication><IsActiveCompany>true</IsActiveCompany><LatestChange>2005-12-31 00:00:00</LatestChange><ParentCompany id="1022450">Mitsubishi Chemical Holdings Corp</ParentCompany><Status id="L">Launched</Status><StatusDate>2005-12-31 00:00:00</StatusDate><StatusSortCode>13</StatusSortCode><TherapyArea id="746">Infectious disease</TherapyArea></Row><Row><Action id="12379">Therapeutic vaccine</Action><AuthorityGroup>LOCAL_AND_MAJOR</AuthorityGroup><Company id="1064321">Universal Stabilization Technologies Inc</Company><Country id="US">US</Country><Drug id="73077">thermostable vaccines (pulmonary, measles), Universal Stabilization Technologies</Drug><EntityType>Biological</EntityType><HighestDevStatus id="NDR">No Development Reported</HighestDevStatus><HighestDevStatusForInd id="NDR">No Development Reported</HighestDevStatusForInd><Indication id="1">Measles virus infection</Indication><IsActiveCompany>false</IsActiveCompany><LatestChange>2012-10-17 00:00:00</LatestChange><ParentCompany id="1064321">Universal Stabilization Technologies Inc</ParentCompany><Status id="NDR">No Development Reported</Status><StatusDate>2012-10-17 00:00:00</StatusDate><StatusSortCode>2</StatusSortCode><TherapyArea id="746">Infectious disease</TherapyArea></Row><Row><Action id="12364">Live attenuated viral vaccine</Action><AuthorityGroup>LOCAL_AND_MAJOR</AuthorityGroup><Company id="20667">Ramot at Tel Aviv University Ltd</Company><Country id="IL">Israel</Country><Drug id="7566">vaccine (measles), Ramot</Drug><EntityType>Biological</EntityType><HighestDevStatus id="NDR">No Development Reported</HighestDevStatus><HighestDevStatusForInd id="NDR">No Development Reported</HighestDevStatusForInd><Indication id="1">Measles virus infection</Indication><IsActiveCompany>false</IsActiveCompany><LatestChange>2001-06-13 00:00:00</LatestChange><ParentCompany id="25012">Tel Aviv University</ParentCompany><Status id="NDR">No Development Reported</Status><StatusDate>2001-06-13 00:00:00</StatusDate><StatusSortCode>2</StatusSortCode><TherapyArea id="746">Infectious disease</TherapyArea></Row><Row><Action id="12364">Live attenuated viral vaccine</Action><AuthorityGroup>LOCAL_AND_MAJOR</AuthorityGroup><Company id="1002892">VBI Vaccines</Company><Country id="CA">Canada</Country><Drug id="70445">thermostable prophylactic MMR vaccine (intramuscular, measles/mumps/rubella infections), VBI Vaccines</Drug><EntityType>Biological</EntityType><HighestDevStatus id="DR">Discovery</HighestDevStatus><HighestDevStatusForInd id="DR">Discovery</HighestDevStatusForInd><Indication id="1">Measles virus infection</Indication><IsActiveCompany>true</IsActiveCompany><LatestChange>2014-04-29 00:00:00</LatestChange><ParentCompany id="1002892">VBI Vaccines</ParentCompany><Status id="DR">Discovery</Status><StatusDate>2010-11-30 00:00:00</StatusDate><StatusSortCode>6</StatusSortCode><TherapyArea id="746">Infectious disease</TherapyArea></Row><Row><Action id="12378">Prophylactic vaccine</Action><AuthorityGroup>LOCAL_AND_MAJOR</AuthorityGroup><Company id="1071897">Shanghai Institute of Biological Products Co Ltd</Company><Country id="CN">China</Country><Drug id="80154">measles/mumps vaccine (live attenuated), Shanghai Institute of Biological Product</Drug><EntityType>Biological</EntityType><HighestDevStatus id="L">Launched</HighestDevStatus><HighestDevStatusForInd id="L">Launched</HighestDevStatusForInd><Indication id="1">Measles virus infection</Indication><IsActiveCompany>true</IsActiveCompany><LatestChange>2012-08-16 00:00:00</LatestChange><ParentCompany id="1055632">Sinopharm</ParentCompany><Status id="R">Registered</Status><StatusDate>2012-08-16 00:00:00</StatusDate><StatusSortCode>12</StatusSortCode><TherapyArea id="746">Infectious disease</TherapyArea></Row><Row><Action id="59620">Unspecified drug target</Action><AuthorityGroup>LOCAL_AND_MAJOR</AuthorityGroup><Company id="1061250">Lanzhou Institute of Biological Products</Company><Country id="CN">China</Country><Drug id="80208">human immunoglobulin (pH4, intravenous), Lanzhou Institute of Biological Products</Drug><EntityType>Biological</EntityType><HighestDevStatus id="L">Launched</HighestDevStatus><HighestDevStatusForInd id="L">Launched</HighestDevStatusForInd><Indication id="1">Measles virus infection</Indication><IsActiveCompany>true</IsActiveCompany><LatestChange>2004-12-31 00:00:00</LatestChange><ParentCompany id="1055632">Sinopharm</ParentCompany><Status id="L">Launched</Status><StatusDate>2004-12-31 00:00:00</StatusDate><StatusSortCode>13</StatusSortCode><TherapyArea id="746">Infectious disease</TherapyArea></Row><Row><Action id="2953">Anti-inflammatory</Action><AuthorityGroup>LOCAL_AND_MAJOR</AuthorityGroup><Company id="1061250">Lanzhou Institute of Biological Products</Company><Country id="CN">China</Country><Drug id="80208">human immunoglobulin (pH4, intravenous), Lanzhou Institute of Biological Products</Drug><EntityType>Biological</EntityType><HighestDevStatus id="L">Launched</HighestDevStatus><HighestDevStatusForInd id="L">Launched</HighestDevStatusForInd><Indication id="1">Measles virus infection</Indication><IsActiveCompany>true</IsActiveCompany><LatestChange>2004-12-31 00:00:00</LatestChange><ParentCompany id="1055632">Sinopharm</ParentCompany><Status id="R">Registered</Status><StatusDate>2004-12-31 00:00:00</StatusDate><StatusSortCode>12</StatusSortCode><TherapyArea id="746">Infectious disease</TherapyArea></Row><Row><Action id="12378">Prophylactic vaccine</Action><AuthorityGroup>LOCAL_AND_MAJOR</AuthorityGroup><Company id="1056577">Beijing Minhai Biotechnology Co Ltd</Company><Country id="CN">China</Country><Drug id="82024">measles/rubella vaccine (subcutaneous, live), Beijing Minhai Biotechnology</Drug><EntityType>Biological</EntityType><HighestDevStatus id="L">Launched</HighestDevStatus><HighestDevStatusForInd id="L">Launched</HighestDevStatusForInd><Indication id="1">Measles virus infection</Indication><IsActiveCompany>true</IsActiveCompany><LatestChange>2014-10-24 00:00:00</LatestChange><ParentCompany id="1071345">Kangtai Biological Products Co Ltd</ParentCompany><Status id="L">Launched</Status><StatusDate>2014-10-24 00:00:00</StatusDate><StatusSortCode>13</StatusSortCode><TherapyArea id="746">Infectious disease</TherapyArea></Row><Row><Action id="12378">Prophylactic vaccine</Action><AuthorityGroup>LOCAL_AND_MAJOR</AuthorityGroup><Company id="1056577">Beijing Minhai Biotechnology Co Ltd</Company><Country id="CN">China</Country><Drug id="82024">measles/rubella vaccine (subcutaneous, live), Beijing Minhai Biotechnology</Drug><EntityType>Biological</EntityType><HighestDevStatus id="L">Launched</HighestDevStatus><HighestDevStatusForInd id="L">Launched</HighestDevStatusForInd><Indication id="1">Measles virus infection</Indication><IsActiveCompany>true</IsActiveCompany><LatestChange>2014-10-24 00:00:00</LatestChange><ParentCompany id="1071345">Kangtai Biological Products Co Ltd</ParentCompany><Status id="PR">Pre-registration</Status><StatusDate>2010-11-18 00:00:00</StatusDate><StatusSortCode>11</StatusSortCode><TherapyArea id="746">Infectious disease</TherapyArea></Row><Row><Action id="12364">Live attenuated viral vaccine</Action><AuthorityGroup>LOCAL_AND_MAJOR</AuthorityGroup><Company id="1056577">Beijing Minhai Biotechnology Co Ltd</Company><Country id="CN">China</Country><Drug id="82024">measles/rubella vaccine (subcutaneous, live), Beijing Minhai Biotechnology</Drug><EntityType>Biological</EntityType><HighestDevStatus id="L">Launched</HighestDevStatus><HighestDevStatusForInd id="L">Launched</HighestDevStatusForInd><Indication id="1">Measles virus infection</Indication><IsActiveCompany>true</IsActiveCompany><LatestChange>2014-10-24 00:00:00</LatestChange><ParentCompany id="1071345">Kangtai Biological Products Co Ltd</ParentCompany><Status id="PR">Pre-registration</Status><StatusDate>2010-11-18 00:00:00</StatusDate><StatusSortCode>11</StatusSortCode><TherapyArea id="746">Infectious disease</TherapyArea></Row><Row><Action id="991">Antiviral</Action><AuthorityGroup>LOCAL_AND_MAJOR</AuthorityGroup><Company id="1077144">Hebei Da'an Pharmaceutical Co Ltd</Company><Country id="CN">China</Country><Drug id="82763">human immunoglobulin (intramuscular, measles/hepatitis virus infection), Hebei Da'an Pharmaceutical</Drug><EntityType>Biological</EntityType><HighestDevStatus id="R">Registered</HighestDevStatus><HighestDevStatusForInd id="R">Registered</HighestDevStatusForInd><Indication id="1">Measles virus infection</Indication><IsActiveCompany>true</IsActiveCompany><LatestChange>2013-10-25 00:00:00</LatestChange><ParentCompany id="1077144">Hebei Da'an Pharmaceutical Co Ltd</ParentCompany><Status id="R">Registered</Status><StatusDate>2013-10-25 00:00:00</StatusDate><StatusSortCode>12</StatusSortCode><TherapyArea id="746">Infectious disease</TherapyArea></Row><Row><Action id="12378">Prophylactic vaccine</Action><AuthorityGroup>LOCAL_AND_MAJOR</AuthorityGroup><Company id="1059311">Bio-Manguinhos/Fiocruz</Company><Country id="BR">Brazil</Country><Drug id="94952">MMR vaccine, Bio-Manguinhos/Fiocruz</Drug><EntityType>Biological</EntityType><HighestDevStatus id="C3">Phase 3 Clinical</HighestDevStatus><HighestDevStatusForInd id="C3">Phase 3 Clinical</HighestDevStatusForInd><Indication id="1">Measles virus infection</Indication><IsActiveCompany>true</IsActiveCompany><LatestChange>2015-04-13 00:00:00</LatestChange><ParentCompany id="16154">Fundacao Oswaldo Cruz (Fiocruz)</ParentCompany><Status id="C3">Phase 3 Clinical</Status><StatusDate>2015-04-13 00:00:00</StatusDate><StatusSortCode>10</StatusSortCode><TherapyArea id="746">Infectious disease</TherapyArea></Row><Row><Action id="12364">Live attenuated viral vaccine</Action><AuthorityGroup>OTHER</AuthorityGroup><Company id="19962">SmithKline Beecham plc</Company><Country id="BE">Belgium</Country><Drug id="11457">Priorix</Drug><EntityType>Biological</EntityType><HighestDevStatus id="L">Launched</HighestDevStatus><HighestDevStatusForInd id="L">Launched</HighestDevStatusForInd><Indication id="1">Measles virus infection</Indication><IsActiveCompany>true</IsActiveCompany><LatestChange>2012-06-29 00:00:00</LatestChange><ParentCompany id="28355">GlaxoSmithKline plc</ParentCompany><Status id="R">Registered</Status><StatusDate>1998-03-25 00:00:00</StatusDate><StatusSortCode>12</StatusSortCode><TherapyArea id="746">Infectious disease</TherapyArea></Row><Row><Action id="12378">Prophylactic vaccine</Action><AuthorityGroup>OTHER</AuthorityGroup><Company id="19962">SmithKline Beecham plc</Company><Country id="DK">Denmark</Country><Drug id="11457">Priorix</Drug><EntityType>Biological</EntityType><HighestDevStatus id="L">Launched</HighestDevStatus><HighestDevStatusForInd id="L">Launched</HighestDevStatusForInd><Indication id="1">Measles virus infection</Indication><IsActiveCompany>true</IsActiveCompany><LatestChange>2012-06-29 00:00:00</LatestChange><ParentCompany id="28355">GlaxoSmithKline plc</ParentCompany><Status id="R">Registered</Status><StatusDate>1999-06-10 00:00:00</StatusDate><StatusSortCode>12</StatusSortCode><TherapyArea id="746">Infectious disease</TherapyArea></Row><Row><Action id="12364">Live attenuated viral vaccine</Action><AuthorityGroup>OTHER</AuthorityGroup><Company id="19962">SmithKline Beecham plc</Company><Country id="IE">Ireland</Country><Drug id="11457">Priorix</Drug><EntityType>Biological</EntityType><HighestDevStatus id="L">Launched</HighestDevStatus><HighestDevStatusForInd id="L">Launched</HighestDevStatusForInd><Indication id="1">Measles virus infection</Indication><IsActiveCompany>true</IsActiveCompany><LatestChange>2012-06-29 00:00:00</LatestChange><ParentCompany id="28355">GlaxoSmithKline plc</ParentCompany><Status id="R">Registered</Status><StatusDate>1998-07-27 00:00:00</StatusDate><StatusSortCode>12</StatusSortCode><TherapyArea id="746">Infectious disease</TherapyArea></Row><Row><Action id="12378">Prophylactic vaccine</Action><AuthorityGroup>OTHER</AuthorityGroup><Company id="19962">SmithKline Beecham plc</Company><Country id="IE">Ireland</Country><Drug id="11457">Priorix</Drug><EntityType>Biological</EntityType><HighestDevStatus id="L">Launched</HighestDevStatus><HighestDevStatusForInd id="L">Launched</HighestDevStatusForInd><Indication id="1">Measles virus infection</Indication><IsActiveCompany>true</IsActiveCompany><LatestChange>2012-06-29 00:00:00</LatestChange><ParentCompany id="28355">GlaxoSmithKline plc</ParentCompany><Status id="R">Registered</Status><StatusDate>1998-07-27 00:00:00</StatusDate><StatusSortCode>12</StatusSortCode><TherapyArea id="746">Infectious disease</TherapyArea></Row><Row><Action id="12378">Prophylactic vaccine</Action><AuthorityGroup>OTHER</AuthorityGroup><Company id="28355">GlaxoSmithKline plc</Company><Country id="GR">Greece</Country><Drug id="11457">Priorix</Drug><EntityType>Biological</EntityType><HighestDevStatus id="L">Launched</HighestDevStatus><HighestDevStatusForInd id="L">Launched</HighestDevStatusForInd><Indication id="1">Measles virus infection</Indication><IsActiveCompany>true</IsActiveCompany><LatestChange>2012-06-29 00:00:00</LatestChange><ParentCompany id="28355">GlaxoSmithKline plc</ParentCompany><Status id="R">Registered</Status><StatusDate>1998-11-02 00:00:00</StatusDate><StatusSortCode>12</StatusSortCode><TherapyArea id="746">Infectious disease</TherapyArea></Row><Row><Action id="12364">Live attenuated viral vaccine</Action><AuthorityGroup>OTHER</AuthorityGroup><Company id="28355">GlaxoSmithKline plc</Company><Country id="MT">Malta</Country><Drug id="11457">Priorix</Drug><EntityType>Biological</EntityType><HighestDevStatus id="L">Launched</HighestDevStatus><HighestDevStatusForInd id="L">Launched</HighestDevStatusForInd><Indication id="1">Measles virus infection</Indication><IsActiveCompany>true</IsActiveCompany><LatestChange>2012-06-29 00:00:00</LatestChange><ParentCompany id="28355">GlaxoSmithKline plc</ParentCompany><Status id="R">Registered</Status><StatusDate>2006-03-17 00:00:00</StatusDate><StatusSortCode>12</StatusSortCode><TherapyArea id="746">Infectious disease</TherapyArea></Row><Row><Action id="12378">Prophylactic vaccine</Action><AuthorityGroup>OTHER</AuthorityGroup><Company id="28355">GlaxoSmithKline plc</Company><Country id="MT">Malta</Country><Drug id="11457">Priorix</Drug><EntityType>Biological</EntityType><HighestDevStatus id="L">Launched</HighestDevStatus><HighestDevStatusForInd id="L">Launched</HighestDevStatusForInd><Indication id="1">Measles virus infection</Indication><IsActiveCompany>true</IsActiveCompany><LatestChange>2012-06-29 00:00:00</LatestChange><ParentCompany id="28355">GlaxoSmithKline plc</ParentCompany><Status id="R">Registered</Status><StatusDate>2006-03-17 00:00:00</StatusDate><StatusSortCode>12</StatusSortCode><TherapyArea id="746">Infectious disease</TherapyArea></Row><Row><Action id="12378">Prophylactic vaccine</Action><AuthorityGroup>OTHER</AuthorityGroup><Company id="28355">GlaxoSmithKline plc</Company><Country id="NO">Norway</Country><Drug id="11457">Priorix</Drug><EntityType>Biological</EntityType><HighestDevStatus id="L">Launched</HighestDevStatus><HighestDevStatusForInd id="L">Launched</HighestDevStatusForInd><Indication id="1">Measles virus infection</Indication><IsActiveCompany>true</IsActiveCompany><LatestChange>2012-06-29 00:00:00</LatestChange><ParentCompany id="28355">GlaxoSmithKline plc</ParentCompany><Status id="L">Launched</Status><StatusDate>2005-01-01 00:00:00</StatusDate><StatusSortCode>13</StatusSortCode><TherapyArea id="746">Infectious disease</TherapyArea></Row><Row><Action id="12364">Live attenuated viral vaccine</Action><AuthorityGroup>OTHER</AuthorityGroup><Company id="28355">GlaxoSmithKline plc</Company><Country id="NL">Netherlands</Country><Drug id="11457">Priorix</Drug><EntityType>Biological</EntityType><HighestDevStatus id="L">Launched</HighestDevStatus><HighestDevStatusForInd id="L">Launched</HighestDevStatusForInd><Indication id="1">Measles virus infection</Indication><IsActiveCompany>true</IsActiveCompany><LatestChange>2012-06-29 00:00:00</LatestChange><ParentCompany id="28355">GlaxoSmithKline plc</ParentCompany><Status id="R">Registered</Status><StatusDate>2002-12-17 00:00:00</StatusDate><StatusSortCode>12</StatusSortCode><TherapyArea id="746">Infectious disease</TherapyArea></Row><Row><Action id="991">Antiviral</Action><AuthorityGroup>LOCAL_AND_MAJOR</AuthorityGroup><Company id="1054697">Shanxi Kangbao Biological Products Co Ltd</Company><Country id="CN">China</Country><Drug id="81711">human immunoglobulin (im, hepatitis, measles), Shanxi Kangbao Biological Products</Drug><EntityType>Biological</EntityType><HighestDevStatus id="L">Launched</HighestDevStatus><HighestDevStatusForInd id="L">Launched</HighestDevStatusForInd><Indication id="1">Measles virus infection</Indication><IsActiveCompany>true</IsActiveCompany><LatestChange>1998-12-31 00:00:00</LatestChange><ParentCompany id="1054697">Shanxi Kangbao Biological Products Co Ltd</ParentCompany><Status id="L">Launched</Status><StatusDate>1998-12-31 00:00:00</StatusDate><StatusSortCode>13</StatusSortCode><TherapyArea id="746">Infectious disease</TherapyArea></Row><Row><Action id="393">Immunostimulant</Action><AuthorityGroup>LOCAL_AND_MAJOR</AuthorityGroup><Company id="1080922">Guangxi Beisheng Pharmaceutical Co Ltd</Company><Country id="CN">China</Country><Drug id="85734">human immunoglobulin (intramuscular, measles/hepatitis virus infection), Guangxi Beisheng Pharmaceutical</Drug><EntityType>Biological</EntityType><HighestDevStatus id="DX">Discontinued</HighestDevStatus><HighestDevStatusForInd id="DX">Discontinued</HighestDevStatusForInd><Indication id="1">Measles virus infection</Indication><IsActiveCompany>false</IsActiveCompany><LatestChange>2008-11-27 00:00:00</LatestChange><ParentCompany id="1080922">Guangxi Beisheng Pharmaceutical Co Ltd</ParentCompany><Status id="L">Launched</Status><StatusDate>2005-12-31 00:00:00</StatusDate><StatusSortCode>13</StatusSortCode><TherapyArea id="746">Infectious disease</TherapyArea></Row><Row><Action id="12364">Live attenuated viral vaccine</Action><AuthorityGroup>LOCAL_AND_MAJOR</AuthorityGroup><Company id="18077">Merck &amp; Co Inc</Company><Country id="US">US</Country><Drug id="47279">ProQuad</Drug><EntityType>Biological</EntityType><HighestDevStatus id="L">Launched</HighestDevStatus><HighestDevStatusForInd id="L">Launched</HighestDevStatusForInd><Indication id="1">Measles virus infection</Indication><IsActiveCompany>true</IsActiveCompany><LatestChange>2013-01-10 00:00:00</LatestChange><ParentCompany id="18077">Merck &amp; Co Inc</ParentCompany><Status id="R">Registered</Status><StatusDate>2005-09-06 00:00:00</StatusDate><StatusSortCode>12</StatusSortCode><TherapyArea id="746">Infectious disease</TherapyArea></Row><Row><Action id="12378">Prophylactic vaccine</Action><AuthorityGroup>LOCAL_AND_MAJOR</AuthorityGroup><Company id="18077">Merck &amp; Co Inc</Company><Country id="US">US</Country><Drug id="47279">ProQuad</Drug><EntityType>Biological</EntityType><HighestDevStatus id="L">Launched</HighestDevStatus><HighestDevStatusForInd id="L">Launched</HighestDevStatusForInd><Indication id="1">Measles virus infection</Indication><IsActiveCompany>true</IsActiveCompany><LatestChange>2013-01-10 00:00:00</LatestChange><ParentCompany id="18077">Merck &amp; Co Inc</ParentCompany><Status id="C2">Phase 2 Clinical</Status><StatusDate>1986-12-31 00:00:00</StatusDate><StatusSortCode>9</StatusSortCode><TherapyArea id="746">Infectious disease</TherapyArea></Row><Row><Action id="12378">Prophylactic vaccine</Action><AuthorityGroup>LOCAL_AND_MAJOR</AuthorityGroup><Company id="18077">Merck &amp; Co Inc</Company><Country id="US">US</Country><Drug id="47279">ProQuad</Drug><EntityType>Biological</EntityType><HighestDevStatus id="L">Launched</HighestDevStatus><HighestDevStatusForInd id="L">Launched</HighestDevStatusForInd><Indication id="1">Measles virus infection</Indication><IsActiveCompany>true</IsActiveCompany><LatestChange>2013-01-10 00:00:00</LatestChange><ParentCompany id="18077">Merck &amp; Co Inc</ParentCompany><Status id="L">Launched</Status><StatusDate>2005-09-30 00:00:00</StatusDate><StatusSortCode>13</StatusSortCode><TherapyArea id="746">Infectious disease</TherapyArea></Row><Row><Action id="12375">Toxoid vaccine</Action><AuthorityGroup>OTHER</AuthorityGroup><Company id="23408">Sanofi Pasteur MSD</Company><Country id="BE">Belgium</Country><Drug id="47279">ProQuad</Drug><EntityType>Biological</EntityType><HighestDevStatus id="L">Launched</HighestDevStatus><HighestDevStatusForInd id="L">Launched</HighestDevStatusForInd><Indication id="1">Measles virus infection</Indication><IsActiveCompany>true</IsActiveCompany><LatestChange>2013-01-10 00:00:00</LatestChange><ParentCompany id="18077">Merck &amp; Co Inc</ParentCompany><Status id="R">Registered</Status><StatusDate>2006-04-05 00:00:00</StatusDate><StatusSortCode>12</StatusSortCode><TherapyArea id="746">Infectious disease</TherapyArea></Row><Row><Action id="12378">Prophylactic vaccine</Action><AuthorityGroup>OTHER</AuthorityGroup><Company id="23408">Sanofi Pasteur MSD</Company><Country id="NL">Netherlands</Country><Drug id="47279">ProQuad</Drug><EntityType>Biological</EntityType><HighestDevStatus id="L">Launched</HighestDevStatus><HighestDevStatusForInd id="L">Launched</HighestDevStatusForInd><Indication id="1">Measles virus infection</Indication><IsActiveCompany>true</IsActiveCompany><LatestChange>2013-01-10 00:00:00</LatestChange><ParentCompany id="18077">Merck &amp; Co Inc</ParentCompany><Status id="R">Registered</Status><StatusDate>2006-04-06 00:00:00</StatusDate><StatusSortCode>12</StatusSortCode><TherapyArea id="746">Infectious disease</TherapyArea></Row><Row><Action id="12378">Prophylactic vaccine</Action><AuthorityGroup>OTHER</AuthorityGroup><Company id="22127">Sanofi Pasteur</Company><Country id="CH">Switzerland</Country><Drug id="89684">M-M-RvaxPRO</Drug><EntityType>Biological</EntityType><HighestDevStatus id="L">Launched</HighestDevStatus><HighestDevStatusForInd id="L">Launched</HighestDevStatusForInd><Indication id="1">Measles virus infection</Indication><IsActiveCompany>true</IsActiveCompany><LatestChange>2008-06-01 00:00:00</LatestChange><ParentCompany id="1009547">Sanofi</ParentCompany><Status id="L">Launched</Status><StatusDate>2008-06-01 00:00:00</StatusDate><StatusSortCode>13</StatusSortCode><TherapyArea id="746">Infectious disease</TherapyArea></Row><Row><Action id="59620">Unspecified drug target</Action><AuthorityGroup>LOCAL_AND_MAJOR</AuthorityGroup><Company id="1041544">Shenzhen Weiwu Guangming Biological Products Co Ltd</Company><Country id="CN">China</Country><Drug id="84800">human immunoglobulin (intramuscular, measles/hepatitis virus infection), Shenzhen Weiwu Guangming Biological Products</Drug><EntityType>Biological</EntityType><HighestDevStatus id="L">Launched</HighestDevStatus><HighestDevStatusForInd id="L">Launched</HighestDevStatusForInd><Indication id="1">Measles virus infection</Indication><IsActiveCompany>true</IsActiveCompany><LatestChange>1999-12-31 00:00:00</LatestChange><ParentCompany id="1041544">Shenzhen Weiwu Guangming Biological Products Co Ltd</ParentCompany><Status id="R">Registered</Status><StatusDate>1999-12-31 00:00:00</StatusDate><StatusSortCode>12</StatusSortCode><TherapyArea id="746">Infectious disease</TherapyArea></Row><Row><Action id="59620">Unspecified drug target</Action><AuthorityGroup>LOCAL_AND_MAJOR</AuthorityGroup><Company id="1049660">Hualan Biological Engineering Inc</Company><Country id="CN">China</Country><Drug id="79232">human immunoglobulin (intramuscular, measles/hepatitis virus infection), Hualan Biological Engineering</Drug><EntityType>Biological</EntityType><HighestDevStatus id="L">Launched</HighestDevStatus><HighestDevStatusForInd id="L">Launched</HighestDevStatusForInd><Indication id="1">Measles virus infection</Indication><IsActiveCompany>true</IsActiveCompany><LatestChange>1997-12-31 00:00:00</LatestChange><ParentCompany id="1049660">Hualan Biological Engineering Inc</ParentCompany><Status id="R">Registered</Status><StatusDate>1997-12-31 00:00:00</StatusDate><StatusSortCode>12</StatusSortCode><TherapyArea id="746">Infectious disease</TherapyArea></Row><Row><Action id="991">Antiviral</Action><AuthorityGroup>LOCAL_AND_MAJOR</AuthorityGroup><Company id="1049660">Hualan Biological Engineering Inc</Company><Country id="CN">China</Country><Drug id="79232">human immunoglobulin (intramuscular, measles/hepatitis virus infection), Hualan Biological Engineering</Drug><EntityType>Biological</EntityType><HighestDevStatus id="L">Launched</HighestDevStatus><HighestDevStatusForInd id="L">Launched</HighestDevStatusForInd><Indication id="1">Measles virus infection</Indication><IsActiveCompany>true</IsActiveCompany><LatestChange>1997-12-31 00:00:00</LatestChange><ParentCompany id="1049660">Hualan Biological Engineering Inc</ParentCompany><Status id="L">Launched</Status><StatusDate>1997-12-31 00:00:00</StatusDate><StatusSortCode>13</StatusSortCode><TherapyArea id="746">Infectious disease</TherapyArea></Row><Row><Action id="59620">Unspecified drug target</Action><AuthorityGroup>LOCAL_AND_MAJOR</AuthorityGroup><Company id="1061250">Lanzhou Institute of Biological Products</Company><Country id="CN">China</Country><Drug id="80205">human immunoglobulin (plasma-derived, intramuscular), Lanzhou Institute of Biological Products</Drug><EntityType>Biological</EntityType><HighestDevStatus id="L">Launched</HighestDevStatus><HighestDevStatusForInd id="L">Launched</HighestDevStatusForInd><Indication id="1">Measles virus infection</Indication><IsActiveCompany>true</IsActiveCompany><LatestChange>2002-12-31 00:00:00</LatestChange><ParentCompany id="1055632">Sinopharm</ParentCompany><Status id="R">Registered</Status><StatusDate>2002-12-31 00:00:00</StatusDate><StatusSortCode>12</StatusSortCode><TherapyArea id="746">Infectious disease</TherapyArea></Row><Row><Action id="12364">Live attenuated viral vaccine</Action><AuthorityGroup>LOCAL_AND_MAJOR</AuthorityGroup><Company id="1071897">Shanghai Institute of Biological Products Co Ltd</Company><Country id="CN">China</Country><Drug id="79819">measles/mumps/rubella vaccine (live-attenuated), Shanghai Institute of Biological Products</Drug><EntityType>Biological</EntityType><HighestDevStatus id="L">Launched</HighestDevStatus><HighestDevStatusForInd id="L">Launched</HighestDevStatusForInd><Indication id="1">Measles virus infection</Indication><IsActiveCompany>true</IsActiveCompany><LatestChange>2007-12-31 00:00:00</LatestChange><ParentCompany id="1055632">Sinopharm</ParentCompany><Status id="R">Registered</Status><StatusDate>2007-11-15 00:00:00</StatusDate><StatusSortCode>12</StatusSortCode><TherapyArea id="746">Infectious disease</TherapyArea></Row><Row><Action id="991">Antiviral</Action><AuthorityGroup>LOCAL_AND_MAJOR</AuthorityGroup><Company id="1072329">Harbin Pacific Biopharmaceutical Co Ltd</Company><Country id="CN">China</Country><Drug id="80551">human immunoglobulin (intramuscular, measles, hepatitis virus infection), Harbin Pacific Biopharmaceutical Co Ltd</Drug><EntityType>Biological</EntityType><HighestDevStatus id="L">Launched</HighestDevStatus><HighestDevStatusForInd id="L">Launched</HighestDevStatusForInd><Indication id="1">Measles virus infection</Indication><IsActiveCompany>true</IsActiveCompany><LatestChange>1998-12-31 00:00:00</LatestChange><ParentCompany id="1072329">Harbin Pacific Biopharmaceutical Co Ltd</ParentCompany><Status id="R">Registered</Status><StatusDate>1998-12-31 00:00:00</StatusDate><StatusSortCode>12</StatusSortCode><TherapyArea id="746">Infectious disease</TherapyArea></Row><Row><Action id="1596">Immunomodulator</Action><AuthorityGroup>LOCAL_AND_MAJOR</AuthorityGroup><Company id="1072329">Harbin Pacific Biopharmaceutical Co Ltd</Company><Country id="CN">China</Country><Drug id="80551">human immunoglobulin (intramuscular, measles, hepatitis virus infection), Harbin Pacific Biopharmaceutical Co Ltd</Drug><EntityType>Biological</EntityType><HighestDevStatus id="L">Launched</HighestDevStatus><HighestDevStatusForInd id="L">Launched</HighestDevStatusForInd><Indication id="1">Measles virus infection</Indication><IsActiveCompany>true</IsActiveCompany><LatestChange>1998-12-31 00:00:00</LatestChange><ParentCompany id="1072329">Harbin Pacific Biopharmaceutical Co Ltd</ParentCompany><Status id="L">Launched</Status><StatusDate>1998-12-31 00:00:00</StatusDate><StatusSortCode>13</StatusSortCode><TherapyArea id="746">Infectious disease</TherapyArea></Row><Row><Action id="347">RNA polymerase inhibitor</Action><AuthorityGroup>LOCAL_AND_MAJOR</AuthorityGroup><Company id="20573">Emory University</Company><Country id="US">US</Country><Drug id="77538">non-nucleoside RDRP inhibitors (measles virus infection), Emory University</Drug><EntityType>Chemical</EntityType><HighestDevStatus id="DR">Discovery</HighestDevStatus><HighestDevStatusForInd id="DR">Discovery</HighestDevStatusForInd><Indication id="1">Measles virus infection</Indication><IsActiveCompany>true</IsActiveCompany><LatestChange>2012-01-27 00:00:00</LatestChange><ParentCompany id="20573">Emory University</ParentCompany><Status id="DR">Discovery</Status><StatusDate>2007-02-27 00:00:00</StatusDate><StatusSortCode>6</StatusSortCode><TherapyArea id="746">Infectious disease</TherapyArea></Row><Row><Action id="1532">Viral replication inhibitor</Action><AuthorityGroup>LOCAL_AND_MAJOR</AuthorityGroup><Company id="1069047">Emory University Technology Transfer Office</Company><Country id="US">US</Country><Drug id="77538">non-nucleoside RDRP inhibitors (measles virus infection), Emory University</Drug><EntityType>Chemical</EntityType><HighestDevStatus id="DR">Discovery</HighestDevStatus><HighestDevStatusForInd id="DR">Discovery</HighestDevStatusForInd><Indication id="1">Measles virus infection</Indication><IsActiveCompany>true</IsActiveCompany><LatestChange>2012-01-27 00:00:00</LatestChange><ParentCompany id="20573">Emory University</ParentCompany><Status id="DR">Discovery</Status><StatusDate>2012-01-27 00:00:00</StatusDate><StatusSortCode>6</StatusSortCode><TherapyArea id="746">Infectious disease</TherapyArea></Row><Row><Action id="347">RNA polymerase inhibitor</Action><AuthorityGroup>LOCAL_AND_MAJOR</AuthorityGroup><Company id="1069047">Emory University Technology Transfer Office</Company><Country id="US">US</Country><Drug id="77538">non-nucleoside RDRP inhibitors (measles virus infection), Emory University</Drug><EntityType>Chemical</EntityType><HighestDevStatus id="DR">Discovery</HighestDevStatus><HighestDevStatusForInd id="DR">Discovery</HighestDevStatusForInd><Indication id="1">Measles virus infection</Indication><IsActiveCompany>true</IsActiveCompany><LatestChange>2012-01-27 00:00:00</LatestChange><ParentCompany id="20573">Emory University</ParentCompany><Status id="DR">Discovery</Status><StatusDate>2012-01-27 00:00:00</StatusDate><StatusSortCode>6</StatusSortCode><TherapyArea id="746">Infectious disease</TherapyArea></Row><Row><Action id="12378">Prophylactic vaccine</Action><AuthorityGroup>LOCAL_AND_MAJOR</AuthorityGroup><Company id="1027662">Beijing Tiantan Biological Products Co Ltd</Company><Country id="CN">China</Country><Drug id="89450">measles/mumps/rubella/varicella vaccine (live-attenuated), Beijing Tiantan Biological Products</Drug><EntityType>Biological</EntityType><HighestDevStatus id="DR">Discovery</HighestDevStatus><HighestDevStatusForInd id="DR">Discovery</HighestDevStatusForInd><Indication id="1">Measles virus infection</Indication><IsActiveCompany>true</IsActiveCompany><LatestChange>2013-11-12 00:00:00</LatestChange><ParentCompany id="1055632">Sinopharm</ParentCompany><Status id="DR">Discovery</Status><StatusDate>2013-11-12 00:00:00</StatusDate><StatusSortCode>6</StatusSortCode><TherapyArea id="746">Infectious disease</TherapyArea></Row><Row><Action id="12364">Live attenuated viral vaccine</Action><AuthorityGroup>OTHER</AuthorityGroup><Company id="24166">GlaxoSmithKline Biologicals</Company><Country id="BE">Belgium</Country><Drug id="17141">Priorix-Tetra</Drug><EntityType>Biological</EntityType><HighestDevStatus id="L">Launched</HighestDevStatus><HighestDevStatusForInd id="L">Launched</HighestDevStatusForInd><Indication id="1">Measles virus infection</Indication><IsActiveCompany>false</IsActiveCompany><LatestChange>2008-01-10 00:00:00</LatestChange><ParentCompany id="28355">GlaxoSmithKline plc</ParentCompany><Status id="C2">Phase 2 Clinical</Status><StatusDate>1998-02-01 00:00:00</StatusDate><StatusSortCode>9</StatusSortCode><TherapyArea id="746">Infectious disease</TherapyArea></Row><Row><Action id="12364">Live attenuated viral vaccine</Action><AuthorityGroup>OTHER</AuthorityGroup><Company id="28355">GlaxoSmithKline plc</Company><Country id="LV">Latvia</Country><Drug id="17141">Priorix-Tetra</Drug><EntityType>Biological</EntityType><HighestDevStatus id="L">Launched</HighestDevStatus><HighestDevStatusForInd id="L">Launched</HighestDevStatusForInd><Indication id="1">Measles virus infection</Indication><IsActiveCompany>true</IsActiveCompany><LatestChange>2008-01-10 00:00:00</LatestChange><ParentCompany id="28355">GlaxoSmithKline plc</ParentCompany><Status id="R">Registered</Status><StatusDate>2007-12-05 00:00:00</StatusDate><StatusSortCode>12</StatusSortCode><TherapyArea id="746">Infectious disease</TherapyArea></Row><Row><Action id="12378">Prophylactic vaccine</Action><AuthorityGroup>OTHER</AuthorityGroup><Company id="28355">GlaxoSmithKline plc</Company><Country id="IS">Iceland</Country><Drug id="17141">Priorix-Tetra</Drug><EntityType>Biological</EntityType><HighestDevStatus id="L">Launched</HighestDevStatus><HighestDevStatusForInd id="L">Launched</HighestDevStatusForInd><Indication id="1">Measles virus infection</Indication><IsActiveCompany>true</IsActiveCompany><LatestChange>2008-01-10 00:00:00</LatestChange><ParentCompany id="28355">GlaxoSmithKline plc</ParentCompany><Status id="R">Registered</Status><StatusDate>2007-08-23 00:00:00</StatusDate><StatusSortCode>12</StatusSortCode><TherapyArea id="746">Infectious disease</TherapyArea></Row><Row><Action id="12378">Prophylactic vaccine</Action><AuthorityGroup>OTHER</AuthorityGroup><Company id="24766">Crucell Switzerland AG</Company><Country id="CH">Switzerland</Country><Drug id="41069">second-generation MMR vaccine, Berna</Drug><EntityType>Biological</EntityType><HighestDevStatus id="NDR">No Development Reported</HighestDevStatus><HighestDevStatusForInd id="NDR">No Development Reported</HighestDevStatusForInd><Indication id="1">Measles virus infection</Indication><IsActiveCompany>false</IsActiveCompany><LatestChange>2006-03-28 00:00:00</LatestChange><ParentCompany id="17332">Johnson &amp; Johnson</ParentCompany><Status id="C3">Phase 3 Clinical</Status><StatusDate>2004-08-31 00:00:00</StatusDate><StatusSortCode>10</StatusSortCode><TherapyArea id="746">Infectious disease</TherapyArea></Row><Row><Action id="12370">Recombinant viral vector vaccine</Action><AuthorityGroup>LOCAL_AND_MAJOR</AuthorityGroup><Company id="24244">Bavarian Nordic A/S</Company><Country id="DK">Denmark</Country><Drug id="54328">MVA-mBN85B</Drug><EntityType>Biological</EntityType><HighestDevStatus id="NDR">No Development Reported</HighestDevStatus><HighestDevStatusForInd id="NDR">No Development Reported</HighestDevStatusForInd><Indication id="1">Measles virus infection</Indication><IsActiveCompany>false</IsActiveCompany><LatestChange>2011-11-29 00:00:00</LatestChange><ParentCompany id="24244">Bavarian Nordic A/S</ParentCompany><Status id="DR">Discovery</Status><StatusDate>2005-03-04 00:00:00</StatusDate><StatusSortCode>6</StatusSortCode><TherapyArea id="746">Infectious disease</TherapyArea></Row><Row><Action id="12364">Live attenuated viral vaccine</Action><AuthorityGroup>LOCAL_AND_MAJOR</AuthorityGroup><Company id="1032149">Aktiv-Dry LLC</Company><Country id="US">US</Country><Drug id="57263">measles vaccine (inhaled dry powder/CAN-BD), Aktiv-Dry</Drug><EntityType>Biological</EntityType><HighestDevStatus id="C1">Phase 1 Clinical</HighestDevStatus><HighestDevStatusForInd id="C1">Phase 1 Clinical</HighestDevStatusForInd><Indication id="1">Measles virus infection</Indication><IsActiveCompany>true</IsActiveCompany><LatestChange>2012-03-28 00:00:00</LatestChange><ParentCompany id="1032149">Aktiv-Dry LLC</ParentCompany><Status id="DR">Discovery</Status><StatusDate>2005-09-30 00:00:00</StatusDate><StatusSortCode>6</StatusSortCode><TherapyArea id="746">Infectious disease</TherapyArea></Row><Row><Action id="12378">Prophylactic vaccine</Action><AuthorityGroup>LOCAL_AND_MAJOR</AuthorityGroup><Company id="20667">Ramot at Tel Aviv University Ltd</Company><Country id="IL">Israel</Country><Drug id="7566">vaccine (measles), Ramot</Drug><EntityType>Biological</EntityType><HighestDevStatus id="NDR">No Development Reported</HighestDevStatus><HighestDevStatusForInd id="NDR">No Development Reported</HighestDevStatusForInd><Indication id="1">Measles virus infection</Indication><IsActiveCompany>false</IsActiveCompany><LatestChange>2001-06-13 00:00:00</LatestChange><ParentCompany id="25012">Tel Aviv University</ParentCompany><Status id="NDR">No Development Reported</Status><StatusDate>2001-06-13 00:00:00</StatusDate><StatusSortCode>2</StatusSortCode><TherapyArea id="746">Infectious disease</TherapyArea></Row><Row><Action id="12364">Live attenuated viral vaccine</Action><AuthorityGroup>LOCAL_AND_MAJOR</AuthorityGroup><Company id="1027662">Beijing Tiantan Biological Products Co Ltd</Company><Country id="CN">China</Country><Drug id="79155">measles/rubella vaccine (subcutaneous, live), Beijing Tiantan Biological Products</Drug><EntityType>Biological</EntityType><HighestDevStatus id="L">Launched</HighestDevStatus><HighestDevStatusForInd id="L">Launched</HighestDevStatusForInd><Indication id="1">Measles virus infection</Indication><IsActiveCompany>true</IsActiveCompany><LatestChange>2002-12-31 00:00:00</LatestChange><ParentCompany id="1055632">Sinopharm</ParentCompany><Status id="R">Registered</Status><StatusDate>2002-12-31 00:00:00</StatusDate><StatusSortCode>12</StatusSortCode><TherapyArea id="746">Infectious disease</TherapyArea></Row><Row><Action id="991">Antiviral</Action><AuthorityGroup>LOCAL_AND_MAJOR</AuthorityGroup><Company id="1064321">Universal Stabilization Technologies Inc</Company><Country id="US">US</Country><Drug id="73077">thermostable vaccines (pulmonary, measles), Universal Stabilization Technologies</Drug><EntityType>Biological</EntityType><HighestDevStatus id="NDR">No Development Reported</HighestDevStatus><HighestDevStatusForInd id="NDR">No Development Reported</HighestDevStatusForInd><Indication id="1">Measles virus infection</Indication><IsActiveCompany>false</IsActiveCompany><LatestChange>2012-10-17 00:00:00</LatestChange><ParentCompany id="1064321">Universal Stabilization Technologies Inc</ParentCompany><Status id="NDR">No Development Reported</Status><StatusDate>2012-10-17 00:00:00</StatusDate><StatusSortCode>2</StatusSortCode><TherapyArea id="746">Infectious disease</TherapyArea></Row><Row><Action id="393">Immunostimulant</Action><AuthorityGroup>LOCAL_AND_MAJOR</AuthorityGroup><Company id="1087965">Guizhou Taibang Biological Products Co Ltd</Company><Country id="CN">China</Country><Drug id="87540">human immunoglobulin (intramuscular, measles/hepatitis virus infection), Guizhou Taibang Biological Products</Drug><EntityType>Biological</EntityType><HighestDevStatus id="L">Launched</HighestDevStatus><HighestDevStatusForInd id="L">Launched</HighestDevStatusForInd><Indication id="1">Measles virus infection</Indication><IsActiveCompany>true</IsActiveCompany><LatestChange>2000-12-31 00:00:00</LatestChange><ParentCompany id="1041423">China Biologic Products Inc</ParentCompany><Status id="R">Registered</Status><StatusDate>2000-12-31 00:00:00</StatusDate><StatusSortCode>12</StatusSortCode><TherapyArea id="746">Infectious disease</TherapyArea></Row><Row><Action id="59620">Unspecified drug target</Action><AuthorityGroup>LOCAL_AND_MAJOR</AuthorityGroup><Company id="1076477">Banghe Pharmaceutical Co Ltd</Company><Country id="CN">China</Country><Drug id="85214">human immunoglobulin (intramuscular, measles/hepatitis virus infection), Banghe Pharmaceutical</Drug><EntityType>Biological</EntityType><HighestDevStatus id="L">Launched</HighestDevStatus><HighestDevStatusForInd id="L">Launched</HighestDevStatusForInd><Indication id="1">Measles virus infection</Indication><IsActiveCompany>true</IsActiveCompany><LatestChange>2002-12-31 00:00:00</LatestChange><ParentCompany id="1076477">Banghe Pharmaceutical Co Ltd</ParentCompany><Status id="R">Registered</Status><StatusDate>2002-12-31 00:00:00</StatusDate><StatusSortCode>12</StatusSortCode><TherapyArea id="746">Infectious disease</TherapyArea></Row><Row><Action id="393">Immunostimulant</Action><AuthorityGroup>LOCAL_AND_MAJOR</AuthorityGroup><Company id="1076477">Banghe Pharmaceutical Co Ltd</Company><Country id="CN">China</Country><Drug id="85214">human immunoglobulin (intramuscular, measles/hepatitis virus infection), Banghe Pharmaceutical</Drug><EntityType>Biological</EntityType><HighestDevStatus id="L">Launched</HighestDevStatus><HighestDevStatusForInd id="L">Launched</HighestDevStatusForInd><Indication id="1">Measles virus infection</Indication><IsActiveCompany>true</IsActiveCompany><LatestChange>2002-12-31 00:00:00</LatestChange><ParentCompany id="1076477">Banghe Pharmaceutical Co Ltd</ParentCompany><Status id="R">Registered</Status><StatusDate>2002-12-31 00:00:00</StatusDate><StatusSortCode>12</StatusSortCode><TherapyArea id="746">Infectious disease</TherapyArea></Row><Row><Action id="12364">Live attenuated viral vaccine</Action><AuthorityGroup>LOCAL_AND_MAJOR</AuthorityGroup><Company id="1056577">Beijing Minhai Biotechnology Co Ltd</Company><Country id="CN">China</Country><Drug id="82024">measles/rubella vaccine (subcutaneous, live), Beijing Minhai Biotechnology</Drug><EntityType>Biological</EntityType><HighestDevStatus id="L">Launched</HighestDevStatus><HighestDevStatusForInd id="L">Launched</HighestDevStatusForInd><Indication id="1">Measles virus infection</Indication><IsActiveCompany>true</IsActiveCompany><LatestChange>2014-10-24 00:00:00</LatestChange><ParentCompany id="1071345">Kangtai Biological Products Co Ltd</ParentCompany><Status id="R">Registered</Status><StatusDate>2012-10-30 00:00:00</StatusDate><StatusSortCode>12</StatusSortCode><TherapyArea id="746">Infectious disease</TherapyArea></Row><Row><Action id="1596">Immunomodulator</Action><AuthorityGroup>LOCAL_AND_MAJOR</AuthorityGroup><Company id="1077144">Hebei Da'an Pharmaceutical Co Ltd</Company><Country id="CN">China</Country><Drug id="82763">human immunoglobulin (intramuscular, measles/hepatitis virus infection), Hebei Da'an Pharmaceutical</Drug><EntityType>Biological</EntityType><HighestDevStatus id="R">Registered</HighestDevStatus><HighestDevStatusForInd id="R">Registered</HighestDevStatusForInd><Indication id="1">Measles virus infection</Indication><IsActiveCompany>true</IsActiveCompany><LatestChange>2013-10-25 00:00:00</LatestChange><ParentCompany id="1077144">Hebei Da'an Pharmaceutical Co Ltd</ParentCompany><Status id="L">Launched</Status><StatusDate>2006-12-31 00:00:00</StatusDate><StatusSortCode>13</StatusSortCode><TherapyArea id="746">Infectious disease</TherapyArea></Row><Row><Action id="59620">Unspecified drug target</Action><AuthorityGroup>LOCAL_AND_MAJOR</AuthorityGroup><Company id="1077144">Hebei Da'an Pharmaceutical Co Ltd</Company><Country id="CN">China</Country><Drug id="82763">human immunoglobulin (intramuscular, measles/hepatitis virus infection), Hebei Da'an Pharmaceutical</Drug><EntityType>Biological</EntityType><HighestDevStatus id="R">Registered</HighestDevStatus><HighestDevStatusForInd id="R">Registered</HighestDevStatusForInd><Indication id="1">Measles virus infection</Indication><IsActiveCompany>true</IsActiveCompany><LatestChange>2013-10-25 00:00:00</LatestChange><ParentCompany id="1077144">Hebei Da'an Pharmaceutical Co Ltd</ParentCompany><Status id="W">Withdrawn</Status><StatusDate>2012-08-03 00:00:00</StatusDate><StatusSortCode>4</StatusSortCode><TherapyArea id="746">Infectious disease</TherapyArea></Row><Row><Action id="59620">Unspecified drug target</Action><AuthorityGroup>LOCAL_AND_MAJOR</AuthorityGroup><Company id="1081842">Sichuan Yuanda Shuyang Pharmaceutical Co Ltd</Company><Country id="CN">China</Country><Drug id="84689">human immunoglobulin (intramuscular, measles/hepatitis virus infection), Sichuan Yuanda Shuyang Pharmaceutical</Drug><EntityType>Biological</EntityType><HighestDevStatus id="L">Launched</HighestDevStatus><HighestDevStatusForInd id="L">Launched</HighestDevStatusForInd><Indication id="1">Measles virus infection</Indication><IsActiveCompany>true</IsActiveCompany><LatestChange>1998-12-31 00:00:00</LatestChange><ParentCompany id="1081842">Sichuan Yuanda Shuyang Pharmaceutical Co Ltd</ParentCompany><Status id="R">Registered</Status><StatusDate>1998-12-31 00:00:00</StatusDate><StatusSortCode>12</StatusSortCode><TherapyArea id="746">Infectious disease</TherapyArea></Row><Row><Action id="393">Immunostimulant</Action><AuthorityGroup>LOCAL_AND_MAJOR</AuthorityGroup><Company id="1079335">Guangdong Weilun Biological Products Co Ltd</Company><Country id="CN">China</Country><Drug id="84826">human immunoglobulin (intramuscular, measles/hepatitis virus infection), Guangdong Weilun Biological Products</Drug><EntityType>Biological</EntityType><HighestDevStatus id="L">Launched</HighestDevStatus><HighestDevStatusForInd id="L">Launched</HighestDevStatusForInd><Indication id="1">Measles virus infection</Indication><IsActiveCompany>true</IsActiveCompany><LatestChange>2000-12-31 00:00:00</LatestChange><ParentCompany id="1079335">Guangdong Weilun Biological Products Co Ltd</ParentCompany><Status id="R">Registered</Status><StatusDate>2000-12-31 00:00:00</StatusDate><StatusSortCode>12</StatusSortCode><TherapyArea id="746">Infectious disease</TherapyArea></Row><Row><Action id="59620">Unspecified drug target</Action><AuthorityGroup>LOCAL_AND_MAJOR</AuthorityGroup><Company id="1071897">Shanghai Institute of Biological Products Co Ltd</Company><Country id="CN">China</Country><Drug id="80171">human immunoglobulin (intramuscular), Shanghai Institute of Biological Products</Drug><EntityType>Biological</EntityType><HighestDevStatus id="L">Launched</HighestDevStatus><HighestDevStatusForInd id="L">Launched</HighestDevStatusForInd><Indication id="1">Measles virus infection</Indication><IsActiveCompany>true</IsActiveCompany><LatestChange>1997-12-31 00:00:00</LatestChange><ParentCompany id="1055632">Sinopharm</ParentCompany><Status id="L">Launched</Status><StatusDate>1997-12-31 00:00:00</StatusDate><StatusSortCode>13</StatusSortCode><TherapyArea id="746">Infectious disease</TherapyArea></Row><Row><Action id="991">Antiviral</Action><AuthorityGroup>LOCAL_AND_MAJOR</AuthorityGroup><Company id="1071897">Shanghai Institute of Biological Products Co Ltd</Company><Country id="CN">China</Country><Drug id="80171">human immunoglobulin (intramuscular), Shanghai Institute of Biological Products</Drug><EntityType>Biological</EntityType><HighestDevStatus id="L">Launched</HighestDevStatus><HighestDevStatusForInd id="L">Launched</HighestDevStatusForInd><Indication id="1">Measles virus infection</Indication><IsActiveCompany>true</IsActiveCompany><LatestChange>1997-12-31 00:00:00</LatestChange><ParentCompany id="1055632">Sinopharm</ParentCompany><Status id="R">Registered</Status><StatusDate>1997-12-31 00:00:00</StatusDate><StatusSortCode>12</StatusSortCode><TherapyArea id="746">Infectious disease</TherapyArea></Row><Row><Action id="393">Immunostimulant</Action><AuthorityGroup>LOCAL_AND_MAJOR</AuthorityGroup><Company id="1061250">Lanzhou Institute of Biological Products</Company><Country id="CN">China</Country><Drug id="80208">human immunoglobulin (pH4, intravenous), Lanzhou Institute of Biological Products</Drug><EntityType>Biological</EntityType><HighestDevStatus id="L">Launched</HighestDevStatus><HighestDevStatusForInd id="L">Launched</HighestDevStatusForInd><Indication id="1">Measles virus infection</Indication><IsActiveCompany>true</IsActiveCompany><LatestChange>2004-12-31 00:00:00</LatestChange><ParentCompany id="1055632">Sinopharm</ParentCompany><Status id="R">Registered</Status><StatusDate>2004-12-31 00:00:00</StatusDate><StatusSortCode>12</StatusSortCode><TherapyArea id="746">Infectious disease</TherapyArea></Row><Row><Action id="12378">Prophylactic vaccine</Action><AuthorityGroup>OTHER</AuthorityGroup><Company id="19962">SmithKline Beecham plc</Company><Country id="CN">China</Country><Drug id="11457">Priorix</Drug><EntityType>Biological</EntityType><HighestDevStatus id="L">Launched</HighestDevStatus><HighestDevStatusForInd id="L">Launched</HighestDevStatusForInd><Indication id="1">Measles virus infection</Indication><IsActiveCompany>true</IsActiveCompany><LatestChange>2012-06-29 00:00:00</LatestChange><ParentCompany id="28355">GlaxoSmithKline plc</ParentCompany><Status id="R">Registered</Status><StatusDate>1998-12-25 00:00:00</StatusDate><StatusSortCode>12</StatusSortCode><TherapyArea id="746">Infectious disease</TherapyArea></Row><Row><Action id="12378">Prophylactic vaccine</Action><AuthorityGroup>OTHER</AuthorityGroup><Company id="19962">SmithKline Beecham plc</Company><Country id="FR">France</Country><Drug id="11457">Priorix</Drug><EntityType>Biological</EntityType><HighestDevStatus id="L">Launched</HighestDevStatus><HighestDevStatusForInd id="L">Launched</HighestDevStatusForInd><Indication id="1">Measles virus infection</Indication><IsActiveCompany>true</IsActiveCompany><LatestChange>2012-06-29 00:00:00</LatestChange><ParentCompany id="28355">GlaxoSmithKline plc</ParentCompany><Status id="L">Launched</Status><StatusDate>1999-10-13 00:00:00</StatusDate><StatusSortCode>13</StatusSortCode><TherapyArea id="746">Infectious disease</TherapyArea></Row><Row><Action id="12378">Prophylactic vaccine</Action><AuthorityGroup>OTHER</AuthorityGroup><Company id="19962">SmithKline Beecham plc</Company><Country id="DE">Germany</Country><Drug id="11457">Priorix</Drug><EntityType>Biological</EntityType><HighestDevStatus id="L">Launched</HighestDevStatus><HighestDevStatusForInd id="L">Launched</HighestDevStatusForInd><Indication id="1">Measles virus infection</Indication><IsActiveCompany>true</IsActiveCompany><LatestChange>2012-06-29 00:00:00</LatestChange><ParentCompany id="28355">GlaxoSmithKline plc</ParentCompany><Status id="L">Launched</Status><StatusDate>1998-03-25 00:00:00</StatusDate><StatusSortCode>13</StatusSortCode><TherapyArea id="746">Infectious disease</TherapyArea></Row><Row><Action id="12364">Live attenuated viral vaccine</Action><AuthorityGroup>OTHER</AuthorityGroup><Company id="28355">GlaxoSmithKline plc</Company><Country id="PR">Puerto Rico</Country><Drug id="11457">Priorix</Drug><EntityType>Biological</EntityType><HighestDevStatus id="L">Launched</HighestDevStatus><HighestDevStatusForInd id="L">Launched</HighestDevStatusForInd><Indication id="1">Measles virus infection</Indication><IsActiveCompany>true</IsActiveCompany><LatestChange>2012-06-29 00:00:00</LatestChange><ParentCompany id="28355">GlaxoSmithKline plc</ParentCompany><Status id="C3">Phase 3 Clinical</Status><StatusDate>2012-06-29 00:00:00</StatusDate><StatusSortCode>10</StatusSortCode><TherapyArea id="746">Infectious disease</TherapyArea></Row><Row><Action id="12364">Live attenuated viral vaccine</Action><AuthorityGroup>OTHER</AuthorityGroup><Company id="28355">GlaxoSmithKline plc</Company><Country id="NO">Norway</Country><Drug id="11457">Priorix</Drug><EntityType>Biological</EntityType><HighestDevStatus id="L">Launched</HighestDevStatus><HighestDevStatusForInd id="L">Launched</HighestDevStatusForInd><Indication id="1">Measles virus infection</Indication><IsActiveCompany>true</IsActiveCompany><LatestChange>2012-06-29 00:00:00</LatestChange><ParentCompany id="28355">GlaxoSmithKline plc</ParentCompany><Status id="L">Launched</Status><StatusDate>2005-01-01 00:00:00</StatusDate><StatusSortCode>13</StatusSortCode><TherapyArea id="746">Infectious disease</TherapyArea></Row><Row><Action id="12378">Prophylactic vaccine</Action><AuthorityGroup>OTHER</AuthorityGroup><Company id="28355">GlaxoSmithKline plc</Company><Country id="NL">Netherlands</Country><Drug id="11457">Priorix</Drug><EntityType>Biological</EntityType><HighestDevStatus id="L">Launched</HighestDevStatus><HighestDevStatusForInd id="L">Launched</HighestDevStatusForInd><Indication id="1">Measles virus infection</Indication><IsActiveCompany>true</IsActiveCompany><LatestChange>2012-06-29 00:00:00</LatestChange><ParentCompany id="28355">GlaxoSmithKline plc</ParentCompany><Status id="R">Registered</Status><StatusDate>2002-12-17 00:00:00</StatusDate><StatusSortCode>12</StatusSortCode><TherapyArea id="746">Infectious disease</TherapyArea></Row><Row><Action id="393">Immunostimulant</Action><AuthorityGroup>LOCAL_AND_MAJOR</AuthorityGroup><Company id="1054697">Shanxi Kangbao Biological Products Co Ltd</Company><Country id="CN">China</Country><Drug id="81711">human immunoglobulin (im, hepatitis, measles), Shanxi Kangbao Biological Products</Drug><EntityType>Biological</EntityType><HighestDevStatus id="L">Launched</HighestDevStatus><HighestDevStatusForInd id="L">Launched</HighestDevStatusForInd><Indication id="1">Measles virus infection</Indication><IsActiveCompany>true</IsActiveCompany><LatestChange>1998-12-31 00:00:00</LatestChange><ParentCompany id="1054697">Shanxi Kangbao Biological Products Co Ltd</ParentCompany><Status id="R">Registered</Status><StatusDate>1998-12-31 00:00:00</StatusDate><StatusSortCode>12</StatusSortCode><TherapyArea id="746">Infectious disease</TherapyArea></Row><Row><Action id="991">Antiviral</Action><AuthorityGroup>LOCAL_AND_MAJOR</AuthorityGroup><Company id="1054697">Shanxi Kangbao Biological Products Co Ltd</Company><Country id="CN">China</Country><Drug id="81711">human immunoglobulin (im, hepatitis, measles), Shanxi Kangbao Biological Products</Drug><EntityType>Biological</EntityType><HighestDevStatus id="L">Launched</HighestDevStatus><HighestDevStatusForInd id="L">Launched</HighestDevStatusForInd><Indication id="1">Measles virus infection</Indication><IsActiveCompany>true</IsActiveCompany><LatestChange>1998-12-31 00:00:00</LatestChange><ParentCompany id="1054697">Shanxi Kangbao Biological Products Co Ltd</ParentCompany><Status id="R">Registered</Status><StatusDate>1998-12-31 00:00:00</StatusDate><StatusSortCode>12</StatusSortCode><TherapyArea id="746">Infectious disease</TherapyArea></Row><Row><Action id="393">Immunostimulant</Action><AuthorityGroup>LOCAL_AND_MAJOR</AuthorityGroup><Company id="1054697">Shanxi Kangbao Biological Products Co Ltd</Company><Country id="CN">China</Country><Drug id="81711">human immunoglobulin (im, hepatitis, measles), Shanxi Kangbao Biological Products</Drug><EntityType>Biological</EntityType><HighestDevStatus id="L">Launched</HighestDevStatus><HighestDevStatusForInd id="L">Launched</HighestDevStatusForInd><Indication id="1">Measles virus infection</Indication><IsActiveCompany>true</IsActiveCompany><LatestChange>1998-12-31 00:00:00</LatestChange><ParentCompany id="1054697">Shanxi Kangbao Biological Products Co Ltd</ParentCompany><Status id="L">Launched</Status><StatusDate>1998-12-31 00:00:00</StatusDate><StatusSortCode>13</StatusSortCode><TherapyArea id="746">Infectious disease</TherapyArea></Row><Row><Action id="991">Antiviral</Action><AuthorityGroup>LOCAL_AND_MAJOR</AuthorityGroup><Company id="1051158">Goff Hill Ltd</Company><Country id="CA">Canada</Country><Drug id="65451">antiviral therapeutics (viral infections/measles/multiple sclerosis), Goff Hill</Drug><EntityType>Chemical</EntityType><HighestDevStatus id="CU">Clinical</HighestDevStatus><HighestDevStatusForInd id="CU">Clinical</HighestDevStatusForInd><Indication id="1">Measles virus infection</Indication><IsActiveCompany>true</IsActiveCompany><LatestChange>2014-11-06 00:00:00</LatestChange><ParentCompany id="1051158">Goff Hill Ltd</ParentCompany><Status id="DR">Discovery</Status><StatusDate>2008-06-02 00:00:00</StatusDate><StatusSortCode>6</StatusSortCode><TherapyArea id="746">Infectious disease</TherapyArea></Row><Row><Action id="12375">Toxoid vaccine</Action><AuthorityGroup>LOCAL_AND_MAJOR</AuthorityGroup><Company id="18077">Merck &amp; Co Inc</Company><Country id="US">US</Country><Drug id="47279">ProQuad</Drug><EntityType>Biological</EntityType><HighestDevStatus id="L">Launched</HighestDevStatus><HighestDevStatusForInd id="L">Launched</HighestDevStatusForInd><Indication id="1">Measles virus infection</Indication><IsActiveCompany>true</IsActiveCompany><LatestChange>2013-01-10 00:00:00</LatestChange><ParentCompany id="18077">Merck &amp; Co Inc</ParentCompany><Status id="PR">Pre-registration</Status><StatusDate>2004-08-31 00:00:00</StatusDate><StatusSortCode>11</StatusSortCode><TherapyArea id="746">Infectious disease</TherapyArea></Row><Row><Action id="12375">Toxoid vaccine</Action><AuthorityGroup>LOCAL_AND_MAJOR</AuthorityGroup><Company id="23408">Sanofi Pasteur MSD</Company><Country id="XW">Western Europe</Country><Drug id="47279">ProQuad</Drug><EntityType>Biological</EntityType><HighestDevStatus id="L">Launched</HighestDevStatus><HighestDevStatusForInd id="L">Launched</HighestDevStatusForInd><Indication id="1">Measles virus infection</Indication><IsActiveCompany>true</IsActiveCompany><LatestChange>2013-01-10 00:00:00</LatestChange><ParentCompany id="18077">Merck &amp; Co Inc</ParentCompany><Status id="PR">Pre-registration</Status><StatusDate>2004-10-18 00:00:00</StatusDate><StatusSortCode>11</StatusSortCode><TherapyArea id="746">Infectious disease</TherapyArea></Row><Row><Action id="12378">Prophylactic vaccine</Action><AuthorityGroup>OTHER</AuthorityGroup><Company id="23408">Sanofi Pasteur MSD</Company><Country id="LV">Latvia</Country><Drug id="47279">ProQuad</Drug><EntityType>Biological</EntityType><HighestDevStatus id="L">Launched</HighestDevStatus><HighestDevStatusForInd id="L">Launched</HighestDevStatusForInd><Indication id="1">Measles virus infection</Indication><IsActiveCompany>true</IsActiveCompany><LatestChange>2013-01-10 00:00:00</LatestChange><ParentCompany id="18077">Merck &amp; Co Inc</ParentCompany><Status id="R">Registered</Status><StatusDate>2006-04-06 00:00:00</StatusDate><StatusSortCode>12</StatusSortCode><TherapyArea id="746">Infectious disease</TherapyArea></Row><Row><Action id="393">Immunostimulant</Action><AuthorityGroup>LOCAL_AND_MAJOR</AuthorityGroup><Company id="1080922">Guangxi Beisheng Pharmaceutical Co Ltd</Company><Country id="CN">China</Country><Drug id="85734">human immunoglobulin (intramuscular, measles/hepatitis virus infection), Guangxi Beisheng Pharmaceutical</Drug><EntityType>Biological</EntityType><HighestDevStatus id="DX">Discontinued</HighestDevStatus><HighestDevStatusForInd id="DX">Discontinued</HighestDevStatusForInd><Indication id="1">Measles virus infection</Indication><IsActiveCompany>false</IsActiveCompany><LatestChange>2008-11-27 00:00:00</LatestChange><ParentCompany id="1080922">Guangxi Beisheng Pharmaceutical Co Ltd</ParentCompany><Status id="R">Registered</Status><StatusDate>2005-12-31 00:00:00</StatusDate><StatusSortCode>12</StatusSortCode><TherapyArea id="746">Infectious disease</TherapyArea></Row><Row><Action id="991">Antiviral</Action><AuthorityGroup>LOCAL_AND_MAJOR</AuthorityGroup><Company id="1080922">Guangxi Beisheng Pharmaceutical Co Ltd</Company><Country id="CN">China</Country><Drug id="85734">human immunoglobulin (intramuscular, measles/hepatitis virus infection), Guangxi Beisheng Pharmaceutical</Drug><EntityType>Biological</EntityType><HighestDevStatus id="DX">Discontinued</HighestDevStatus><HighestDevStatusForInd id="DX">Discontinued</HighestDevStatusForInd><Indication id="1">Measles virus infection</Indication><IsActiveCompany>false</IsActiveCompany><LatestChange>2008-11-27 00:00:00</LatestChange><ParentCompany id="1080922">Guangxi Beisheng Pharmaceutical Co Ltd</ParentCompany><Status id="DX">Discontinued</Status><StatusDate>2008-11-27 00:00:00</StatusDate><StatusSortCode>3</StatusSortCode><TherapyArea id="746">Infectious disease</TherapyArea></Row><Row><Action id="12378">Prophylactic vaccine</Action><AuthorityGroup>LOCAL_AND_MAJOR</AuthorityGroup><Company id="18077">Merck &amp; Co Inc</Company><Country id="US">US</Country><Drug id="3643">MMR vaccine, Merck &amp; Co</Drug><EntityType>Biological</EntityType><HighestDevStatus id="L">Launched</HighestDevStatus><HighestDevStatusForInd id="L">Launched</HighestDevStatusForInd><Indication id="1">Measles virus infection</Indication><IsActiveCompany>true</IsActiveCompany><LatestChange>2013-05-07 00:00:00</LatestChange><ParentCompany id="18077">Merck &amp; Co Inc</ParentCompany><Status id="L">Launched</Status><StatusDate>1978-12-31 00:00:00</StatusDate><StatusSortCode>13</StatusSortCode><TherapyArea id="746">Infectious disease</TherapyArea></Row><Row><Action id="12364">Live attenuated viral vaccine</Action><AuthorityGroup>OTHER</AuthorityGroup><Company id="18077">Merck &amp; Co Inc</Company><Country id="EU">EU</Country><Drug id="3643">MMR vaccine, Merck &amp; Co</Drug><EntityType>Biological</EntityType><HighestDevStatus id="L">Launched</HighestDevStatus><HighestDevStatusForInd id="L">Launched</HighestDevStatusForInd><Indication id="1">Measles virus infection</Indication><IsActiveCompany>true</IsActiveCompany><LatestChange>2013-05-07 00:00:00</LatestChange><ParentCompany id="18077">Merck &amp; Co Inc</ParentCompany><Status id="L">Launched</Status><StatusDate>2001-01-09 00:00:00</StatusDate><StatusSortCode>13</StatusSortCode><TherapyArea id="746">Infectious disease</TherapyArea></Row><Row><Action id="12364">Live attenuated viral vaccine</Action><AuthorityGroup>OTHER</AuthorityGroup><Company id="22127">Sanofi Pasteur</Company><Country id="EU">EU</Country><Drug id="89684">M-M-RvaxPRO</Drug><EntityType>Biological</EntityType><HighestDevStatus id="L">Launched</HighestDevStatus><HighestDevStatusForInd id="L">Launched</HighestDevStatusForInd><Indication id="1">Measles virus infection</Indication><IsActiveCompany>true</IsActiveCompany><LatestChange>2008-06-01 00:00:00</LatestChange><ParentCompany id="1009547">Sanofi</ParentCompany><Status id="R">Registered</Status><StatusDate>2006-05-05 00:00:00</StatusDate><StatusSortCode>12</StatusSortCode><TherapyArea id="746">Infectious disease</TherapyArea></Row><Row><Action id="12378">Prophylactic vaccine</Action><AuthorityGroup>OTHER</AuthorityGroup><Company id="22127">Sanofi Pasteur</Company><Country id="EU">EU</Country><Drug id="89684">M-M-RvaxPRO</Drug><EntityType>Biological</EntityType><HighestDevStatus id="L">Launched</HighestDevStatus><HighestDevStatusForInd id="L">Launched</HighestDevStatusForInd><Indication id="1">Measles virus infection</Indication><IsActiveCompany>true</IsActiveCompany><LatestChange>2008-06-01 00:00:00</LatestChange><ParentCompany id="1009547">Sanofi</ParentCompany><Status id="R">Registered</Status><StatusDate>2006-05-05 00:00:00</StatusDate><StatusSortCode>12</StatusSortCode><TherapyArea id="746">Infectious disease</TherapyArea></Row><Row><Action id="12364">Live attenuated viral vaccine</Action><AuthorityGroup>OTHER</AuthorityGroup><Company id="22127">Sanofi Pasteur</Company><Country id="CH">Switzerland</Country><Drug id="89684">M-M-RvaxPRO</Drug><EntityType>Biological</EntityType><HighestDevStatus id="L">Launched</HighestDevStatus><HighestDevStatusForInd id="L">Launched</HighestDevStatusForInd><Indication id="1">Measles virus infection</Indication><IsActiveCompany>true</IsActiveCompany><LatestChange>2008-06-01 00:00:00</LatestChange><ParentCompany id="1009547">Sanofi</ParentCompany><Status id="L">Launched</Status><StatusDate>2008-06-01 00:00:00</StatusDate><StatusSortCode>13</StatusSortCode><TherapyArea id="746">Infectious disease</TherapyArea></Row><Row><Action id="393">Immunostimulant</Action><AuthorityGroup>LOCAL_AND_MAJOR</AuthorityGroup><Company id="1041544">Shenzhen Weiwu Guangming Biological Products Co Ltd</Company><Country id="CN">China</Country><Drug id="84800">human immunoglobulin (intramuscular, measles/hepatitis virus infection), Shenzhen Weiwu Guangming Biological Products</Drug><EntityType>Biological</EntityType><HighestDevStatus id="L">Launched</HighestDevStatus><HighestDevStatusForInd id="L">Launched</HighestDevStatusForInd><Indication id="1">Measles virus infection</Indication><IsActiveCompany>true</IsActiveCompany><LatestChange>1999-12-31 00:00:00</LatestChange><ParentCompany id="1041544">Shenzhen Weiwu Guangming Biological Products Co Ltd</ParentCompany><Status id="R">Registered</Status><StatusDate>1999-12-31 00:00:00</StatusDate><StatusSortCode>12</StatusSortCode><TherapyArea id="746">Infectious disease</TherapyArea></Row><Row><Action id="59620">Unspecified drug target</Action><AuthorityGroup>LOCAL_AND_MAJOR</AuthorityGroup><Company id="1061250">Lanzhou Institute of Biological Products</Company><Country id="CN">China</Country><Drug id="80205">human immunoglobulin (plasma-derived, intramuscular), Lanzhou Institute of Biological Products</Drug><EntityType>Biological</EntityType><HighestDevStatus id="L">Launched</HighestDevStatus><HighestDevStatusForInd id="L">Launched</HighestDevStatusForInd><Indication id="1">Measles virus infection</Indication><IsActiveCompany>true</IsActiveCompany><LatestChange>2002-12-31 00:00:00</LatestChange><ParentCompany id="1055632">Sinopharm</ParentCompany><Status id="L">Launched</Status><StatusDate>2002-12-31 00:00:00</StatusDate><StatusSortCode>13</StatusSortCode><TherapyArea id="746">Infectious disease</TherapyArea></Row><Row><Action id="1596">Immunomodulator</Action><AuthorityGroup>LOCAL_AND_MAJOR</AuthorityGroup><Company id="1072329">Harbin Pacific Biopharmaceutical Co Ltd</Company><Country id="CN">China</Country><Drug id="80551">human immunoglobulin (intramuscular, measles, hepatitis virus infection), Harbin Pacific Biopharmaceutical Co Ltd</Drug><EntityType>Biological</EntityType><HighestDevStatus id="L">Launched</HighestDevStatus><HighestDevStatusForInd id="L">Launched</HighestDevStatusForInd><Indication id="1">Measles virus infection</Indication><IsActiveCompany>true</IsActiveCompany><LatestChange>1998-12-31 00:00:00</LatestChange><ParentCompany id="1072329">Harbin Pacific Biopharmaceutical Co Ltd</ParentCompany><Status id="R">Registered</Status><StatusDate>1998-12-31 00:00:00</StatusDate><StatusSortCode>12</StatusSortCode><TherapyArea id="746">Infectious disease</TherapyArea></Row><Row><Action id="59620">Unspecified drug target</Action><AuthorityGroup>LOCAL_AND_MAJOR</AuthorityGroup><Company id="20691">Utah State University</Company><Country id="US">US</Country><Drug id="38853">coumarin analogs (measles virus), MediChem/Utah State</Drug><EntityType>Chemical</EntityType><HighestDevStatus id="NDR">No Development Reported</HighestDevStatus><HighestDevStatusForInd id="NDR">No Development Reported</HighestDevStatusForInd><Indication id="1">Measles virus infection</Indication><IsActiveCompany>false</IsActiveCompany><LatestChange>2008-02-12 00:00:00</LatestChange><ParentCompany id="20691">Utah State University</ParentCompany><Status id="DR">Discovery</Status><StatusDate>2002-03-21 00:00:00</StatusDate><StatusSortCode>6</StatusSortCode><TherapyArea id="746">Infectious disease</TherapyArea></Row><Row><Action id="59620">Unspecified drug target</Action><AuthorityGroup>LOCAL_AND_MAJOR</AuthorityGroup><Company id="20691">Utah State University</Company><Country id="US">US</Country><Drug id="38853">coumarin analogs (measles virus), MediChem/Utah State</Drug><EntityType>Chemical</EntityType><HighestDevStatus id="NDR">No Development Reported</HighestDevStatus><HighestDevStatusForInd id="NDR">No Development Reported</HighestDevStatusForInd><Indication id="1">Measles virus infection</Indication><IsActiveCompany>false</IsActiveCompany><LatestChange>2008-02-12 00:00:00</LatestChange><ParentCompany id="20691">Utah State University</ParentCompany><Status id="NDR">No Development Reported</Status><StatusDate>2008-02-12 00:00:00</StatusDate><StatusSortCode>2</StatusSortCode><TherapyArea id="746">Infectious disease</TherapyArea></Row><Row><Action id="12378">Prophylactic vaccine</Action><AuthorityGroup>LOCAL_AND_MAJOR</AuthorityGroup><Company id="26857">Centers for Disease Control and Prevention</Company><Country id="US">US</Country><Drug id="72810">measles vaccine (microneedle patch formulation), Centers for Disease Control and Prevention</Drug><EntityType>Biological</EntityType><HighestDevStatus id="NDR">No Development Reported</HighestDevStatus><HighestDevStatusForInd id="NDR">No Development Reported</HighestDevStatusForInd><Indication id="1">Measles virus infection</Indication><IsActiveCompany>false</IsActiveCompany><LatestChange>2013-09-25 00:00:00</LatestChange><ParentCompany id="20516">US Government</ParentCompany><Status id="NDR">No Development Reported</Status><StatusDate>2013-09-25 00:00:00</StatusDate><StatusSortCode>2</StatusSortCode><TherapyArea id="746">Infectious disease</TherapyArea></Row><Row><Action id="12364">Live attenuated viral vaccine</Action><AuthorityGroup>LOCAL_AND_MAJOR</AuthorityGroup><Company id="26857">Centers for Disease Control and Prevention</Company><Country id="US">US</Country><Drug id="72810">measles vaccine (microneedle patch formulation), Centers for Disease Control and Prevention</Drug><EntityType>Biological</EntityType><HighestDevStatus id="NDR">No Development Reported</HighestDevStatus><HighestDevStatusForInd id="NDR">No Development Reported</HighestDevStatusForInd><Indication id="1">Measles virus infection</Indication><IsActiveCompany>false</IsActiveCompany><LatestChange>2013-09-25 00:00:00</LatestChange><ParentCompany id="20516">US Government</ParentCompany><Status id="DR">Discovery</Status><StatusDate>2011-07-16 00:00:00</StatusDate><StatusSortCode>6</StatusSortCode><TherapyArea id="746">Infectious disease</TherapyArea></Row><Row><Action id="12364">Live attenuated viral vaccine</Action><AuthorityGroup>OTHER</AuthorityGroup><Company id="24166">GlaxoSmithKline Biologicals</Company><Country id="BE">Belgium</Country><Drug id="17141">Priorix-Tetra</Drug><EntityType>Biological</EntityType><HighestDevStatus id="L">Launched</HighestDevStatus><HighestDevStatusForInd id="L">Launched</HighestDevStatusForInd><Indication id="1">Measles virus infection</Indication><IsActiveCompany>false</IsActiveCompany><LatestChange>2008-01-10 00:00:00</LatestChange><ParentCompany id="28355">GlaxoSmithKline plc</ParentCompany><Status id="C3">Phase 3 Clinical</Status><StatusDate>1999-06-16 00:00:00</StatusDate><StatusSortCode>10</StatusSortCode><TherapyArea id="746">Infectious disease</TherapyArea></Row><Row><Action id="12378">Prophylactic vaccine</Action><AuthorityGroup>LOCAL_AND_MAJOR</AuthorityGroup><Company id="28355">GlaxoSmithKline plc</Company><Country id="XW">Western Europe</Country><Drug id="17141">Priorix-Tetra</Drug><EntityType>Biological</EntityType><HighestDevStatus id="L">Launched</HighestDevStatus><HighestDevStatusForInd id="L">Launched</HighestDevStatusForInd><Indication id="1">Measles virus infection</Indication><IsActiveCompany>true</IsActiveCompany><LatestChange>2008-01-10 00:00:00</LatestChange><ParentCompany id="28355">GlaxoSmithKline plc</ParentCompany><Status id="PR">Pre-registration</Status><StatusDate>2004-04-30 00:00:00</StatusDate><StatusSortCode>11</StatusSortCode><TherapyArea id="746">Infectious disease</TherapyArea></Row><Row><Action id="12364">Live attenuated viral vaccine</Action><AuthorityGroup>LOCAL_AND_MAJOR</AuthorityGroup><Company id="28355">GlaxoSmithKline plc</Company><Country id="XW">Western Europe</Country><Drug id="17141">Priorix-Tetra</Drug><EntityType>Biological</EntityType><HighestDevStatus id="L">Launched</HighestDevStatus><HighestDevStatusForInd id="L">Launched</HighestDevStatusForInd><Indication id="1">Measles virus infection</Indication><IsActiveCompany>true</IsActiveCompany><LatestChange>2008-01-10 00:00:00</LatestChange><ParentCompany id="28355">GlaxoSmithKline plc</ParentCompany><Status id="PR">Pre-registration</Status><StatusDate>2004-04-30 00:00:00</StatusDate><StatusSortCode>11</StatusSortCode><TherapyArea id="746">Infectious disease</TherapyArea></Row><Row><Action id="1532">Viral replication inhibitor</Action><AuthorityGroup>LOCAL_AND_MAJOR</AuthorityGroup><Company id="25282">University of Catania</Company><Country id="IT">Italy</Country><Drug id="16787">ON-1</Drug><EntityType>Chemical</EntityType><HighestDevStatus id="NDR">No Development Reported</HighestDevStatus><HighestDevStatusForInd id="NDR">No Development Reported</HighestDevStatusForInd><Indication id="1">Measles virus infection</Indication><IsActiveCompany>false</IsActiveCompany><LatestChange>2008-08-07 00:00:00</LatestChange><ParentCompany id="25282">University of Catania</ParentCompany><Status id="NDR">No Development Reported</Status><StatusDate>2008-08-07 00:00:00</StatusDate><StatusSortCode>2</StatusSortCode><TherapyArea id="746">Infectious disease</TherapyArea></Row><Row><Action id="1532">Viral replication inhibitor</Action><AuthorityGroup>LOCAL_AND_MAJOR</AuthorityGroup><Company id="25282">University of Catania</Company><Country id="IT">Italy</Country><Drug id="16787">ON-1</Drug><EntityType>Chemical</EntityType><HighestDevStatus id="NDR">No Development Reported</HighestDevStatus><HighestDevStatusForInd id="NDR">No Development Reported</HighestDevStatusForInd><Indication id="1">Measles virus infection</Indication><IsActiveCompany>false</IsActiveCompany><LatestChange>2008-08-07 00:00:00</LatestChange><ParentCompany id="25282">University of Catania</ParentCompany><Status id="DR">Discovery</Status><StatusDate>1999-03-31 00:00:00</StatusDate><StatusSortCode>6</StatusSortCode><TherapyArea id="746">Infectious disease</TherapyArea></Row><Row><Action id="12378">Prophylactic vaccine</Action><AuthorityGroup>LOCAL_AND_MAJOR</AuthorityGroup><Company id="20596">Johns Hopkins University</Company><Country id="US">US</Country><Drug id="57445">DNA vaccine (measles, Vaxfectin), Vical/Johns Hopkins University</Drug><EntityType>Biological</EntityType><HighestDevStatus id="NDR">No Development Reported</HighestDevStatus><HighestDevStatusForInd id="NDR">No Development Reported</HighestDevStatusForInd><Indication id="1">Measles virus infection</Indication><IsActiveCompany>false</IsActiveCompany><LatestChange>2012-11-30 00:00:00</LatestChange><ParentCompany id="20596">Johns Hopkins University</ParentCompany><Status id="DR">Discovery</Status><StatusDate>1997-06-30 00:00:00</StatusDate><StatusSortCode>6</StatusSortCode><TherapyArea id="746">Infectious disease</TherapyArea></Row><Row><Action id="12370">Recombinant viral vector vaccine</Action><AuthorityGroup>OTHER</AuthorityGroup><Company id="24244">Bavarian Nordic A/S</Company><Country id="ZA">South Africa</Country><Drug id="54328">MVA-mBN85B</Drug><EntityType>Biological</EntityType><HighestDevStatus id="NDR">No Development Reported</HighestDevStatus><HighestDevStatusForInd id="NDR">No Development Reported</HighestDevStatusForInd><Indication id="1">Measles virus infection</Indication><IsActiveCompany>false</IsActiveCompany><LatestChange>2011-11-29 00:00:00</LatestChange><ParentCompany id="24244">Bavarian Nordic A/S</ParentCompany><Status id="C2">Phase 2 Clinical</Status><StatusDate>2009-06-30 00:00:00</StatusDate><StatusSortCode>9</StatusSortCode><TherapyArea id="746">Infectious disease</TherapyArea></Row><Row><Action id="1532">Viral replication inhibitor</Action><AuthorityGroup>LOCAL_AND_MAJOR</AuthorityGroup><Company id="1051158">Goff Hill Ltd</Company><Country id="CA">Canada</Country><Drug id="65451">antiviral therapeutics (viral infections/measles/multiple sclerosis), Goff Hill</Drug><EntityType>Chemical</EntityType><HighestDevStatus id="CU">Clinical</HighestDevStatus><HighestDevStatusForInd id="CU">Clinical</HighestDevStatusForInd><Indication id="1">Measles virus infection</Indication><IsActiveCompany>true</IsActiveCompany><LatestChange>2014-11-06 00:00:00</LatestChange><ParentCompany id="1051158">Goff Hill Ltd</ParentCompany><Status id="CU">Clinical</Status><StatusDate>2010-01-27 00:00:00</StatusDate><StatusSortCode>7</StatusSortCode><TherapyArea id="746">Infectious disease</TherapyArea></Row><Row><Action id="59620">Unspecified drug target</Action><AuthorityGroup>LOCAL_AND_MAJOR</AuthorityGroup><Company id="1054697">Shanxi Kangbao Biological Products Co Ltd</Company><Country id="CN">China</Country><Drug id="81711">human immunoglobulin (im, hepatitis, measles), Shanxi Kangbao Biological Products</Drug><EntityType>Biological</EntityType><HighestDevStatus id="L">Launched</HighestDevStatus><HighestDevStatusForInd id="L">Launched</HighestDevStatusForInd><Indication id="1">Measles virus infection</Indication><IsActiveCompany>true</IsActiveCompany><LatestChange>1998-12-31 00:00:00</LatestChange><ParentCompany id="1054697">Shanxi Kangbao Biological Products Co Ltd</ParentCompany><Status id="R">Registered</Status><StatusDate>1998-12-31 00:00:00</StatusDate><StatusSortCode>12</StatusSortCode><TherapyArea id="746">Infectious disease</TherapyArea></Row><Row><Action id="12378">Prophylactic vaccine</Action><AuthorityGroup>LOCAL_AND_MAJOR</AuthorityGroup><Company id="19962">SmithKline Beecham plc</Company><Country id="GB">UK</Country><Drug id="11457">Priorix</Drug><EntityType>Biological</EntityType><HighestDevStatus id="L">Launched</HighestDevStatus><HighestDevStatusForInd id="L">Launched</HighestDevStatusForInd><Indication id="1">Measles virus infection</Indication><IsActiveCompany>true</IsActiveCompany><LatestChange>2012-06-29 00:00:00</LatestChange><ParentCompany id="28355">GlaxoSmithKline plc</ParentCompany><Status id="R">Registered</Status><StatusDate>1998-03-25 00:00:00</StatusDate><StatusSortCode>12</StatusSortCode><TherapyArea id="746">Infectious disease</TherapyArea></Row><Row><Action id="12378">Prophylactic vaccine</Action><AuthorityGroup>OTHER</AuthorityGroup><Company id="19962">SmithKline Beecham plc</Company><Country id="BE">Belgium</Country><Drug id="11457">Priorix</Drug><EntityType>Biological</EntityType><HighestDevStatus id="L">Launched</HighestDevStatus><HighestDevStatusForInd id="L">Launched</HighestDevStatusForInd><Indication id="1">Measles virus infection</Indication><IsActiveCompany>true</IsActiveCompany><LatestChange>2012-06-29 00:00:00</LatestChange><ParentCompany id="28355">GlaxoSmithKline plc</ParentCompany><Status id="R">Registered</Status><StatusDate>1998-03-25 00:00:00</StatusDate><StatusSortCode>12</StatusSortCode><TherapyArea id="746">Infectious disease</TherapyArea></Row><Row><Action id="12364">Live attenuated viral vaccine</Action><AuthorityGroup>OTHER</AuthorityGroup><Company id="19962">SmithKline Beecham plc</Company><Country id="CN">China</Country><Drug id="11457">Priorix</Drug><EntityType>Biological</EntityType><HighestDevStatus id="L">Launched</HighestDevStatus><HighestDevStatusForInd id="L">Launched</HighestDevStatusForInd><Indication id="1">Measles virus infection</Indication><IsActiveCompany>true</IsActiveCompany><LatestChange>2012-06-29 00:00:00</LatestChange><ParentCompany id="28355">GlaxoSmithKline plc</ParentCompany><Status id="L">Launched</Status><StatusDate>1998-12-31 00:00:00</StatusDate><StatusSortCode>13</StatusSortCode><TherapyArea id="746">Infectious disease</TherapyArea></Row><Row><Action id="12378">Prophylactic vaccine</Action><AuthorityGroup>LOCAL_AND_MAJOR</AuthorityGroup><Company id="19962">SmithKline Beecham plc</Company><Country id="GB">UK</Country><Drug id="11457">Priorix</Drug><EntityType>Biological</EntityType><HighestDevStatus id="L">Launched</HighestDevStatus><HighestDevStatusForInd id="L">Launched</HighestDevStatusForInd><Indication id="1">Measles virus infection</Indication><IsActiveCompany>true</IsActiveCompany><LatestChange>2012-06-29 00:00:00</LatestChange><ParentCompany id="28355">GlaxoSmithKline plc</ParentCompany><Status id="L">Launched</Status><StatusDate>1998-05-22 00:00:00</StatusDate><StatusSortCode>13</StatusSortCode><TherapyArea id="746">Infectious disease</TherapyArea></Row><Row><Action id="12364">Live attenuated viral vaccine</Action><AuthorityGroup>OTHER</AuthorityGroup><Company id="28355">GlaxoSmithKline plc</Company><Country id="KR">South Korea</Country><Drug id="11457">Priorix</Drug><EntityType>Biological</EntityType><HighestDevStatus id="L">Launched</HighestDevStatus><HighestDevStatusForInd id="L">Launched</HighestDevStatusForInd><Indication id="1">Measles virus infection</Indication><IsActiveCompany>true</IsActiveCompany><LatestChange>2012-06-29 00:00:00</LatestChange><ParentCompany id="28355">GlaxoSmithKline plc</ParentCompany><Status id="C3">Phase 3 Clinical</Status><StatusDate>2012-06-29 00:00:00</StatusDate><StatusSortCode>10</StatusSortCode><TherapyArea id="746">Infectious disease</TherapyArea></Row><Row><Action id="12364">Live attenuated viral vaccine</Action><AuthorityGroup>LOCAL_AND_MAJOR</AuthorityGroup><Company id="28355">GlaxoSmithKline plc</Company><Country id="US">US</Country><Drug id="11457">Priorix</Drug><EntityType>Biological</EntityType><HighestDevStatus id="L">Launched</HighestDevStatus><HighestDevStatusForInd id="L">Launched</HighestDevStatusForInd><Indication id="1">Measles virus infection</Indication><IsActiveCompany>true</IsActiveCompany><LatestChange>2012-06-29 00:00:00</LatestChange><ParentCompany id="28355">GlaxoSmithKline plc</ParentCompany><Status id="C3">Phase 3 Clinical</Status><StatusDate>2012-06-29 00:00:00</StatusDate><StatusSortCode>10</StatusSortCode><TherapyArea id="746">Infectious disease</TherapyArea></Row><Row><Action id="12364">Live attenuated viral vaccine</Action><AuthorityGroup>LOCAL_AND_MAJOR</AuthorityGroup><Company id="1059311">Bio-Manguinhos/Fiocruz</Company><Country id="BR">Brazil</Country><Drug id="94952">MMR vaccine, Bio-Manguinhos/Fiocruz</Drug><EntityType>Biological</EntityType><HighestDevStatus id="C3">Phase 3 Clinical</HighestDevStatus><HighestDevStatusForInd id="C3">Phase 3 Clinical</HighestDevStatusForInd><Indication id="1">Measles virus infection</Indication><IsActiveCompany>true</IsActiveCompany><LatestChange>2015-04-13 00:00:00</LatestChange><ParentCompany id="16154">Fundacao Oswaldo Cruz (Fiocruz)</ParentCompany><Status id="C3">Phase 3 Clinical</Status><StatusDate>2015-04-13 00:00:00</StatusDate><StatusSortCode>10</StatusSortCode><TherapyArea id="746">Infectious disease</TherapyArea></Row><Row><Action id="59620">Unspecified drug target</Action><AuthorityGroup>LOCAL_AND_MAJOR</AuthorityGroup><Company id="1081842">Sichuan Yuanda Shuyang Pharmaceutical Co Ltd</Company><Country id="CN">China</Country><Drug id="84689">human immunoglobulin (intramuscular, measles/hepatitis virus infection), Sichuan Yuanda Shuyang Pharmaceutical</Drug><EntityType>Biological</EntityType><HighestDevStatus id="L">Launched</HighestDevStatus><HighestDevStatusForInd id="L">Launched</HighestDevStatusForInd><Indication id="1">Measles virus infection</Indication><IsActiveCompany>true</IsActiveCompany><LatestChange>1998-12-31 00:00:00</LatestChange><ParentCompany id="1081842">Sichuan Yuanda Shuyang Pharmaceutical Co Ltd</ParentCompany><Status id="L">Launched</Status><StatusDate>1998-12-31 00:00:00</StatusDate><StatusSortCode>13</StatusSortCode><TherapyArea id="746">Infectious disease</TherapyArea></Row><Row><Action id="12378">Prophylactic vaccine</Action><AuthorityGroup>LOCAL_AND_MAJOR</AuthorityGroup><Company id="1071897">Shanghai Institute of Biological Products Co Ltd</Company><Country id="CN">China</Country><Drug id="80154">measles/mumps vaccine (live attenuated), Shanghai Institute of Biological Product</Drug><EntityType>Biological</EntityType><HighestDevStatus id="L">Launched</HighestDevStatus><HighestDevStatusForInd id="L">Launched</HighestDevStatusForInd><Indication id="1">Measles virus infection</Indication><IsActiveCompany>true</IsActiveCompany><LatestChange>2012-08-16 00:00:00</LatestChange><ParentCompany id="1055632">Sinopharm</ParentCompany><Status id="L">Launched</Status><StatusDate>2000-12-31 00:00:00</StatusDate><StatusSortCode>13</StatusSortCode><TherapyArea id="746">Infectious disease</TherapyArea></Row><Row><Action id="12364">Live attenuated viral vaccine</Action><AuthorityGroup>LOCAL_AND_MAJOR</AuthorityGroup><Company id="1071897">Shanghai Institute of Biological Products Co Ltd</Company><Country id="CN">China</Country><Drug id="80154">measles/mumps vaccine (live attenuated), Shanghai Institute of Biological Product</Drug><EntityType>Biological</EntityType><HighestDevStatus id="L">Launched</HighestDevStatus><HighestDevStatusForInd id="L">Launched</HighestDevStatusForInd><Indication id="1">Measles virus infection</Indication><IsActiveCompany>true</IsActiveCompany><LatestChange>2012-08-16 00:00:00</LatestChange><ParentCompany id="1055632">Sinopharm</ParentCompany><Status id="L">Launched</Status><StatusDate>2000-12-31 00:00:00</StatusDate><StatusSortCode>13</StatusSortCode><TherapyArea id="746">Infectious disease</TherapyArea></Row><Row><Action id="393">Immunostimulant</Action><AuthorityGroup>LOCAL_AND_MAJOR</AuthorityGroup><Company id="1071897">Shanghai Institute of Biological Products Co Ltd</Company><Country id="CN">China</Country><Drug id="80171">human immunoglobulin (intramuscular), Shanghai Institute of Biological Products</Drug><EntityType>Biological</EntityType><HighestDevStatus id="L">Launched</HighestDevStatus><HighestDevStatusForInd id="L">Launched</HighestDevStatusForInd><Indication id="1">Measles virus infection</Indication><IsActiveCompany>true</IsActiveCompany><LatestChange>1997-12-31 00:00:00</LatestChange><ParentCompany id="1055632">Sinopharm</ParentCompany><Status id="R">Registered</Status><StatusDate>1997-12-31 00:00:00</StatusDate><StatusSortCode>12</StatusSortCode><TherapyArea id="746">Infectious disease</TherapyArea></Row><Row><Action id="12378">Prophylactic vaccine</Action><AuthorityGroup>LOCAL_AND_MAJOR</AuthorityGroup><Company id="1061252">Wuhan Institute of Biological Products Co Ltd</Company><Country id="CN">China</Country><Drug id="87292">measles/Japanese encephalitis vaccine (live attenuated), Wuhan Institute of Biological Products</Drug><EntityType>Biological</EntityType><HighestDevStatus id="DR">Discovery</HighestDevStatus><HighestDevStatusForInd id="DR">Discovery</HighestDevStatusForInd><Indication id="1">Measles virus infection</Indication><IsActiveCompany>true</IsActiveCompany><LatestChange>2008-10-31 00:00:00</LatestChange><ParentCompany id="1055632">Sinopharm</ParentCompany><Status id="DR">Discovery</Status><StatusDate>2008-10-31 00:00:00</StatusDate><StatusSortCode>6</StatusSortCode><TherapyArea id="746">Infectious disease</TherapyArea></Row><Row><Action id="59620">Unspecified drug target</Action><AuthorityGroup>LOCAL_AND_MAJOR</AuthorityGroup><Company id="1079335">Guangdong Weilun Biological Products Co Ltd</Company><Country id="CN">China</Country><Drug id="84826">human immunoglobulin (intramuscular, measles/hepatitis virus infection), Guangdong Weilun Biological Products</Drug><EntityType>Biological</EntityType><HighestDevStatus id="L">Launched</HighestDevStatus><HighestDevStatusForInd id="L">Launched</HighestDevStatusForInd><Indication id="1">Measles virus infection</Indication><IsActiveCompany>true</IsActiveCompany><LatestChange>2000-12-31 00:00:00</LatestChange><ParentCompany id="1079335">Guangdong Weilun Biological Products Co Ltd</ParentCompany><Status id="R">Registered</Status><StatusDate>2000-12-31 00:00:00</StatusDate><StatusSortCode>12</StatusSortCode><TherapyArea id="746">Infectious disease</TherapyArea></Row><Row><Action id="59620">Unspecified drug target</Action><AuthorityGroup>LOCAL_AND_MAJOR</AuthorityGroup><Company id="1087965">Guizhou Taibang Biological Products Co Ltd</Company><Country id="CN">China</Country><Drug id="87540">human immunoglobulin (intramuscular, measles/hepatitis virus infection), Guizhou Taibang Biological Products</Drug><EntityType>Biological</EntityType><HighestDevStatus id="L">Launched</HighestDevStatus><HighestDevStatusForInd id="L">Launched</HighestDevStatusForInd><Indication id="1">Measles virus infection</Indication><IsActiveCompany>true</IsActiveCompany><LatestChange>2000-12-31 00:00:00</LatestChange><ParentCompany id="1041423">China Biologic Products Inc</ParentCompany><Status id="L">Launched</Status><StatusDate>2000-12-31 00:00:00</StatusDate><StatusSortCode>13</StatusSortCode><TherapyArea id="746">Infectious disease</TherapyArea></Row><Row><Action id="393">Immunostimulant</Action><AuthorityGroup>LOCAL_AND_MAJOR</AuthorityGroup><Company id="1087965">Guizhou Taibang Biological Products Co Ltd</Company><Country id="CN">China</Country><Drug id="87540">human immunoglobulin (intramuscular, measles/hepatitis virus infection), Guizhou Taibang Biological Products</Drug><EntityType>Biological</EntityType><HighestDevStatus id="L">Launched</HighestDevStatus><HighestDevStatusForInd id="L">Launched</HighestDevStatusForInd><Indication id="1">Measles virus infection</Indication><IsActiveCompany>true</IsActiveCompany><LatestChange>2000-12-31 00:00:00</LatestChange><ParentCompany id="1041423">China Biologic Products Inc</ParentCompany><Status id="L">Launched</Status><StatusDate>2000-12-31 00:00:00</StatusDate><StatusSortCode>13</StatusSortCode><TherapyArea id="746">Infectious disease</TherapyArea></Row><Row><Action id="59620">Unspecified drug target</Action><AuthorityGroup>LOCAL_AND_MAJOR</AuthorityGroup><Company id="1087965">Guizhou Taibang Biological Products Co Ltd</Company><Country id="CN">China</Country><Drug id="87540">human immunoglobulin (intramuscular, measles/hepatitis virus infection), Guizhou Taibang Biological Products</Drug><EntityType>Biological</EntityType><HighestDevStatus id="L">Launched</HighestDevStatus><HighestDevStatusForInd id="L">Launched</HighestDevStatusForInd><Indication id="1">Measles virus infection</Indication><IsActiveCompany>true</IsActiveCompany><LatestChange>2000-12-31 00:00:00</LatestChange><ParentCompany id="1041423">China Biologic Products Inc</ParentCompany><Status id="R">Registered</Status><StatusDate>2000-12-31 00:00:00</StatusDate><StatusSortCode>12</StatusSortCode><TherapyArea id="746">Infectious disease</TherapyArea></Row><Row><Action id="12364">Live attenuated viral vaccine</Action><AuthorityGroup>LOCAL_AND_MAJOR</AuthorityGroup><Company id="1027662">Beijing Tiantan Biological Products Co Ltd</Company><Country id="CN">China</Country><Drug id="79144">measles/mumps/rubella vaccine (live-attenuated),  Beijing Tiantan Biological Products</Drug><EntityType>Biological</EntityType><HighestDevStatus id="L">Launched</HighestDevStatus><HighestDevStatusForInd id="L">Launched</HighestDevStatusForInd><Indication id="1">Measles virus infection</Indication><IsActiveCompany>true</IsActiveCompany><LatestChange>2002-12-31 00:00:00</LatestChange><ParentCompany id="1055632">Sinopharm</ParentCompany><Status id="R">Registered</Status><StatusDate>2002-12-31 00:00:00</StatusDate><StatusSortCode>12</StatusSortCode><TherapyArea id="746">Infectious disease</TherapyArea></Row><Row><Action id="12378">Prophylactic vaccine</Action><AuthorityGroup>LOCAL_AND_MAJOR</AuthorityGroup><Company id="30063">BIKEN</Company><Country id="JP">Japan</Country><Drug id="66592">Mearubik</Drug><EntityType>Biological</EntityType><HighestDevStatus id="L">Launched</HighestDevStatus><HighestDevStatusForInd id="L">Launched</HighestDevStatusForInd><Indication id="1">Measles virus infection</Indication><IsActiveCompany>true</IsActiveCompany><LatestChange>2005-12-31 00:00:00</LatestChange><ParentCompany id="20653">Osaka University</ParentCompany><Status id="L">Launched</Status><StatusDate>2005-12-31 00:00:00</StatusDate><StatusSortCode>13</StatusSortCode><TherapyArea id="746">Infectious disease</TherapyArea></Row><Row><Action id="12364">Live attenuated viral vaccine</Action><AuthorityGroup>OTHER</AuthorityGroup><Company id="18077">Merck &amp; Co Inc</Company><Country id="TW">Taiwan</Country><Drug id="3643">MMR vaccine, Merck &amp; Co</Drug><EntityType>Biological</EntityType><HighestDevStatus id="L">Launched</HighestDevStatus><HighestDevStatusForInd id="L">Launched</HighestDevStatusForInd><Indication id="1">Measles virus infection</Indication><IsActiveCompany>true</IsActiveCompany><LatestChange>2013-05-07 00:00:00</LatestChange><ParentCompany id="18077">Merck &amp; Co Inc</ParentCompany><Status id="R">Registered</Status><StatusDate>1982-04-16 00:00:00</StatusDate><StatusSortCode>12</StatusSortCode><TherapyArea id="746">Infectious disease</TherapyArea></Row><Row><Action id="12378">Prophylactic vaccine</Action><AuthorityGroup>OTHER</AuthorityGroup><Company id="18077">Merck &amp; Co Inc</Company><Country id="KR">South Korea</Country><Drug id="47279">ProQuad</Drug><EntityType>Biological</EntityType><HighestDevStatus id="L">Launched</HighestDevStatus><HighestDevStatusForInd id="L">Launched</HighestDevStatusForInd><Indication id="1">Measles virus infection</Indication><IsActiveCompany>true</IsActiveCompany><LatestChange>2013-01-10 00:00:00</LatestChange><ParentCompany id="18077">Merck &amp; Co Inc</ParentCompany><Status id="R">Registered</Status><StatusDate>2008-01-31 00:00:00</StatusDate><StatusSortCode>12</StatusSortCode><TherapyArea id="746">Infectious disease</TherapyArea></Row><Row><Action id="12378">Prophylactic vaccine</Action><AuthorityGroup>OTHER</AuthorityGroup><Company id="18077">Merck &amp; Co Inc</Company><Country id="KR">South Korea</Country><Drug id="47279">ProQuad</Drug><EntityType>Biological</EntityType><HighestDevStatus id="L">Launched</HighestDevStatus><HighestDevStatusForInd id="L">Launched</HighestDevStatusForInd><Indication id="1">Measles virus infection</Indication><IsActiveCompany>true</IsActiveCompany><LatestChange>2013-01-10 00:00:00</LatestChange><ParentCompany id="18077">Merck &amp; Co Inc</ParentCompany><Status id="L">Launched</Status><StatusDate>2008-02-01 00:00:00</StatusDate><StatusSortCode>13</StatusSortCode><TherapyArea id="746">Infectious disease</TherapyArea></Row><Row><Action id="12378">Prophylactic vaccine</Action><AuthorityGroup>OTHER</AuthorityGroup><Company id="18077">Merck &amp; Co Inc</Company><Country id="GB">UK</Country><Drug id="47279">ProQuad</Drug><EntityType>Biological</EntityType><HighestDevStatus id="L">Launched</HighestDevStatus><HighestDevStatusForInd id="L">Launched</HighestDevStatusForInd><Indication id="1">Measles virus infection</Indication><IsActiveCompany>true</IsActiveCompany><LatestChange>2013-01-10 00:00:00</LatestChange><ParentCompany id="18077">Merck &amp; Co Inc</ParentCompany><Status id="PR">Pre-registration</Status><StatusDate>2013-01-10 00:00:00</StatusDate><StatusSortCode>11</StatusSortCode><TherapyArea id="746">Infectious disease</TherapyArea></Row><Row><Action id="12378">Prophylactic vaccine</Action><AuthorityGroup>OTHER</AuthorityGroup><Company id="23408">Sanofi Pasteur MSD</Company><Country id="ES">Spain</Country><Drug id="47279">ProQuad</Drug><EntityType>Biological</EntityType><HighestDevStatus id="L">Launched</HighestDevStatus><HighestDevStatusForInd id="L">Launched</HighestDevStatusForInd><Indication id="1">Measles virus infection</Indication><IsActiveCompany>true</IsActiveCompany><LatestChange>2013-01-10 00:00:00</LatestChange><ParentCompany id="18077">Merck &amp; Co Inc</ParentCompany><Status id="R">Registered</Status><StatusDate>2006-04-21 00:00:00</StatusDate><StatusSortCode>12</StatusSortCode><TherapyArea id="746">Infectious disease</TherapyArea></Row><Row><Action id="12375">Toxoid vaccine</Action><AuthorityGroup>OTHER</AuthorityGroup><Company id="23408">Sanofi Pasteur MSD</Company><Country id="EU">EU</Country><Drug id="47279">ProQuad</Drug><EntityType>Biological</EntityType><HighestDevStatus id="L">Launched</HighestDevStatus><HighestDevStatusForInd id="L">Launched</HighestDevStatusForInd><Indication id="1">Measles virus infection</Indication><IsActiveCompany>true</IsActiveCompany><LatestChange>2013-01-10 00:00:00</LatestChange><ParentCompany id="18077">Merck &amp; Co Inc</ParentCompany><Status id="L">Launched</Status><StatusDate>2006-04-30 00:00:00</StatusDate><StatusSortCode>13</StatusSortCode><TherapyArea id="746">Infectious disease</TherapyArea></Row><Row><Action id="12375">Toxoid vaccine</Action><AuthorityGroup>OTHER</AuthorityGroup><Company id="23408">Sanofi Pasteur MSD</Company><Country id="NL">Netherlands</Country><Drug id="47279">ProQuad</Drug><EntityType>Biological</EntityType><HighestDevStatus id="L">Launched</HighestDevStatus><HighestDevStatusForInd id="L">Launched</HighestDevStatusForInd><Indication id="1">Measles virus infection</Indication><IsActiveCompany>true</IsActiveCompany><LatestChange>2013-01-10 00:00:00</LatestChange><ParentCompany id="18077">Merck &amp; Co Inc</ParentCompany><Status id="R">Registered</Status><StatusDate>2006-04-06 00:00:00</StatusDate><StatusSortCode>12</StatusSortCode><TherapyArea id="746">Infectious disease</TherapyArea></Row><Row><Action id="12364">Live attenuated viral vaccine</Action><AuthorityGroup>OTHER</AuthorityGroup><Company id="23408">Sanofi Pasteur MSD</Company><Country id="LV">Latvia</Country><Drug id="47279">ProQuad</Drug><EntityType>Biological</EntityType><HighestDevStatus id="L">Launched</HighestDevStatus><HighestDevStatusForInd id="L">Launched</HighestDevStatusForInd><Indication id="1">Measles virus infection</Indication><IsActiveCompany>true</IsActiveCompany><LatestChange>2013-01-10 00:00:00</LatestChange><ParentCompany id="18077">Merck &amp; Co Inc</ParentCompany><Status id="R">Registered</Status><StatusDate>2006-04-06 00:00:00</StatusDate><StatusSortCode>12</StatusSortCode><TherapyArea id="746">Infectious disease</TherapyArea></Row><Row><Action id="12375">Toxoid vaccine</Action><AuthorityGroup>OTHER</AuthorityGroup><Company id="23408">Sanofi Pasteur MSD</Company><Country id="LV">Latvia</Country><Drug id="47279">ProQuad</Drug><EntityType>Biological</EntityType><HighestDevStatus id="L">Launched</HighestDevStatus><HighestDevStatusForInd id="L">Launched</HighestDevStatusForInd><Indication id="1">Measles virus infection</Indication><IsActiveCompany>true</IsActiveCompany><LatestChange>2013-01-10 00:00:00</LatestChange><ParentCompany id="18077">Merck &amp; Co Inc</ParentCompany><Status id="R">Registered</Status><StatusDate>2006-04-06 00:00:00</StatusDate><StatusSortCode>12</StatusSortCode><TherapyArea id="746">Infectious disease</TherapyArea></Row><Row><Action id="991">Antiviral</Action><AuthorityGroup>LOCAL_AND_MAJOR</AuthorityGroup><Company id="1041544">Shenzhen Weiwu Guangming Biological Products Co Ltd</Company><Country id="CN">China</Country><Drug id="84800">human immunoglobulin (intramuscular, measles/hepatitis virus infection), Shenzhen Weiwu Guangming Biological Products</Drug><EntityType>Biological</EntityType><HighestDevStatus id="L">Launched</HighestDevStatus><HighestDevStatusForInd id="L">Launched</HighestDevStatusForInd><Indication id="1">Measles virus infection</Indication><IsActiveCompany>true</IsActiveCompany><LatestChange>1999-12-31 00:00:00</LatestChange><ParentCompany id="1041544">Shenzhen Weiwu Guangming Biological Products Co Ltd</ParentCompany><Status id="L">Launched</Status><StatusDate>1999-12-31 00:00:00</StatusDate><StatusSortCode>13</StatusSortCode><TherapyArea id="746">Infectious disease</TherapyArea></Row><Row><Action id="1545">Anticancer</Action><AuthorityGroup>LOCAL_AND_MAJOR</AuthorityGroup><Company id="16450">Gilead Sciences Inc</Company><Country id="US">US</Country><Drug id="9218">GS-438</Drug><EntityType>Chemical</EntityType><HighestDevStatus id="DX">Discontinued</HighestDevStatus><HighestDevStatusForInd id="DX">Discontinued</HighestDevStatusForInd><Indication id="1">Measles virus infection</Indication><IsActiveCompany>false</IsActiveCompany><LatestChange>1997-09-18 00:00:00</LatestChange><ParentCompany id="16450">Gilead Sciences Inc</ParentCompany><Status id="DR">Discovery</Status><StatusDate>1995-09-01 00:00:00</StatusDate><StatusSortCode>6</StatusSortCode><TherapyArea id="746">Infectious disease</TherapyArea></Row><Row><Action id="1545">Anticancer</Action><AuthorityGroup>LOCAL_AND_MAJOR</AuthorityGroup><Company id="16450">Gilead Sciences Inc</Company><Country id="US">US</Country><Drug id="9218">GS-438</Drug><EntityType>Chemical</EntityType><HighestDevStatus id="DX">Discontinued</HighestDevStatus><HighestDevStatusForInd id="DX">Discontinued</HighestDevStatusForInd><Indication id="1">Measles virus infection</Indication><IsActiveCompany>false</IsActiveCompany><LatestChange>1997-09-18 00:00:00</LatestChange><ParentCompany id="16450">Gilead Sciences Inc</ParentCompany><Status id="DX">Discontinued</Status><StatusDate>1997-09-18 00:00:00</StatusDate><StatusSortCode>3</StatusSortCode><TherapyArea id="746">Infectious disease</TherapyArea></Row><Row><Action id="59620">Unspecified drug target</Action><AuthorityGroup>LOCAL_AND_MAJOR</AuthorityGroup><Company id="16450">Gilead Sciences Inc</Company><Country id="US">US</Country><Drug id="9218">GS-438</Drug><EntityType>Chemical</EntityType><HighestDevStatus id="DX">Discontinued</HighestDevStatus><HighestDevStatusForInd id="DX">Discontinued</HighestDevStatusForInd><Indication id="1">Measles virus infection</Indication><IsActiveCompany>false</IsActiveCompany><LatestChange>1997-09-18 00:00:00</LatestChange><ParentCompany id="16450">Gilead Sciences Inc</ParentCompany><Status id="DX">Discontinued</Status><StatusDate>1997-09-18 00:00:00</StatusDate><StatusSortCode>3</StatusSortCode><TherapyArea id="746">Infectious disease</TherapyArea></Row><Row><Action id="12378">Prophylactic vaccine</Action><AuthorityGroup>LOCAL_AND_MAJOR</AuthorityGroup><Company id="1049946">BioNet-Asia Co Ltd</Company><Country id="TH">Thailand</Country><Drug id="91397">measles/mumps/rubella vaccine, BioNet-Asia</Drug><EntityType>Biological</EntityType><HighestDevStatus id="L">Launched</HighestDevStatus><HighestDevStatusForInd id="L">Launched</HighestDevStatusForInd><Indication id="1">Measles virus infection</Indication><IsActiveCompany>true</IsActiveCompany><LatestChange>2014-05-26 00:00:00</LatestChange><ParentCompany id="1049946">BioNet-Asia Co Ltd</ParentCompany><Status id="L">Launched</Status><StatusDate>2014-05-26 00:00:00</StatusDate><StatusSortCode>13</StatusSortCode><TherapyArea id="746">Infectious disease</TherapyArea></Row><Row><Action id="12364">Live attenuated viral vaccine</Action><AuthorityGroup>LOCAL_AND_MAJOR</AuthorityGroup><Company id="1071897">Shanghai Institute of Biological Products Co Ltd</Company><Country id="CN">China</Country><Drug id="79819">measles/mumps/rubella vaccine (live-attenuated), Shanghai Institute of Biological Products</Drug><EntityType>Biological</EntityType><HighestDevStatus id="L">Launched</HighestDevStatus><HighestDevStatusForInd id="L">Launched</HighestDevStatusForInd><Indication id="1">Measles virus infection</Indication><IsActiveCompany>true</IsActiveCompany><LatestChange>2007-12-31 00:00:00</LatestChange><ParentCompany id="1055632">Sinopharm</ParentCompany><Status id="L">Launched</Status><StatusDate>2007-12-31 00:00:00</StatusDate><StatusSortCode>13</StatusSortCode><TherapyArea id="746">Infectious disease</TherapyArea></Row><Row><Action id="2953">Anti-inflammatory</Action><AuthorityGroup>LOCAL_AND_MAJOR</AuthorityGroup><Company id="1072329">Harbin Pacific Biopharmaceutical Co Ltd</Company><Country id="CN">China</Country><Drug id="80551">human immunoglobulin (intramuscular, measles, hepatitis virus infection), Harbin Pacific Biopharmaceutical Co Ltd</Drug><EntityType>Biological</EntityType><HighestDevStatus id="L">Launched</HighestDevStatus><HighestDevStatusForInd id="L">Launched</HighestDevStatusForInd><Indication id="1">Measles virus infection</Indication><IsActiveCompany>true</IsActiveCompany><LatestChange>1998-12-31 00:00:00</LatestChange><ParentCompany id="1072329">Harbin Pacific Biopharmaceutical Co Ltd</ParentCompany><Status id="L">Launched</Status><StatusDate>1998-12-31 00:00:00</StatusDate><StatusSortCode>13</StatusSortCode><TherapyArea id="746">Infectious disease</TherapyArea></Row><Row><Action id="12378">Prophylactic vaccine</Action><AuthorityGroup>OTHER</AuthorityGroup><Company id="20947">World Health Organization</Company><Country id="MX">Mexico</Country><Drug id="56118">measles vaccine (inhaled aerosol), WHO</Drug><EntityType>Biological</EntityType><HighestDevStatus id="NDR">No Development Reported</HighestDevStatus><HighestDevStatusForInd id="NDR">No Development Reported</HighestDevStatusForInd><Indication id="1">Measles virus infection</Indication><IsActiveCompany>false</IsActiveCompany><LatestChange>2011-12-29 00:00:00</LatestChange><ParentCompany id="20947">World Health Organization</ParentCompany><Status id="C2">Phase 2 Clinical</Status><StatusDate>2006-09-06 00:00:00</StatusDate><StatusSortCode>9</StatusSortCode><TherapyArea id="746">Infectious disease</TherapyArea></Row><Row><Action id="12364">Live attenuated viral vaccine</Action><AuthorityGroup>OTHER</AuthorityGroup><Company id="20947">World Health Organization</Company><Country id="MX">Mexico</Country><Drug id="56118">measles vaccine (inhaled aerosol), WHO</Drug><EntityType>Biological</EntityType><HighestDevStatus id="NDR">No Development Reported</HighestDevStatus><HighestDevStatusForInd id="NDR">No Development Reported</HighestDevStatusForInd><Indication id="1">Measles virus infection</Indication><IsActiveCompany>false</IsActiveCompany><LatestChange>2011-12-29 00:00:00</LatestChange><ParentCompany id="20947">World Health Organization</ParentCompany><Status id="CU">Clinical</Status><StatusDate>2002-10-31 00:00:00</StatusDate><StatusSortCode>7</StatusSortCode><TherapyArea id="746">Infectious disease</TherapyArea></Row></Rowset>